,tid,pref_name,lig_chemblid,aid,outcome,title,nnrank,prob
2126,CHEMBL2534,3-phosphoinositide dependent protein kinase-1,CHEMBL2347053,739584,Active,inhibition of pdk1  unknown origin after 10 mins by mobility shift assay,13.5,0.45549458
1265,CHEMBL2534,3-phosphoinositide dependent protein kinase-1,CHEMBL3884319,1336010,Active,inhibition of human recombinant full length his tagged pdk1 expressed in baculovirus expression system,27.5,0.5044466
873,CHEMBL3706,ADAM17,CHEMBL43704,215593,Inactive,inhibitory activity against tace,2.0,0.36540344
234,CHEMBL220,Acetylcholinesterase,CHEMBL3958499,1330795,Active,inhibition of electric eel ache using acetylthiocholine iodide as substrate incubated for 5 mins followed by substrate addition measured for 1 min by ellman's method,1.0,0.6673177
1575,CHEMBL220,Acetylcholinesterase,CHEMBL3338962,1166296,Active,inhibition of electric eel ache by ellman's method,136.0,0.6673177
2155,CHEMBL220,Acetylcholinesterase,CHEMBL3897721,1318844,Active,inhibition of wistar rat brain ache using acetylthiochloline iodide as substrate after 30 mins by ellman's method,1.0,0.6673177
303,CHEMBL220,Acetylcholinesterase,CHEMBL322343,272365,Active,inhibition of bovine erythrocyte ache,1.0,0.6673177
2125,CHEMBL220,Acetylcholinesterase,CHEMBL397100,300873,Inactive,inhibition of recombinant human ache activity,1.0,0.6673177
302,CHEMBL220,Acetylcholinesterase,CHEMBL322343,243153,Active,in vitro inhibitory activity against bovine acetylcholinesterase,1.0,0.6673177
299,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30682,Active,compound was evaluated for the inhibition of acetylcholinesterase of bovine erythrocytes,1.0,0.6673177
1416,CHEMBL220,Acetylcholinesterase,CHEMBL3628053,1252806,Active,inhibition of human recombinant ache using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition by ellman's method,1.0,0.6673177
300,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30692,Active,inhibition of acetylcholinesterase  ache activity in bovine erythrocytes,1.0,0.6673177
301,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30692,Active,inhibition of acetylcholinesterase  ache activity in bovine erythrocytes,1.0,0.6673177
1723,CHEMBL220,Acetylcholinesterase,CHEMBL240045,300873,Inactive,inhibition of recombinant human ache activity,1.0,0.67272043
690,CHEMBL220,Acetylcholinesterase,CHEMBL3934708,1318844,Active,inhibition of wistar rat brain ache using acetylthiochloline iodide as substrate after 30 mins by ellman's method,1.0,0.6673177
1452,CHEMBL223,Alpha-1d adrenergic receptor,CHEMBL3758665,1275241,Active,displacement of [3h] prazosin from human adra1a receptor,66.0,0.66072166
1202,CHEMBL223,Alpha-1d adrenergic receptor,CHEMBL3758913,1275241,Active,displacement of [3h] prazosin from human adra1a receptor,17.5,0.66072166
709,CHEMBL223,Alpha-1d adrenergic receptor,CHEMBL3760063,1275241,Active,displacement of [3h] prazosin from human adra1a receptor,11.5,0.66072166
1388,CHEMBL1871,Androgen Receptor,CHEMBL1370,625228,Active,drugmatrix: androgen  testosterone ar radioligand binding  ligand: [3h] mibolerone ,1.5,0.49024773
1389,CHEMBL1871,Androgen Receptor,CHEMBL1370,625228,Active,drugmatrix: androgen  testosterone ar radioligand binding  ligand: [3h] mibolerone ,1.5,0.49024773
142,CHEMBL4822,Beta-secretase 1,CHEMBL3938461,1344819,Active,time resolved endpoint proteolysis assay: inhibitor compounds prepared at 3 xd7 the desired final concentration in 1 xd7 bace assay buffer  20 mm sodium acetate ph 5 0 10% glycerol 0 1% brij 35 supplemented with 7 5% dmso are pre incubated with an equal volume of autobace 2 enzyme diluted in 1 xd7 bace assay buffer  final enzyme concentration 1 nm in black 384 well nunc plates for 30 minutes at 30 xb0 c the assay is initiated by addition of an equal volume of the qsy7 eisevnldaefc eu amide substrate  200 nm final concentration km8  x3bc m for 4  x3bc m for autobace 2 prepared in 1 xd7 bace assay buffer supplemented with 7 5% dmso and incubated for 90 minutes at 30 xb0 c dmso is present at 5% final concentration in the assay following laser excitation of sample wells at 320 nm the fluorescence signal at 620 nm is collected for 400 ms following a 50  x3bc s delay on a rubystar htrf plate reader  bmg labtechnologies ,1.0,0.9554367
341,CHEMBL4822,Beta-secretase 1,CHEMBL3670929,1257989,Active,immunofluorescence resonance energy transfer  fret assay: the fret assay was performed essentially as described in gruninger leitch et al journal of biological chemistry  2002 277 7 4687 93  substrate and inhibitor profile of bace  beta secretase and comparison with other mammalian aspartic proteases in summary a peptide is designed that is cleaved by the protease the peptide is labelled with dabcyl at the n terminus and lucifer yellow at the c terminus such that for an intact peptide the lucifer yellow fluorescence is quenched by the dabcyl when the peptide is cut by bace2 the quenching is removed and a fluorescent signal is generated the assay was performed as described in grueninger et al 2002 at ph 4 5 using a substrate concentration of 5  x3bc m a fret peptide based on the tmem27 sequence was devised dabcyl qtleflkips lucy  seq id no: 1 bace2 had a high activity against this sequence which is unrelated to the known app based substrates conversely bace1 had i,1.0,0.9554367
342,CHEMBL4822,Beta-secretase 1,CHEMBL3670929,1257990,Active,immunofluorescence resonance energy transfer  fret assay: the fret assay was performed essentially as described in gruninger leitch et al journal of biological chemistry  2002 277 7 4687 93  substrate and inhibitor profile of bace  beta secretase and comparison with other mammalian aspartic proteases in summary a peptide is designed that is cleaved by the protease the peptide is labelled with dabcyl at the n terminus and lucifer yellow at the c terminus such that for an intact peptide the lucifer yellow fluorescence is quenched by the dabcyl when the peptide is cut by bace2 the quenching is removed and a fluorescent signal is generated the assay was performed as described in grueninger et al 2002 at ph 4 5 using a substrate concentration of 5  x3bc m a fret peptide based on the tmem27 sequence was devised dabcyl qtleflkips lucy  seq id no: 1 bace2 had a high activity against this sequence which is unrelated to the known app based substrates conversely bace1 had i,1.0,0.9554367
1708,CHEMBL1914,Butyrylcholinesterase,CHEMBL3604192,1240923,Active,inhibition of equine serum bche using atc iodide substrate by ellman's assay,1.0,0.33761528
1944,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3950538,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e,1.0,0.42355976
563,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL1259076,517909,Active,displacement of [3h]cp55940 from rat brain cb1 receptor,1.0,0.42355976
1511,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL4102348,1433068,Active,displacement of [3h]cp 55 940 from cb1 receptor in rat brain membranes by scintillation counting method,1.5,0.42355976
326,CHEMBL261,Carbonic anhydrase I,CHEMBL215917,271037,Active,inhibition of human cloned ca1 by co2 hydration assay,1.0,0.99130726
71,CHEMBL261,Carbonic anhydrase I,CHEMBL2070210,678515,Active,inhibition of human ca1 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique,1.0,0.99130726
1876,CHEMBL261,Carbonic anhydrase I,CHEMBL3137754,50354,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,1.0,0.7831893
404,CHEMBL261,Carbonic anhydrase I,CHEMBL453731,347428,Active,inhibition of human recombinant ca1 by stopped flow co2 hydration assay,2.0,0.95775115
69,CHEMBL261,Carbonic anhydrase I,CHEMBL1242794,512001,Active,inhibition of human cloned ca1 after 15 mins by stopped flow co2 hydration assay,1.0,0.99130726
0,CHEMBL261,Carbonic anhydrase I,CHEMBL2326507,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.5,0.9599063
275,CHEMBL261,Carbonic anhydrase I,CHEMBL2321923,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.5,0.9599063
77,CHEMBL261,Carbonic anhydrase I,CHEMBL2148105,687196,Active,inhibition of human recombinant cytosolic ca1 preincubated for 15 mins by stopped flow co2 hydration method,1.0,0.99130726
1965,CHEMBL261,Carbonic anhydrase I,CHEMBL477748,667533,Active,noncompetitive inhibition of human ca1 using 4npa as substrate for 3 mins by lineweaver burk plot analysis,4.0,0.7831893
89,CHEMBL261,Carbonic anhydrase I,CHEMBL232816,295289,Active,inhibition of human recombinant ca1 after 15 mins by co2 hydration stopped flow assay,1.0,0.95775115
224,CHEMBL261,Carbonic anhydrase I,CHEMBL2326509,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method,13.0,0.9599063
200,CHEMBL261,Carbonic anhydrase I,CHEMBL387402,670600,Active,neuroprotective activity in wistar rat hippocampal ca1 region assessed as change in field excitatory postsynaptic potential at basal conditions at 1 to 5 um by electrophysiological analysis,11.5,0.9599063
199,CHEMBL261,Carbonic anhydrase I,CHEMBL387402,670598,Inactive,neuroprotective activity in wistar rat acute hippocampal ca1 region assessed as protection from oxygen glucose deprivation induced anoxia depolarization at 1 um administered 15 mins before and during 7 mins oxygen deprivation challenge,11.5,0.9599063
102,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,47713,Active,inhibition of human carbonic anhydrase i  cai ,2.0,0.99130726
103,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 ,2.0,0.99130726
104,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,2.0,0.99130726
105,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,263636,Active,inhibition of human recombinant ca1,2.0,0.99130726
106,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,367820,Active,inhibition of human recombinant ca1 by stopped flow co2 hydrase assay,2.0,0.99130726
107,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,436563,Active,inhibition of human recombinant ca1 by stopped flow co2 assay,2.0,0.99130726
108,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,459696,Active,inhibition of brucella suis ca1 expressed in escherichia coli bl21 de3 by stopped flow co2 hydration assay,2.0,0.99130726
109,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,552127,Active,inhibition of human recombinant ca1 by stopped flow co2 hydration assay,2.0,0.99130726
421,CHEMBL261,Carbonic anhydrase I,CHEMBL3138427,50354,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,1.0,0.7831893
114,CHEMBL261,Carbonic anhydrase I,CHEMBL196871,47710,Active,inhibition of human recombinant carbonic anhydrase i  ca1 ,1.0,0.95775115
530,CHEMBL261,Carbonic anhydrase I,CHEMBL2326508,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method,5.0,0.9599063
1623,CHEMBL261,Carbonic anhydrase I,CHEMBL68253,552127,Active,inhibition of human recombinant ca1 by stopped flow co2 hydration assay,2.0,0.80513495
17,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,239250,Active,inhibitory activity against beta carbonic anhydrase  cab from methanobacterium thermoautotrophicum,2.0,0.99130726
1624,CHEMBL261,Carbonic anhydrase I,CHEMBL68253,724722,Active,inhibition of human recombinant wild type ca1 by stopped flow co2 hydration method,2.0,0.80513495
580,CHEMBL261,Carbonic anhydrase I,CHEMBL24147,1238074,Active,competitive inhibition of human erythrocytes ca1 using 4 nitrophenylacetate as substrate by lineweaver burk plot analysis,1.5,0.95539093
1668,CHEMBL261,Carbonic anhydrase I,CHEMBL103302,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 ,1.0,0.7831893
19,CHEMBL261,Carbonic anhydrase I,CHEMBL2326506,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.5,0.9599063
16,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,2.0,0.99130726
15,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 ,2.0,0.99130726
14,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,47713,Active,inhibition of human carbonic anhydrase i  cai ,2.0,0.99130726
12,CHEMBL261,Carbonic anhydrase I,CHEMBL215276,271037,Active,inhibition of human cloned ca1 by co2 hydration assay,1.0,0.99130726
1015,CHEMBL261,Carbonic anhydrase I,CHEMBL332549,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,3.0,0.7831893
772,CHEMBL261,Carbonic anhydrase I,CHEMBL1662,416125,Active,inhibition of human erythrocyte ca1 esterase activity using 4 nitrophenyl acetate substrate,58.5,0.7831893
1022,CHEMBL261,Carbonic anhydrase I,CHEMBL355001,552127,Active,inhibition of human recombinant ca1 by stopped flow co2 hydration assay,2.0,0.80513495
1368,CHEMBL261,Carbonic anhydrase I,CHEMBL166223,639299,Active,inhibition of human ca1 pre incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red based stopped flow co2 hydrase assay,1.0,0.80513495
463,CHEMBL261,Carbonic anhydrase I,CHEMBL121922,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,1.0,0.7831893
1035,CHEMBL261,Carbonic anhydrase I,CHEMBL124165,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,1.0,0.7831893
829,CHEMBL261,Carbonic anhydrase I,CHEMBL3138176,50354,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 ,1.0,0.7831893
2,CHEMBL261,Carbonic anhydrase I,CHEMBL215355,271037,Active,inhibition of human cloned ca1 by co2 hydration assay,1.0,0.99130726
674,CHEMBL261,Carbonic anhydrase I,CHEMBL316875,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 ,1.0,0.7831893
249,CHEMBL205,Carbonic anhydrase II,CHEMBL395543,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry,1.5,0.94884604
85,CHEMBL205,Carbonic anhydrase II,CHEMBL2326508,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.0,0.9691119
426,CHEMBL205,Carbonic anhydrase II,CHEMBL183419,1262264,Active,inhibition of human ca2 incubated for 15 mins prior to testing by stopped flow co2 hydrase assay,5.5,0.991682
198,CHEMBL205,Carbonic anhydrase II,CHEMBL234507,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry,6.0,0.94884604
119,CHEMBL205,Carbonic anhydrase II,CHEMBL442798,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry,2.0,0.94884604
7,CHEMBL205,Carbonic anhydrase II,CHEMBL2326507,727275,Active,inhibition of human ca2 ala65ser and asn67gln double mutant expressed in escherichia coli strain bl21  de3 after 6 hrs by stopped flow co2 hydration method,1.5,0.9691119
6,CHEMBL205,Carbonic anhydrase II,CHEMBL2326507,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.5,0.9691119
86,CHEMBL205,Carbonic anhydrase II,CHEMBL2326508,727275,Active,inhibition of human ca2 ala65ser and asn67gln double mutant expressed in escherichia coli strain bl21  de3 after 6 hrs by stopped flow co2 hydration method,1.0,0.9691119
425,CHEMBL205,Carbonic anhydrase II,CHEMBL183419,552128,Active,inhibition of human recombinant ca2 by stopped flow co2 hydration assay,5.5,0.991682
256,CHEMBL205,Carbonic anhydrase II,CHEMBL394355,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry,2.0,0.94884604
20,CHEMBL205,Carbonic anhydrase II,CHEMBL1200739,552128,Active,inhibition of human recombinant ca2 by stopped flow co2 hydration assay,9.0,0.94884604
51,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,724721,Active,inhibition of human recombinant wild type ca2 by stopped flow co2 hydration method,1.5,0.94884604
52,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,758952,Active,inhibition of human recombinant ca2 by co2 hydration assay,1.5,0.94884604
53,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,1235241,Active,inhibition of human ca2 after 15 mins by stopped flow/co2 hydration assay,1.5,0.94884604
54,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,1461934,Active,inhibition of human ca2 incubated for 15 mins by stopped flow co2 hydration assay,1.5,0.94884604
410,CHEMBL205,Carbonic anhydrase II,CHEMBL1644696,1235241,Active,inhibition of human ca2 after 15 mins by stopped flow/co2 hydration assay,6.0,0.94884604
409,CHEMBL205,Carbonic anhydrase II,CHEMBL1644696,724721,Active,inhibition of human recombinant wild type ca2 by stopped flow co2 hydration method,6.0,0.94884604
79,CHEMBL205,Carbonic anhydrase II,CHEMBL2326509,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.0,0.9691119
361,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,1235241,Active,inhibition of human ca2 after 15 mins by stopped flow/co2 hydration assay,3.0,0.94884604
360,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,758952,Active,inhibition of human recombinant ca2 by co2 hydration assay,3.0,0.94884604
362,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,1461934,Active,inhibition of human ca2 incubated for 15 mins by stopped flow co2 hydration assay,3.0,0.94884604
692,CHEMBL205,Carbonic anhydrase II,CHEMBL2326506,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.5,0.9691119
21,CHEMBL205,Carbonic anhydrase II,CHEMBL1200739,1262264,Active,inhibition of human ca2 incubated for 15 mins prior to testing by stopped flow co2 hydrase assay,9.0,0.94884604
851,CHEMBL205,Carbonic anhydrase II,CHEMBL355001,552128,Active,inhibition of human recombinant ca2 by stopped flow co2 hydration assay,2.0,0.83739305
812,CHEMBL205,Carbonic anhydrase II,CHEMBL68253,552128,Active,inhibition of human recombinant ca2 by stopped flow co2 hydration assay,2.0,0.83739305
693,CHEMBL205,Carbonic anhydrase II,CHEMBL2326506,727275,Active,inhibition of human ca2 ala65ser and asn67gln double mutant expressed in escherichia coli strain bl21  de3 after 6 hrs by stopped flow co2 hydration method,1.5,0.9691119
359,CHEMBL205,Carbonic anhydrase II,CHEMBL1644697,724721,Active,inhibition of human recombinant wild type ca2 by stopped flow co2 hydration method,3.0,0.94884604
411,CHEMBL205,Carbonic anhydrase II,CHEMBL1644696,1461934,Active,inhibition of human ca2 incubated for 15 mins by stopped flow co2 hydration assay,6.0,0.94884604
355,CHEMBL205,Carbonic anhydrase II,CHEMBL2321923,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method,1.5,0.9691119
2027,CHEMBL3594,Carbonic anhydrase IX,CHEMBL2070204,678517,Active,inhibition of human ca9 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique,84.5,0.79081845
205,CHEMBL3594,Carbonic anhydrase IX,CHEMBL3798303,1295826,Active,binding affinity to human recombinant ca9 catalytic domain by fluorescence based thermal shift assay,1.0,0.9811067
1207,CHEMBL3594,Carbonic anhydrase IX,CHEMBL467897,352789,Active,inhibition of human ca9 catalytic domain by co2 hydration stopped flow assay,1.5,0.79081845
254,CHEMBL3594,Carbonic anhydrase IX,CHEMBL521690,352789,Active,inhibition of human ca9 catalytic domain by co2 hydration stopped flow assay,1.5,0.79081845
206,CHEMBL3594,Carbonic anhydrase IX,CHEMBL3798303,1295838,Active,slow rate dissociation at human recombinant ca9 catalytic domain after 30 sec by surface plasmon resonance assay,1.0,0.9811067
2024,CHEMBL3242,Carbonic anhydrase XII,CHEMBL468945,352790,Active,inhibition of human ca12 catalytic domain by co2 hydration stopped flow assay,1.5,0.6760878
1717,CHEMBL3242,Carbonic anhydrase XII,CHEMBL446518,539682,Active,inhibition of human recombinant ca12 catalytic domain by stopped flow co2 hydration method,1.0,0.73930216
306,CHEMBL3242,Carbonic anhydrase XII,CHEMBL2070209,678518,Active,inhibition of human ca12 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique,1.0,0.9155568
1989,CHEMBL3242,Carbonic anhydrase XII,CHEMBL521690,352790,Active,inhibition of human ca12 catalytic domain by co2 hydration stopped flow assay,1.5,0.6760878
1217,CHEMBL3242,Carbonic anhydrase XII,CHEMBL1290219,539682,Active,inhibition of human recombinant ca12 catalytic domain by stopped flow co2 hydration method,2.0,0.73930216
1148,CHEMBL3242,Carbonic anhydrase XII,CHEMBL4078936,1433067,Active,inhibition of human ca12 by stopped flow co2 hydration method,1.0,0.9155568
188,CHEMBL3242,Carbonic anhydrase XII,CHEMBL2323124,725593,Active,inhibition of human ca12 by stopped flow assay,1.0,0.9155568
1154,CHEMBL3242,Carbonic anhydrase XII,CHEMBL466234,352790,Active,inhibition of human ca12 catalytic domain by co2 hydration stopped flow assay,1.5,0.6760878
1020,CHEMBL308,Cyclin-dependent kinase 1,CHEMBL1908394,1450948,Inactive,inhibition of wee1 in hek293t cells assessed as decrease in cdk1 phosphorylation at tyr15 at 0 01 to 10 um after 6 hrs by western blot method,27.0,0.31661135
1019,CHEMBL308,Cyclin-dependent kinase 1,CHEMBL1908394,1450941,Inactive,inhibition of wee1 in human mda mb 231 cells assessed as decrease in cdk1 phosphorylation at tyr 15 at 0 1 to 10 um after 6 hrs by western blot method,27.0,0.31661135
1512,CHEMBL308,Cyclin-dependent kinase 1,CHEMBL1964252,55538,Active,inhibitory activity against human cyclin dependent kinase 1  cdk1 ,1.0,0.327951
1936,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL31965,256632,Inactive,average binding constant for cdk2 nanot active at 10 um,62.0,0.69358784
282,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL50,298693,Active,inhibition of cdk2,9.0,0.77997816
63,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL226471,288462,Active,inhibition of cdk2,4.5,0.80821955
337,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL535,479518,Inactive,inhibition of cdk2,3.0,0.9468965
336,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL535,256632,Inactive,average binding constant for cdk2 nanot active at 10 um,3.0,0.9468965
2063,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL553,256632,Inactive,average binding constant for cdk2 nanot active at 10 um,8.0,0.7199298
704,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL1973540,53362,Active,inhibitory activity against human cyclin dependent kinase 2  cdk2 ,1.0,0.9662481
703,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL1973540,53361,Active,evaluated for inhibition of human cyclin dependent kinase 2  cdk2 ,1.0,0.9662481
529,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL24828,256632,Inactive,average binding constant for cdk2 nanot active at 10 um,20.0,0.7760213
267,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL502835,624844,Active,binding constant for cdk2 kinase domain,140.0,0.26031378
1942,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL272387,320938,Active,inhibition of cdk2,14.0,0.060484596
1941,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL272387,53362,Active,inhibitory activity against human cyclin dependent kinase 2  cdk2 ,14.0,0.060484596
1988,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL50,298693,Active,inhibition of cdk2,114.0,0.086668484
2062,CHEMBL1907601,Cyclin-dependent kinase 4/cyclin D1,CHEMBL1287853,624781,Active,binding constant for cdk4 cyclind3 kinase domain,68.0,0.19259071
2061,CHEMBL1907601,Cyclin-dependent kinase 4/cyclin D1,CHEMBL1287853,624780,Active,binding constant for cdk4 cyclind1 kinase domain,68.0,0.19259071
1040,CHEMBL1907601,Cyclin-dependent kinase 4/cyclin D1,CHEMBL1721885,624780,Active,binding constant for cdk4 cyclind1 kinase domain,46.0,0.17156242
1566,CHEMBL1907601,Cyclin-dependent kinase 4/cyclin D1,CHEMBL1908397,624780,Active,binding constant for cdk4 cyclind1 kinase domain,20.0,0.18448395
1567,CHEMBL1907601,Cyclin-dependent kinase 4/cyclin D1,CHEMBL1908397,624781,Active,binding constant for cdk4 cyclind3 kinase domain,20.0,0.18448395
1041,CHEMBL1907601,Cyclin-dependent kinase 4/cyclin D1,CHEMBL1721885,624781,Active,binding constant for cdk4 cyclind3 kinase domain,46.0,0.17156242
82,CHEMBL2722,Cytochrome P450 11B2,CHEMBL1440486,1344534,Active,cellular inhibition assay: v79mz cells expressing human cyp11b1 and human cyp11b2 genes respectively were grown on 24 well cell culture plates  8 xd7 10^5 cells per well with 1 9 cm^2 culture area per well in 1 ml dmem culture medium until confluence before testing the dmem culture medium was removed and 450  x3bc l of fresh dmem containing the inhibitor in at least three different concentrations for determining the ic50 value was added to each well every value was determined at least three times after a pre incubation step of 60 min at 37 xb0 c the reaction was started by the addition of 50  x3bc l of dmem containing the substrate 11 deoxycorticosterone  containing 0 15  x3bc ci of [1 2 3h] 11 deoxycorticosterone dissolved in ethanol final concentration 100 nm the v79mzh11b1 cells were incubated for 25 min the v79mzh11b2 cells were incubated for 50 min controls were treated in the same way without inhibitors the maximum dmso concentration in each well was 1% e,1.0,0.94335514
445,CHEMBL2722,Cytochrome P450 11B2,CHEMBL2011250,1344534,Active,cellular inhibition assay: v79mz cells expressing human cyp11b1 and human cyp11b2 genes respectively were grown on 24 well cell culture plates  8 xd7 10^5 cells per well with 1 9 cm^2 culture area per well in 1 ml dmem culture medium until confluence before testing the dmem culture medium was removed and 450  x3bc l of fresh dmem containing the inhibitor in at least three different concentrations for determining the ic50 value was added to each well every value was determined at least three times after a pre incubation step of 60 min at 37 xb0 c the reaction was started by the addition of 50  x3bc l of dmem containing the substrate 11 deoxycorticosterone  containing 0 15  x3bc ci of [1 2 3h] 11 deoxycorticosterone dissolved in ethanol final concentration 100 nm the v79mzh11b1 cells were incubated for 25 min the v79mzh11b2 cells were incubated for 50 min controls were treated in the same way without inhibitors the maximum dmso concentration in each well was 1% e,1.0,0.94335514
989,CHEMBL2722,Cytochrome P450 11B2,CHEMBL1172842,491986,Active,inhibition of human cyp11b2 expressed in hamster v79mzh cells,1.5,0.94335514
1157,CHEMBL340,Cytochrome P450 3A4,CHEMBL42,1209941,Active,drug metabolism in supersomes expressing human recombinant cyp3a4 assessed as enzyme mediated total gsh conjugate formation after 15 mins by michaelis menten equation analysis,1.0,0.35123658
1158,CHEMBL340,Cytochrome P450 3A4,CHEMBL42,1209962,Active,drug metabolism in supersomes expressing human recombinant cyp3a4 assessed as enzyme mediated n demethyl clozapine metabolite formation after 15 mins by michaelis menten equation analysis,1.0,0.35123658
1159,CHEMBL340,Cytochrome P450 3A4,CHEMBL42,1210071,Active,inhibition of cyp3a4 in human liver microsomes using testosterone substrate by lc ms/ms method,1.0,0.35123658
1156,CHEMBL340,Cytochrome P450 3A4,CHEMBL42,678717,Active,inhibition of human cyp3a4 assessed as ratio of ic50 in absence of nadph to ic50 for presence of nadph using 7 benzyloxyquinoline as substrate after 30 mins,1.0,0.35123658
1950,CHEMBL340,Cytochrome P450 3A4,CHEMBL411,1255428,Active,antagonist activity against pxr in human hepg2 cells assessed as inhibition of rifaximin induced cyp3a4 gene expression at 25 um after 18 hrs by quantitative real time pcr analysis,2.0,0.34125876
1948,CHEMBL340,Cytochrome P450 3A4,CHEMBL411,678717,Active,inhibition of human cyp3a4 assessed as ratio of ic50 in absence of nadph to ic50 for presence of nadph using 7 benzyloxyquinoline as substrate after 30 mins,2.0,0.34125876
807,CHEMBL340,Cytochrome P450 3A4,CHEMBL41,1215347,Active,time dependent inhibition of cyp3a4 in human liver microsomes assessed as conversion of testosterone to 6beta hydroxytestosterone at 0 01 to 100 um preincubated for 60 mins followed by testosterone treatment measured after 10 mins by lc ms/ms analysis in presence of nadph,1.0,0.19978233
1949,CHEMBL340,Cytochrome P450 3A4,CHEMBL411,1255427,Active,activity at pxr in human hepg2 cells assessed as up regulation of rifaximin induced cyp3a4 gene expression at 25 um after 18 hrs by quantitative real time pcr analysis,2.0,0.34125876
1947,CHEMBL340,Cytochrome P450 3A4,CHEMBL411,678716,Active,inhibition of human cyp3a4 assessed as ratio of ic50 in absence of nadph to ic50 for presence of nadph using diethoxyfluorescein as substrate after 30 mins,2.0,0.34125876
808,CHEMBL340,Cytochrome P450 3A4,CHEMBL41,1215348,Active,time dependent inhibition of cyp3a4 in human liver microsomes assessed as conversion of testosterone to 6beta hydroxytestosterone at 0 01 to 100 um preincubated for 60 mins followed by testosterone treatment measured after 10 mins by lc ms/ms analysis,1.0,0.19978233
809,CHEMBL340,Cytochrome P450 3A4,CHEMBL41,1215349,Active,time dependent inhibition of cyp3a4 in human liver microsomes assessed as conversion of testosterone to 6beta hydroxytestosterone at 0 01 to 100 um preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined cyp450 ic50 shift assay in presence of nadph,1.0,0.19978233
810,CHEMBL340,Cytochrome P450 3A4,CHEMBL41,1215350,Active,time dependent inhibition of cyp3a4 in human liver microsomes assessed as conversion of testosterone to 6beta hydroxytestosterone at 0 01 to 100 um preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined cyp450 ic50 shift assay,1.0,0.19978233
1122,CHEMBL340,Cytochrome P450 3A4,CHEMBL2436978,775443,Active,inhibition of cyp3a4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by hplc/ms analysis,1.0,0.18906955
1155,CHEMBL340,Cytochrome P450 3A4,CHEMBL42,678716,Active,inhibition of human cyp3a4 assessed as ratio of ic50 in absence of nadph to ic50 for presence of nadph using diethoxyfluorescein as substrate after 30 mins,1.0,0.35123658
2047,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504905,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,41.0,0.5753804
1419,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,145.0,0.47554094
2046,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
1420,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,145.0,0.47554094
2045,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
1421,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,145.0,0.47554094
2044,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,41.0,0.5753804
2042,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
2041,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
1422,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,145.0,0.47554094
2040,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
2039,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
1417,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,145.0,0.47554094
1602,CHEMBL236,Delta opioid receptor,CHEMBL964,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,25.0,0.7932704
2048,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
2043,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,41.0,0.5753804
2049,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,41.0,0.5753804
2051,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588411,Inactive,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprd1 homodimerization,41.0,0.5753804
1665,CHEMBL236,Delta opioid receptor,CHEMBL1479,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,17.0,0.7906079
2050,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588408,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput dose response assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,41.0,0.5753804
1926,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,93.0,0.47582877
1927,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,93.0,0.47582877
1598,CHEMBL236,Delta opioid receptor,CHEMBL964,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,25.0,0.7932704
1599,CHEMBL236,Delta opioid receptor,CHEMBL964,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,25.0,0.7932704
1666,CHEMBL236,Delta opioid receptor,CHEMBL1479,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,17.0,0.7906079
1928,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,93.0,0.47582877
1925,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,93.0,0.47582877
1924,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,93.0,0.47582877
1923,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,93.0,0.47582877
1664,CHEMBL236,Delta opioid receptor,CHEMBL1479,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,17.0,0.7906079
1663,CHEMBL236,Delta opioid receptor,CHEMBL1479,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,17.0,0.7906079
1600,CHEMBL236,Delta opioid receptor,CHEMBL964,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,25.0,0.7932704
1418,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,145.0,0.47554094
1601,CHEMBL236,Delta opioid receptor,CHEMBL964,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,25.0,0.7932704
1662,CHEMBL236,Delta opioid receptor,CHEMBL1479,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,17.0,0.7906079
2052,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588435,Active,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprm1 homodimerization,41.0,0.5753804
1667,CHEMBL236,Delta opioid receptor,CHEMBL1479,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,17.0,0.7906079
1597,CHEMBL236,Delta opioid receptor,CHEMBL964,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,25.0,0.7932704
1558,CHEMBL238,Dopamine transporter,CHEMBL11,360444,Inactive,displacement of [3h]rti82 from dat in rat striatal membrane,1.5,0.84747285
1845,CHEMBL238,Dopamine transporter,CHEMBL3085027,257284,Active,displacement of [3h]win from dat in rat brain membrane,1.0,0.8281606
1844,CHEMBL238,Dopamine transporter,CHEMBL3085029,257284,Active,displacement of [3h]win from dat in rat brain membrane,1.0,0.8281606
1856,CHEMBL238,Dopamine transporter,CHEMBL562476,431885,Active,inhibition of [3h]win 35428 binding to human recombinant dat expressed in cho cells by scintillation counting,3.0,0.82290965
1199,CHEMBL238,Dopamine transporter,CHEMBL450769,393257,Active,displacement of [125i]rti55 from human dat expressed in hek cells,1.0,0.82290965
1857,CHEMBL238,Dopamine transporter,CHEMBL450987,393256,Active,inhibition of [3h]dopamine reuptake at human dat expressed in hek cells,1.0,0.82290965
1381,CHEMBL238,Dopamine transporter,CHEMBL3085032,257284,Active,displacement of [3h]win from dat in rat brain membrane,1.5,0.8281606
1462,CHEMBL238,Dopamine transporter,CHEMBL460406,393256,Active,inhibition of [3h]dopamine reuptake at human dat expressed in hek cells,1.0,0.82290965
1463,CHEMBL238,Dopamine transporter,CHEMBL460406,393257,Active,displacement of [125i]rti55 from human dat expressed in hek cells,1.0,0.82290965
1198,CHEMBL238,Dopamine transporter,CHEMBL450769,393256,Active,inhibition of [3h]dopamine reuptake at human dat expressed in hek cells,1.0,0.82290965
1033,CHEMBL238,Dopamine transporter,CHEMBL1201066,1164249,Active,inhibition of human dat expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay,1.0,0.82290965
1744,CHEMBL238,Dopamine transporter,CHEMBL3085025,257284,Active,displacement of [3h]win from dat in rat brain membrane,10.0,0.6791371
1106,CHEMBL238,Dopamine transporter,CHEMBL549,499949,Active,displacement of [3h]win 35428 from dat in rat caudate putamen by scintillation counting,8.0,0.8557211
923,CHEMBL238,Dopamine transporter,CHEMBL4094047,1439846,Active,inhibition of [3h] 5 dopamine reuptake in human dat expressed in hek293 cells by microbeta liquid scintillation counting method,1.0,0.82290965
286,CHEMBL238,Dopamine transporter,CHEMBL257593,331704,Active,inhibition of [3h]da uptake at human recombinant dat expressed in hek293 cells,1.0,0.82290965
1557,CHEMBL238,Dopamine transporter,CHEMBL11,351888,Active,inhibition of [3h]dopamine uptake at human dat expressed in hek293 cells,1.5,0.84747285
1201,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1725279,586673,Active,activation of nrf2/are in rat pc12 cells assessed as ho 1 protein induction at 10 um after 5 hrs pretreated with mek1 inhibitor pd98059 for 1 hr before compound addition by western blot analysis,5.0,0.6567018
1621,CHEMBL3983,Dual specificity protein kinase TTK,CHEMBL941,256599,Inactive,average binding constant for ttk nanot active at 10 um,51.5,0.21319297
1409,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,15.5,0.90082204
945,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
944,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
1902,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3956820,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.0,0.7846366
322,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay,3.5,0.6541782
323,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay,3.5,0.6541782
324,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay,3.5,0.6541782
325,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay,3.5,0.6541782
708,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,6.0,0.89436775
67,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
943,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
328,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
329,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
330,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
331,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
946,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
1477,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3959160,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,3.0,0.7159023
1922,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3917220,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,2.0,0.76007766
706,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,6.0,0.89436775
1556,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3968233,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,2.0,0.7449832
544,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
1278,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting,1.0,0.8890553
1279,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting,1.0,0.8890553
543,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
542,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
541,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
540,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
539,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
538,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
537,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354185,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening,2.0,0.70443475
1501,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3986135,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,2.0,0.76007766
1499,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3900059,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.0,0.7846366
1707,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3884319,1336032,Active,inhibition of human recombinant gst tagged egfr cytoplasmic domain  668 to 1210 residues expressed in baculovirus expression system,2.5,0.75723106
705,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,6.0,0.89436775
707,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,6.0,0.89436775
740,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
741,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
66,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
370,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa,180.5,0.8116568
371,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa,180.5,0.8116568
883,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
882,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1359,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
1360,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775624,Active,inhibition of wild type egfr  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
369,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa,180.5,0.8116568
1375,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3934134,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.5,0.7846366
815,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3968192,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.5,0.7846366
1820,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1725279,256664,Inactive,average binding constant for egfr nanot active at 10 um,13.5,0.8497163
852,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3924147,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.0,0.7846366
1406,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,15.5,0.90082204
1407,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,15.5,0.90082204
1408,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,15.5,0.90082204
462,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3981432,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,2.0,0.7449832
368,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3735648,1312467,Active,inhibition of n terminal gst tagged recombinant human egfr t790m/l858r double mutant  696 residues expressed in insect sf21 cells using poly glu tyr 4:1 as substrate incubated for 60 mins by elisa,180.5,0.8116568
884,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
885,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
65,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
742,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
743,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
352,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3959516,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.0,0.7846366
744,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1352,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
1353,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
1354,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
1355,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
745,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1356,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
746,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
747,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1357,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
1358,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay,2.0,0.60948396
424,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3931427,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.0,0.7846366
64,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
1620,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3947643,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,4.0,0.7449832
1051,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
2082,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2038,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3958678,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,2.0,0.7449832
2081,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2080,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
1277,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting,1.0,0.8890553
1050,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
2079,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
1049,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
2072,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770071,Active,cytotoxicity against human nci h1975 cells harboring egfr l858r/t970m double mutant assessed as growth inhibition after 72 hrs by sytox green nucleic acid staining based fluorescence assay,1.0,0.6299386
2114,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3945072,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,2.0,0.76007766
1244,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL438536,320573,Active,inhibition of egfr,1.0,0.7159023
2078,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2077,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2076,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2031,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3905501,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,1.0,0.7846366
2075,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2074,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2083,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2084,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2073,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770081,Active,inhibition of wild type egfr phosphorylation in human lovo cells after 2 hrs by fluorescence assay,1.0,0.6299386
1052,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1061,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
1062,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
2085,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay,1.0,0.6299386
1064,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
120,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3916828,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay,2.0,0.7449832
2089,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
1056,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1054,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1063,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay,1.0,0.89436775
1053,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1276,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting,1.0,0.8890553
2088,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2087,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2086,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay,1.0,0.6299386
2071,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770070,Active,cytotoxicity against human pc9 cells harboring egfr exon 19 deletion activating mutant assessed as growth inhibition after 72 hrs by sytox green nucleic acid staining based fluorescence assay,1.0,0.6299386
1055,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant,1.0,0.89436775
1868,CHEMBL206,Estrogen receptor alpha,CHEMBL1084534,482352,Active,agonist activity at eralpha expressed in yeast assessed as alpha galactosidase activity,18.0,0.80920315
1300,CHEMBL206,Estrogen receptor alpha,CHEMBL1082422,482353,Active,agonist activity at eralpha expressed in yeast assessed as alpha galactosidase activity relative to e2,1.0,0.80920315
1299,CHEMBL206,Estrogen receptor alpha,CHEMBL1082422,482352,Active,agonist activity at eralpha expressed in yeast assessed as alpha galactosidase activity,1.0,0.80920315
1048,CHEMBL206,Estrogen receptor alpha,CHEMBL204222,262172,Active,binding affinity to eralpha,1.0,0.80920315
1121,CHEMBL206,Estrogen receptor alpha,CHEMBL3234627,1127147,Inactive,agonist activity at eralpha  unknown origin harboring n terminal af1 domain deleted mutant expressed in human hepg2 cells assessed as transcriptional activation after 24 hrs by ere luciferase reporter gene assay,1.0,0.80920315
903,CHEMBL242,Estrogen receptor beta,CHEMBL2401849,759300,Active,cytotoxicity against eralpha and erbeta deficient human mda mb 231 cells assessed as growth inhibition after 72 hrs by mtt assay,16.5,0.66865087
905,CHEMBL242,Estrogen receptor beta,CHEMBL2401849,759311,Active,cytotoxicity against eralpha deficient human du145 cells expressing erbeta assessed as growth inhibition after 72 hrs by mtt assay,16.5,0.66865087
904,CHEMBL242,Estrogen receptor beta,CHEMBL2401849,759301,Active,cytotoxicity against human mcf7 cells expressing eralpha and erbeta assessed as growth inhibition after 72 hrs by mtt assay,16.5,0.66865087
1257,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL315546,415657,Active,inhibition of fgfr1 in mouse nih/3t3 cells assessed as inhibition of afgf stimulated pp90 phosphoprotein phosphorylation by immunoblotting,13.5,0.20501342
1931,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL101253,503213,Inactive,decrease in fgfr1 mrna expression in adult zebrafish tail fin at 500 um measured on day 2 post treatment by in situ hybridization assay,84.0,0.7393109
1200,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL607707,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,25.0,0.8592734
194,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3933000,1340075,Active,inhibition of fgfr1  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay,1.5,0.9628973
724,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL428690,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,120.5,0.9087604
2169,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3976424,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.0,0.7879133
385,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL31965,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,7.0,0.9257673
1075,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL941,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,30.0,0.78264946
29,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.9652915
1258,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL315546,415658,Active,inhibition of fgfr1 in mouse nih/3t3 cells assessed as inhibition of acidic fgf stimulated erk1 phosphorylation by immunoblotting,13.5,0.20501342
1256,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL315546,415655,Active,inhibition of acidic fgf stimulated fgfr1 tyrosine autophosphorylation in mouse nih/3t3 cells by immunoblotting,13.5,0.20501342
1701,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3952638,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.0,0.7879133
44,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL553,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,1.0,0.9919458
304,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3913492,1340075,Active,inhibition of fgfr1  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay,1.5,0.9628973
1930,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL101253,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,84.0,0.7393109
125,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3401361,1193339,Active,inhibition of fgfr1  unknown origin after 90 mins by tr fret assay,1.0,0.87308085
31,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344881,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.9652915
2097,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL10,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,19.0,0.57717496
1261,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL315546,1431254,Active,inhibition of fgf induced fgfr1 autophosphorylation in mouse nih 3t3 cells preincubated for 5 mins followed by fgf stimulation for 5 mins in presence of [gamma 32p]atp by sds page based autoradiography,13.5,0.20501342
2110,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3927229,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.0,0.7879133
1260,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL315546,1431253,Active,inhibition of fgfr1 kinase domain  unknown origin ,13.5,0.20501342
1901,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3948944,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.0,0.7879133
30,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.9652915
1751,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL124660,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um,4.0,0.88172454
1259,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL315546,415659,Active,inhibition of fgfr1 in mouse nih/3t3 cells assessed as inhibition of acidic fgf stimulated erk2 phosphorylation by immunoblotting,13.5,0.20501342
32,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344882,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.9652915
959,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3914013,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.0,0.7879133
308,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.84556895
309,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3941999,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.84556895
307,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.84556895
422,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3701266,1259179,Active,inhibition assay: when setting conditions for the measurement of the inhibitory effect of the compounds on fgfr2 kinase activity fl peptide 22  caliper life sciences inc was used as a substrate the purified recombinant human fgfr2 protein used in the test was purchased from carna biosciences inc in the measurement of the inhibitory effect of the compounds first a test compound was gradually diluted with dimethylsulfoxide  dmso to a concentration that was 20 times higher than the final concentration next the purified human fgfr2 protein fl peptide 22  final concentration: 1 5  mu m magnesium chloride  final concentration: 5 mm atp  final concentration: 75  mu m and the test compound dmso solution  final concentration of dmso: 5% were added to a reaction buffer  15 mm tris hcl ph 7 5 0 01% tween 20 2 mm dtt and the mixture was incubated at 25 degree c for 120 minutes to perform a kinase reaction edta  final concentration: 30 mm diluted with a separation buffer,1.0,0.9325546
876,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL4092990,1431256,Active,inhibition of fgfr2  unknown origin ,1.0,0.9325546
423,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3701266,1259179,Active,inhibition assay: when setting conditions for the measurement of the inhibitory effect of the compounds on fgfr2 kinase activity fl peptide 22  caliper life sciences inc was used as a substrate the purified recombinant human fgfr2 protein used in the test was purchased from carna biosciences inc in the measurement of the inhibitory effect of the compounds first a test compound was gradually diluted with dimethylsulfoxide  dmso to a concentration that was 20 times higher than the final concentration next the purified human fgfr2 protein fl peptide 22  final concentration: 1 5  mu m magnesium chloride  final concentration: 5 mm atp  final concentration: 75  mu m and the test compound dmso solution  final concentration of dmso: 5% were added to a reaction buffer  15 mm tris hcl ph 7 5 0 01% tween 20 2 mm dtt and the mixture was incubated at 25 degree c for 120 minutes to perform a kinase reaction edta  final concentration: 30 mm diluted with a separation buffer,1.0,0.9325546
439,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3686884,1258477,Active,adp glo kinase assay: in this assay the inhibitory activity of a test substance against the tyrosine kinase activity of fgfr2 protein is measured to each well of a flat bottom 96 well white plate  sumitomo bakelite co ltd ms 8496w 10 ul of fgfr2 protein  cama biosciences inc 08434 solution diluted to 1 ug/ml with an assay buffer  20 mm hepes naoh 0 01% triton x 100 2 mm dtt and 5 mm mgcl2 10 ul of an assay buffer solution containing csk tide substrate  ana spec inc 63843 in a final concentration of 1000 nm and atp  promega corporation v9102 in a final concentration of 35 um and 5 ul of a test substance diluted with the assay buffer were added and the reaction was performed at room temperature for 1 hour  kinase reaction for measuring kinase activity adp glo kinase assay  promega corporation v9102 was used after the reaction 25 ul of adp glo reagent was added to each well of the plate and the reaction was performed at room temperature for 40 minutes ,36.0,0.9325546
415,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3701274,1259179,Active,inhibition assay: when setting conditions for the measurement of the inhibitory effect of the compounds on fgfr2 kinase activity fl peptide 22  caliper life sciences inc was used as a substrate the purified recombinant human fgfr2 protein used in the test was purchased from carna biosciences inc in the measurement of the inhibitory effect of the compounds first a test compound was gradually diluted with dimethylsulfoxide  dmso to a concentration that was 20 times higher than the final concentration next the purified human fgfr2 protein fl peptide 22  final concentration: 1 5  mu m magnesium chloride  final concentration: 5 mm atp  final concentration: 75  mu m and the test compound dmso solution  final concentration of dmso: 5% were added to a reaction buffer  15 mm tris hcl ph 7 5 0 01% tween 20 2 mm dtt and the mixture was incubated at 25 degree c for 120 minutes to perform a kinase reaction edta  final concentration: 30 mm diluted with a separation buffer,1.0,0.9325546
414,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3701274,1259179,Active,inhibition assay: when setting conditions for the measurement of the inhibitory effect of the compounds on fgfr2 kinase activity fl peptide 22  caliper life sciences inc was used as a substrate the purified recombinant human fgfr2 protein used in the test was purchased from carna biosciences inc in the measurement of the inhibitory effect of the compounds first a test compound was gradually diluted with dimethylsulfoxide  dmso to a concentration that was 20 times higher than the final concentration next the purified human fgfr2 protein fl peptide 22  final concentration: 1 5  mu m magnesium chloride  final concentration: 5 mm atp  final concentration: 75  mu m and the test compound dmso solution  final concentration of dmso: 5% were added to a reaction buffer  15 mm tris hcl ph 7 5 0 01% tween 20 2 mm dtt and the mixture was incubated at 25 degree c for 120 minutes to perform a kinase reaction edta  final concentration: 30 mm diluted with a separation buffer,1.0,0.9325546
1397,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3982659,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.84556895
1398,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3982659,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.84556895
877,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL4092990,1431284,Active,inhibition of fgfr2 v564m mutant  unknown origin ,1.0,0.9325546
440,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3686884,1258477,Active,adp glo kinase assay: in this assay the inhibitory activity of a test substance against the tyrosine kinase activity of fgfr2 protein is measured to each well of a flat bottom 96 well white plate  sumitomo bakelite co ltd ms 8496w 10 ul of fgfr2 protein  cama biosciences inc 08434 solution diluted to 1 ug/ml with an assay buffer  20 mm hepes naoh 0 01% triton x 100 2 mm dtt and 5 mm mgcl2 10 ul of an assay buffer solution containing csk tide substrate  ana spec inc 63843 in a final concentration of 1000 nm and atp  promega corporation v9102 in a final concentration of 35 um and 5 ul of a test substance diluted with the assay buffer were added and the reaction was performed at room temperature for 1 hour  kinase reaction for measuring kinase activity adp glo kinase assay  promega corporation v9102 was used after the reaction 25 ul of adp glo reagent was added to each well of the plate and the reaction was performed at room temperature for 40 minutes ,36.0,0.9325546
1320,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3927229,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.5,0.75484604
750,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3948944,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.5,0.75484604
225,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL103667,256654,Inactive,average binding constant for fgfr2 nanot active at 10 um,42.0,0.91146266
1105,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3900101,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.84556895
226,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL103667,636437,Active,inhibition of fgfr2,42.0,0.91146266
1036,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL1725279,256654,Inactive,average binding constant for fgfr2 nanot active at 10 um,158.0,0.8483103
2018,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3911943,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.5,0.75484604
1275,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3957409,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.37006506
774,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3952638,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.5,0.75484604
1104,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3900101,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.84556895
1274,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3957409,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.37006506
1498,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3944659,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.75484604
1387,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL428690,256624,Inactive,average binding constant for fgfr3 nanot active at 10 um,168.0,0.72137403
738,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL553,256624,Inactive,average binding constant for fgfr3 nanot active at 10 um,29.5,0.96236545
727,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3941999,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.8770028
24,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3401368,1193341,Active,inhibition of fgfr3  unknown origin after 90 mins by tr fret assay,146.5,0.9181553
11,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3948944,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.5,0.7708096
726,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.8770028
725,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.8770028
274,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3401364,1193341,Active,inhibition of fgfr3  unknown origin after 90 mins by tr fret assay,85.5,0.9181553
111,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL103667,256624,Inactive,average binding constant for fgfr3 nanot active at 10 um,67.5,0.96399224
405,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL31965,256624,Inactive,average binding constant for fgfr3 nanot active at 10 um,28.0,0.7176989
1722,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL91829,256624,Inactive,average binding constant for fgfr3 nanot active at 10 um,44.5,0.758765
1047,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3911943,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.5,0.7708096
874,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3900101,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.8770028
875,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3900101,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.8770028
556,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3982659,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.8770028
555,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3982659,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.8770028
551,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3401370,1193341,Active,inhibition of fgfr3  unknown origin after 90 mins by tr fret assay,82.5,0.9181553
10,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3787112,1291012,Active,inhibition of fgfr3 k650e mutant  unknown origin in presence of [gamma33p]atp,18.5,0.9184703
1021,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3927229,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,2.5,0.7708096
1850,CHEMBL3973,Fibroblast growth factor receptor 4,CHEMBL3961994,1344881,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.82585174
1851,CHEMBL3973,Fibroblast growth factor receptor 4,CHEMBL3961994,1344882,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.82585174
1849,CHEMBL3973,Fibroblast growth factor receptor 4,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.82585174
1848,CHEMBL3973,Fibroblast growth factor receptor 4,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat,1.5,0.82585174
1638,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1336,1299346,Inactive,inhibition of fak  unknown origin ,10.5,0.7043846
1500,CHEMBL2695,Focal adhesion kinase 1,CHEMBL24828,256640,Inactive,average binding constant for ptk2 nanot active at 10 um,3.0,0.7491347
1637,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1336,256640,Inactive,average binding constant for ptk2 nanot active at 10 um,10.5,0.7043846
1940,CHEMBL2695,Focal adhesion kinase 1,CHEMBL124660,256640,Inactive,average binding constant for ptk2 nanot active at 10 um,47.5,0.52466166
1956,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1421,375148,Active,inhibition of csrc in human pc3 cells assessed as reduction of phosphorylated fak y576/y577 level at 100 nm after 5 hrs by immunoblot,39.0,0.73268384
1957,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1421,375150,Active,inhibition of csrc in human du145 cells assessed as reduction of phosphorylated fak y576/y577 level at 100 nm after 5 hrs by immunoblot,39.0,0.73268384
1958,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1421,1206299,Active,inhibition of src in human mda mb 231 cells assessed as reduction of fak phosphorylation at >0 03 um after 20 hrs by western blot analysis,39.0,0.73268384
1959,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1421,1310136,Active,inhibition of fak phosphorylation at tyrosine 861 in human mda mb 231 cells at 3 to 100 nm preincubated for 1 5 hrs followed by serum stimulation for 1 hr by western blot analysis,39.0,0.73268384
1900,CHEMBL2695,Focal adhesion kinase 1,CHEMBL31965,256640,Inactive,average binding constant for ptk2 nanot active at 10 um,28.0,0.71942335
900,CHEMBL2695,Focal adhesion kinase 1,CHEMBL119385,256640,Inactive,average binding constant for ptk2 nanot active at 10 um,110.5,0.29521984
712,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL477772,1117355,Inactive,human gsk3b kinase inhibition screen,7.0,0.8346977
1867,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL553,1117336,Active,gsk3b pretreated hct116 viability from cell titerglo screen,59.0,0.81358606
1227,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL24828,1117336,Inactive,gsk3b pretreated hct116 viability from cell titerglo screen,75.0,0.8792728
869,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL1421,1117355,Inactive,human gsk3b kinase inhibition screen,54.5,0.81409585
868,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL1421,1117336,Inactive,gsk3b pretreated hct116 viability from cell titerglo screen,54.5,0.81409585
1869,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL31965,1117336,Active,gsk3b pretreated hct116 viability from cell titerglo screen,63.0,0.8082013
1870,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL31965,1117355,Inactive,human gsk3b kinase inhibition screen,63.0,0.8082013
1830,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL1289926,1117355,Inactive,human gsk3b kinase inhibition screen,42.0,0.84259385
1829,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL1289926,1117336,Inactive,gsk3b pretreated hct116 viability from cell titerglo screen,42.0,0.84259385
711,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL477772,1117336,Inactive,gsk3b pretreated hct116 viability from cell titerglo screen,7.0,0.8346977
1655,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL2002702,1117355,Inactive,human gsk3b kinase inhibition screen,6.5,0.8719765
1654,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL2002702,1117336,Inactive,gsk3b pretreated hct116 viability from cell titerglo screen,6.5,0.8719765
1640,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL124660,1117336,Active,gsk3b pretreated hct116 viability from cell titerglo screen,118.0,0.647374
2060,CHEMBL240,HERG,CHEMBL1201203,588834,Active,qhts assay for small molecule inhibitors of the human herg channel activity,9.0,0.54925054
2059,CHEMBL240,HERG,CHEMBL1201203,588834,Active,qhts assay for small molecule inhibitors of the human herg channel activity,9.0,0.54925054
1987,CHEMBL240,HERG,CHEMBL411,624246,Inactive,qhts for small molecule inhibitors of the erg ets/dna interaction,16.5,0.53189224
1986,CHEMBL240,HERG,CHEMBL411,1511,Inactive,primary cell based high throughput screening assay for identification of compounds that protect herg from block by proarrhythmic agents,16.5,0.53189224
2118,CHEMBL240,HERG,CHEMBL128,588834,Inactive,qhts assay for small molecule inhibitors of the human herg channel activity,49.0,0.26916113
2119,CHEMBL240,HERG,CHEMBL128,624246,Inactive,qhts for small molecule inhibitors of the erg ets/dna interaction,49.0,0.26916113
2117,CHEMBL240,HERG,CHEMBL128,1511,Inactive,primary cell based high throughput screening assay for identification of compounds that protect herg from block by proarrhythmic agents,49.0,0.26916113
1574,CHEMBL3717,Hepatocyte growth factor receptor,CHEMBL270754,326763,Active,inhibition of c met,1.5,0.2957809
998,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1343568,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,100.0,0.27656975
773,CHEMBL2093865,Histone deacetylase,CHEMBL227119,291047,Active,inhibition of his tagged hdac1 expressed in sf9 cells by fluorescence based assay,1.0,0.3548927
2146,CHEMBL2093865,Histone deacetylase,CHEMBL3923995,1343568,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,1.0,0.27656975
972,CHEMBL2093865,Histone deacetylase,CHEMBL3287256,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,3.0,0.27656975
971,CHEMBL2093865,Histone deacetylase,CHEMBL3287256,1156054,Active,inhibition of recombinant human hdac1 using ac lys tyr lys epsilon acetyl  amc as substrate after 24 hrs by fluorescence assay,3.0,0.27656975
670,CHEMBL2093865,Histone deacetylase,CHEMBL3655920,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.34368488
671,CHEMBL2093865,Histone deacetylase,CHEMBL3655920,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.34368488
672,CHEMBL2093865,Histone deacetylase,CHEMBL3655920,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.34368488
1195,CHEMBL2093865,Histone deacetylase,CHEMBL3104855,1063056,Active,inhibition of recombinant hdac1  unknown origin using fluor de lys sirt1 as substrate by fluorescence assay,1.0,0.41612846
954,CHEMBL2093865,Histone deacetylase,CHEMBL3981567,1343403,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,37.0,0.31073686
953,CHEMBL2093865,Histone deacetylase,CHEMBL3981567,1343401,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,37.0,0.31073686
952,CHEMBL2093865,Histone deacetylase,CHEMBL3981567,1343397,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,37.0,0.31073686
2145,CHEMBL2093865,Histone deacetylase,CHEMBL3923995,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,1.0,0.27656975
736,CHEMBL2093865,Histone deacetylase,CHEMBL3916028,1343946,Active,hdac enzyme assay: the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature for 10 minutes five u1 of substrate was added to each well the plate was shaken for 60 seconds and placed into a victor 2 microtiter plate reader the devel,14.0,0.34368488
735,CHEMBL2093865,Histone deacetylase,CHEMBL3916028,1343945,Active,hdac enzyme assay: the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature for 10 minutes five u1 of substrate was added to each well the plate was shaken for 60 seconds and placed into a victor 2 microtiter plate reader the devel,14.0,0.34368488
734,CHEMBL2093865,Histone deacetylase,CHEMBL3916028,1343944,Active,hdac enzyme assay: the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature for 10 minutes five u1 of substrate was added to each well the plate was shaken for 60 seconds and placed into a victor 2 microtiter plate reader the devel,14.0,0.34368488
733,CHEMBL2093865,Histone deacetylase,CHEMBL3916028,1343943,Active,hdac enzyme assay: the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature for 10 minutes five u1 of substrate was added to each well the plate was shaken for 60 seconds and placed into a victor 2 microtiter plate reader the devel,14.0,0.34368488
673,CHEMBL2093865,Histone deacetylase,CHEMBL3655920,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.34368488
688,CHEMBL2093865,Histone deacetylase,CHEMBL3601335,1239048,Active,inhibition of recombinant his6 tagged gst fused human hdac1 expressed in baculovirus infected insect high5 cells using ac lys tyr lys epsilon acetyl  amc as substrate after 24 hrs,3.0,0.27656975
1894,CHEMBL2093865,Histone deacetylase,CHEMBL4061025,1454734,Active,inhibition of human hdac1 expressed in human 293t cells preincubated for 15 mins in presence of [3h]acetyl labeled histones measured after 30 mins by liquid scintillation counter method,3.0,0.2845402
2069,CHEMBL2093865,Histone deacetylase,CHEMBL486324,348792,Active,inhibition of human recombinant c terminally flag tagged hdac1,12.0,0.27656975
995,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1156054,Active,inhibition of recombinant human hdac1 using ac lys tyr lys epsilon acetyl  amc as substrate after 24 hrs by fluorescence assay,100.0,0.27656975
996,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,100.0,0.27656975
997,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,100.0,0.27656975
1429,CHEMBL2093865,Histone deacetylase,CHEMBL4063938,1469139,Active,inhibition of full length recombinant human c terminal flag/his tagged hdac1 expressed in baculovirus expression system using boc lys acetyl  amc as substrate preincubated for 1 hr followed by substrate addition measured after 2 hrs by fluorescence assay,5.0,0.2615219
2144,CHEMBL2093865,Histone deacetylase,CHEMBL3923995,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,1.0,0.27656975
1875,CHEMBL2093865,Histone deacetylase,CHEMBL2442696,780588,Active,inhibition of human recombinant hdac1 expressed in baculovirus infected insect high5 cells using ac lys tyr lys  epsilon acetyl  amc as substrate after 3 to 24 hrs by fluorescence assay,6.0,0.27656975
805,CHEMBL2093865,Histone deacetylase,CHEMBL3287253,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,3.0,0.27656975
1168,CHEMBL2093865,Histone deacetylase,CHEMBL3339017,1166496,Active,inhibition of human recombinant full length hdac1 using  ac  lys tyr lys  acetyl  amc substrate after 30 mins,3.5,0.27656975
1430,CHEMBL2093865,Histone deacetylase,CHEMBL4063938,1469171,Active,inhibition of hdac1 in human mv4 11 cells assessed as increase in acetylated histone h3 level at 0 25 to 2 um after 24 hrs by western blot analysis,5.0,0.2615219
806,CHEMBL2093865,Histone deacetylase,CHEMBL3287253,1343568,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,3.0,0.27656975
1628,CHEMBL2093865,Histone deacetylase,CHEMBL3585965,1231807,Active,inhibition of recombinant hdac1  unknown origin incubated for 10 mins using boc lys acetyl  amc fluorogenic substrate by homogeneous fluorescence release assay,1.0,0.2615219
804,CHEMBL2093865,Histone deacetylase,CHEMBL3287253,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,3.0,0.27656975
974,CHEMBL2093865,Histone deacetylase,CHEMBL3287256,1343568,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,3.0,0.27656975
1431,CHEMBL2093865,Histone deacetylase,CHEMBL4063938,1469174,Active,inhibition of hdac1 in human mv4 11 cells assessed as increase in acetylated histone h4 level at 0 25 to 2 um after 24 hrs by western blot analysis,5.0,0.2615219
803,CHEMBL2093865,Histone deacetylase,CHEMBL3287253,1156054,Active,inhibition of recombinant human hdac1 using ac lys tyr lys epsilon acetyl  amc as substrate after 24 hrs by fluorescence assay,3.0,0.27656975
1432,CHEMBL2093865,Histone deacetylase,CHEMBL4063938,1469193,Inactive,downregulation of hdac1 protein expression in human pc3 cells at 1 to 2 um after 24 hrs by western blot method,5.0,0.2615219
973,CHEMBL2093865,Histone deacetylase,CHEMBL3287256,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,3.0,0.27656975
1433,CHEMBL2093865,Histone deacetylase,CHEMBL4063938,1469194,Inactive,downregulation of hdac1 protein expression in human mv4 11 cells at 1 to 2 um after 24 hrs by western blot method,5.0,0.2615219
1135,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,2.0,0.64965516
985,CHEMBL325,Histone deacetylase 1,CHEMBL506834,1263052,Active,inhibition of recombinant hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins using trichostatin a by label free mass spectrometry based samdi assay,1.0,0.8428216
951,CHEMBL325,Histone deacetylase 1,CHEMBL4099064,1472133,Active,inhibition of recombinant human full length c terminal flag tagged hdac1 expressed in fall armyworm sf9 cells using fluorogenic zmal as substrate after 90 mins by fluorimetric analysis,1.0,0.8428216
1140,CHEMBL325,Histone deacetylase 1,CHEMBL481131,343687,Active,inhibition of recombinant hdac1 expressed in hek293 cells,1.0,0.72214764
408,CHEMBL325,Histone deacetylase 1,CHEMBL2178342,711159,Active,inhibition of hdac1 by fluorometric assay,30.0,0.8428216
314,CHEMBL325,Histone deacetylase 1,CHEMBL3110015,1065629,Active,inhibition of human recombinant full length hdac1 using  ac arg gly lys ac as substrate after 60 mins by fluorescence assay,1.5,0.9844917
521,CHEMBL325,Histone deacetylase 1,CHEMBL3640656,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,1.5,0.64965516
312,CHEMBL325,Histone deacetylase 1,CHEMBL2046613,670970,Active,inhibition of human recombinant his6 tagged and gst fuses hdac1 expressed in insect high5 cells using ac lys tyr lys e acetyl  amc as substrate after 24 hrs by fluorescence assay,1.0,0.96543264
1134,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,2.0,0.64965516
315,CHEMBL325,Histone deacetylase 1,CHEMBL3110015,1293433,Active,inhibition of hdac1  unknown origin using boc lys ac  amc as substrate,1.5,0.9844917
39,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343405,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,45.0,0.9752874
1903,CHEMBL325,Histone deacetylase 1,CHEMBL406800,316892,Inactive,inhibition of hdac1,29.5,0.55136085
38,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343403,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,45.0,0.9752874
871,CHEMBL325,Histone deacetylase 1,CHEMBL3693757,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,3.0,0.64965516
522,CHEMBL325,Histone deacetylase 1,CHEMBL3640656,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,1.5,0.64965516
1594,CHEMBL325,Histone deacetylase 1,CHEMBL2337864,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control,6.0,0.8428216
1592,CHEMBL325,Histone deacetylase 1,CHEMBL3693734,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,2.5,0.64965516
1593,CHEMBL325,Histone deacetylase 1,CHEMBL3693734,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,2.5,0.64965516
1520,CHEMBL325,Histone deacetylase 1,CHEMBL3692675,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control ,1.0,0.64965516
41,CHEMBL325,Histone deacetylase 1,CHEMBL564916,434540,Active,inhibition of human hdac1 by fluorimetry,2.0,0.984487
1111,CHEMBL325,Histone deacetylase 1,CHEMBL1934895,637888,Active,inhibition of recombinant human hdac1 using boc l lys acetyl  mca as substrate by fluorogenic enzymatic assay,1.5,0.64965516
1110,CHEMBL325,Histone deacetylase 1,CHEMBL3798925,1296348,Active,inhibition of recombinant human hdac1 using cbz  ac lys amc as substrate preincubated for 90 mins followed by trypsin addition measured after 20 mins by fluorescence assay,1.0,0.8428216
2096,CHEMBL325,Histone deacetylase 1,CHEMBL482094,343687,Active,inhibition of recombinant hdac1 expressed in hek293 cells,1.0,0.72214764
1513,CHEMBL325,Histone deacetylase 1,CHEMBL455735,1263052,Active,inhibition of recombinant hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins using trichostatin a by label free mass spectrometry based samdi assay,1.0,0.8428216
273,CHEMBL325,Histone deacetylase 1,CHEMBL3589699,1233250,Inactive,inhibition of human recombinant hdac1 after 15 mins by fluorogenic assay,1.0,0.65283895
550,CHEMBL325,Histone deacetylase 1,CHEMBL2337872,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control,29.5,0.8428216
969,CHEMBL325,Histone deacetylase 1,CHEMBL3692614,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control ,1.0,0.64965516
36,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343397,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,45.0,0.9752874
1132,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,2.0,0.64965516
37,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343401,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,45.0,0.9752874
968,CHEMBL325,Histone deacetylase 1,CHEMBL3692614,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control ,1.0,0.64965516
1133,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,2.0,0.64965516
1955,CHEMBL325,Histone deacetylase 1,CHEMBL2018443,655909,Active,inhibition of human recombinant hdac1 using rhkkac peptide as substrate incubated for 5 to mins prior to substrate addition measured after 2 hrs,1.0,0.64965516
957,CHEMBL325,Histone deacetylase 1,CHEMBL1214759,499814,Active,inhibition of plasmodium falciparum hdac1,1.0,0.8753446
986,CHEMBL325,Histone deacetylase 1,CHEMBL506834,1371037,Active,inhibition of recombinant plasmodium falciparum hdac1 using hdac substrate 3 after 30 mins by fluorescence assay,1.0,0.8428216
40,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343406,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,45.0,0.9752874
1720,CHEMBL325,Histone deacetylase 1,CHEMBL3693758,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,3.0,0.64965516
872,CHEMBL325,Histone deacetylase 1,CHEMBL3693757,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,3.0,0.64965516
1825,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,5.0,0.8428216
1241,CHEMBL325,Histone deacetylase 1,CHEMBL3797516,1296348,Active,inhibition of recombinant human hdac1 using cbz  ac lys amc as substrate preincubated for 90 mins followed by trypsin addition measured after 20 mins by fluorescence assay,8.0,0.8428216
1098,CHEMBL325,Histone deacetylase 1,CHEMBL4101727,1472115,Inactive,inhibition of hdac1 in human be 2  c cells assessed as effect on histone h3 acetylation at 10 um after 6 hrs by western blot analysis,1.0,0.8428216
1884,CHEMBL325,Histone deacetylase 1,CHEMBL3693727,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,2.0,0.64965516
1242,CHEMBL325,Histone deacetylase 1,CHEMBL3797516,1472115,Inactive,inhibition of hdac1 in human be 2  c cells assessed as effect on histone h3 acetylation at 10 um after 6 hrs by western blot analysis,8.0,0.8428216
2055,CHEMBL325,Histone deacetylase 1,CHEMBL3769415,1280259,Active,inhibition of human hdac1 using  z  ac lys amc as substrate after 90 mins by fluorescence analysis,5.0,0.64965516
1094,CHEMBL325,Histone deacetylase 1,CHEMBL3415448,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,1.0,0.8428216
1095,CHEMBL325,Histone deacetylase 1,CHEMBL3415448,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,1.0,0.8428216
1096,CHEMBL325,Histone deacetylase 1,CHEMBL3415448,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,1.0,0.8428216
1099,CHEMBL325,Histone deacetylase 1,CHEMBL4101727,1472133,Active,inhibition of recombinant human full length c terminal flag tagged hdac1 expressed in fall armyworm sf9 cells using fluorogenic zmal as substrate after 90 mins by fluorimetric analysis,1.0,0.8428216
1255,CHEMBL325,Histone deacetylase 1,CHEMBL264411,324899,Active,inhibition of flag tagged hdac1 expressed in human 293t cells,1.0,0.64965516
1254,CHEMBL325,Histone deacetylase 1,CHEMBL264411,324895,Active,inhibition of hdac1 in rat liver extract,1.0,0.64965516
758,CHEMBL325,Histone deacetylase 1,CHEMBL2431901,772647,Active,inhibition of full length gst tagged recombinant human hdac1 expressed in baculovirus using arg his lys lys  ac as substrate after 1 hr by fluorescence plate reader analysis,6.0,0.8428216
759,CHEMBL325,Histone deacetylase 1,CHEMBL2431901,1173499,Active,inhibition of full length gst tagged human hdac1 using arg his lys lys ac substrate incubated for 2 hrs by fluorescence assay,6.0,0.8428216
760,CHEMBL325,Histone deacetylase 1,CHEMBL3943331,1344598,Active,inhibition assay: hdac inhibition assays were performed by reaction biology corp  malvern pa using isolated human recombinant full length hdac1 and  6 from a baculovirus expression system in sf9 cells an acetylated fluorogenic peptide rhkkac derived from residues 379 382 of p53 was used as substrate the reaction buffer was made up of 50 mm tris hcl ph 8 0 127 mm nacl 2 7 mm kcl 1 mm mgcl2 1 mg/ml bsa and a final concentration of 1% dmso compounds were delivered in dmso and delivered to enzyme mixture with preincubation of 5 10 min followed by substrate addition and incubation for 2 h at 30 xb0 c trichostatin a and developer were added to quench the reaction and generate fluorescence respectively dose response curves were generated starting at 30  x3bc m compound with three fold serial dilutions to generate a 10 dose plot ,1.0,0.64965516
761,CHEMBL325,Histone deacetylase 1,CHEMBL3943331,1344599,Active,inhibition assay: hdac inhibition assays were performed by reaction biology corp  malvern pa using isolated human recombinant full length hdac1 and  6 from a baculovirus expression system in sf9 cells an acetylated fluorogenic peptide rhkkac derived from residues 379 382 of p53 was used as substrate the reaction buffer was made up of 50 mm tris hcl ph 8 0 127 mm nacl 2 7 mm kcl 1 mm mgcl2 1 mg/ml bsa and a final concentration of 1% dmso compounds were delivered in dmso and delivered to enzyme mixture with preincubation of 5 10 min followed by substrate addition and incubation for 2 h at 30 xb0 c trichostatin a and developer were added to quench the reaction and generate fluorescence respectively dose response curves were generated starting at 30  x3bc m compound with three fold serial dilutions to generate a 10 dose plot ,1.0,0.64965516
1721,CHEMBL325,Histone deacetylase 1,CHEMBL3693758,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,3.0,0.64965516
1794,CHEMBL325,Histone deacetylase 1,CHEMBL1214763,499814,Active,inhibition of plasmodium falciparum hdac1,1.0,0.8753446
770,CHEMBL325,Histone deacetylase 1,CHEMBL3793392,1293433,Active,inhibition of hdac1  unknown origin using boc lys ac  amc as substrate,2.5,0.8428216
856,CHEMBL325,Histone deacetylase 1,CHEMBL3415619,1200971,Active,inhibition of hdac1  unknown origin using rhkk ac amc as substrate,1.0,0.8428216
50,CHEMBL325,Histone deacetylase 1,CHEMBL3981567,1343403,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,41.0,0.9757498
1823,CHEMBL325,Histone deacetylase 1,CHEMBL3617543,1246507,Active,inhibition of hdac1  unknown origin using rhkk ac fluorogenic acetylated peptide substrate by fluorometric assay,25.0,0.8428216
1093,CHEMBL325,Histone deacetylase 1,CHEMBL3415448,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,1.0,0.8428216
1968,CHEMBL325,Histone deacetylase 1,CHEMBL3640694,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,3.5,0.64965516
196,CHEMBL325,Histone deacetylase 1,CHEMBL3338404,1164906,Active,inhibition of hdac1  unknown origin using fluorogenic peptide as substrate by fluorescence assay,22.0,0.9844917
48,CHEMBL325,Histone deacetylase 1,CHEMBL3981567,1343397,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,41.0,0.9757498
395,CHEMBL325,Histone deacetylase 1,CHEMBL2337867,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control,14.0,0.8428216
1824,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,5.0,0.8428216
713,CHEMBL325,Histone deacetylase 1,CHEMBL3235790,1127323,Active,inhibition of human hdac1 using fluorogenic tetrapeptide rhkkac as substrate,6.0,0.8428216
910,CHEMBL325,Histone deacetylase 1,CHEMBL263884,324899,Active,inhibition of flag tagged hdac1 expressed in human 293t cells,1.0,0.64965516
909,CHEMBL325,Histone deacetylase 1,CHEMBL263884,324897,Active,inhibition of hdac1 in rat liver extract by trypsin assay,1.0,0.64965516
1243,CHEMBL325,Histone deacetylase 1,CHEMBL3797516,1472133,Active,inhibition of recombinant human full length c terminal flag tagged hdac1 expressed in fall armyworm sf9 cells using fluorogenic zmal as substrate after 90 mins by fluorimetric analysis,8.0,0.8428216
49,CHEMBL325,Histone deacetylase 1,CHEMBL3981567,1343401,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages ,41.0,0.9757498
1828,CHEMBL325,Histone deacetylase 1,CHEMBL2337875,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control,12.0,0.8428216
1969,CHEMBL325,Histone deacetylase 1,CHEMBL3640694,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,3.5,0.64965516
1827,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,5.0,0.8428216
1885,CHEMBL325,Histone deacetylase 1,CHEMBL3693727,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,2.0,0.64965516
1826,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275,5.0,0.8428216
1945,CHEMBL1937,Histone deacetylase 2,CHEMBL1095710,480050,Active,inhibition of human recombinant hdac2,2.0,0.65161073
879,CHEMBL1937,Histone deacetylase 2,CHEMBL1095719,480050,Active,inhibition of human recombinant hdac2,1.5,0.65161073
846,CHEMBL1937,Histone deacetylase 2,CHEMBL4104117,1473145,Active,inhibition of full length recombinant human c terminal gst tagged hdac2 expressed in baculovirus infected insect cells using rhk k ac  amc as substrate after 60 mins by fluorescence assay,1.0,0.65161073
1853,CHEMBL1937,Histone deacetylase 2,CHEMBL470843,417645,Active,inhibition of human hdac2,1.0,0.82534087
1852,CHEMBL1937,Histone deacetylase 2,CHEMBL3356934,1164781,Active,inhibition of hdac2  unknown origin using fluorogenic tetrapeptide rhkk ac substrate by fluorescence assay,1.0,0.82534087
2166,CHEMBL1829,Histone deacetylase 3,CHEMBL2431901,772646,Active,inhibition of full length c terminal his6x tagged recombinant human hdac3 expressed in baculovirus using arg his lys lys  ac as substrate after 1 hr by fluorescence plate reader analysis,1.0,0.48717993
1610,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
1116,CHEMBL1829,Histone deacetylase 3,CHEMBL3917405,1337216,Active,inhibition of full length human recombinant c terminal his tagged hdac3  1 to 428 residues /n terminal gst tagged ncor2  395 to 489 residues expressed in insect cells preincubated with enzyme followed by fluorogenic arg his lys lys ac  amc substrate addition measured after 2 hrs by fluorescence assay,15.5,0.8351714
796,CHEMBL1829,Histone deacetylase 3,CHEMBL3655949,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
794,CHEMBL1829,Histone deacetylase 3,CHEMBL3655949,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
793,CHEMBL1829,Histone deacetylase 3,CHEMBL3655949,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
1115,CHEMBL1829,Histone deacetylase 3,CHEMBL3917405,1337216,Active,inhibition of full length human recombinant c terminal his tagged hdac3  1 to 428 residues /n terminal gst tagged ncor2  395 to 489 residues expressed in insect cells preincubated with enzyme followed by fluorogenic arg his lys lys ac  amc substrate addition measured after 2 hrs by fluorescence assay,15.5,0.8351714
1609,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
1608,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
1611,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
795,CHEMBL1829,Histone deacetylase 3,CHEMBL3655949,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature ,1.0,0.7832104
1515,CHEMBL1829,Histone deacetylase 3,CHEMBL2407716,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis,3.5,0.65622425
1182,CHEMBL1829,Histone deacetylase 3,CHEMBL3793310,1293565,Active,inhibition of full length human recombinant c terminal his tagged hdac3  1 to 428 residues /human recombinant n terminal gst tagged ncor2  395 to 489 residues expressed in insect cells using rhk k ac  amc as substrate incubated for 60 mins by fluorescence assay,1.5,0.844473
2116,CHEMBL1829,Histone deacetylase 3,CHEMBL3693708,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,2.5,0.32551724
1319,CHEMBL1829,Histone deacetylase 3,CHEMBL2407718,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis,3.0,0.678584
1474,CHEMBL1829,Histone deacetylase 3,CHEMBL343448,1250642,Active,inhibition of recombinant human hdac3 after 60 mins by fluorescence assay,3.5,0.7832104
1473,CHEMBL1829,Histone deacetylase 3,CHEMBL343448,1188979,Active,inhibition of hdac3  unknown origin incubated for 30 mins in presence of bsa and dtt by fluorescence assay,3.5,0.7832104
1060,CHEMBL1829,Histone deacetylase 3,CHEMBL4060201,1476139,Active,inhibition of human recombinant hdac3  1 to 428 residues /n terminal gst tagged ncor2  395 to 489 residues expressed in baculovirus infected insect cells in presence of atp,4.0,0.8351714
1183,CHEMBL1829,Histone deacetylase 3,CHEMBL3793310,1293565,Active,inhibition of full length human recombinant c terminal his tagged hdac3  1 to 428 residues /human recombinant n terminal gst tagged ncor2  395 to 489 residues expressed in insect cells using rhk k ac  amc as substrate incubated for 60 mins by fluorescence assay,1.5,0.844473
2115,CHEMBL1829,Histone deacetylase 3,CHEMBL3693708,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 ,2.5,0.32551724
1059,CHEMBL1829,Histone deacetylase 3,CHEMBL4060201,1476139,Active,inhibition of human recombinant hdac3  1 to 428 residues /n terminal gst tagged ncor2  395 to 489 residues expressed in baculovirus infected insect cells in presence of atp,4.0,0.8351714
1351,CHEMBL1829,Histone deacetylase 3,CHEMBL2407723,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis,2.0,0.7556222
1472,CHEMBL1829,Histone deacetylase 3,CHEMBL343448,496803,Active,inhibition of human hdac3,3.5,0.7832104
2167,CHEMBL1829,Histone deacetylase 3,CHEMBL2431901,1173501,Active,inhibition of full length c terminal 6x his tagged human hdac3 using arg his lys lys ac substrate incubated for 2 hrs by fluorescence assay,1.0,0.48717993
1516,CHEMBL1829,Histone deacetylase 3,CHEMBL2407716,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis,3.5,0.65622425
292,CHEMBL1829,Histone deacetylase 3,CHEMBL4063938,1469176,Active,inhibition of hdac3 in human mv4 11 cells assessed as increase in acetylated histone h4 level at 0 25 to 2 um after 24 hrs by western blot analysis,1.0,0.7556222
291,CHEMBL1829,Histone deacetylase 3,CHEMBL4063938,1469173,Active,inhibition of hdac3 in human mv4 11 cells assessed as increase in acetylated histone h3 level at 0 25 to 2 um after 24 hrs by western blot analysis,1.0,0.7556222
1350,CHEMBL1829,Histone deacetylase 3,CHEMBL2407723,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis,2.0,0.7556222
1318,CHEMBL1829,Histone deacetylase 3,CHEMBL2407718,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis,3.0,0.678584
1003,CHEMBL1865,Histone deacetylase 6,CHEMBL3287016,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,1.0,0.77867806
1001,CHEMBL1865,Histone deacetylase 6,CHEMBL3287016,1156059,Inactive,inhibition of recombinant human hdac6 using boc lys epsilon acetyl  amc as substrate at 20 ug/ml after 3 hrs by fluorescence assay,1.0,0.77867806
1264,CHEMBL1865,Histone deacetylase 6,CHEMBL1093041,473174,Active,ex vivo inhibition of human hdac6 in human caco 2 cells by fluorometric cellular activity assay,2.0,0.8156098
684,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1449333,Inactive,inhibition of hdac6 in human cal27cisr cells assessed accumulation of acetylated alpha tubulin at 1 um after 24 hrs by immunoblot analysis,6.0,0.9728462
678,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,607634,Active,inhibition of hdac6 in human hela cells assessed as increase in total lysine acetylation at 0 6 um after 16 hrs by immunofluorescence microscopy,6.0,0.9728462
682,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1401904,Active,inhibition of human recombinant hdac6 using fluor de lys green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay,6.0,0.9728462
681,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1380965,Inactive,inhibition of hdac6 in human hela cells assessed as increase in intracellular acetyl tubulin levels at 1 um after 6 hrs by western blot analysis,6.0,0.9728462
680,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1324233,Active,inhibition of hdac6 in human lncap cells assessed as inhibition of dht induced alpha tubulin deacetylation by measuring increase in alpha tubulin acetylation at 10 um measured after 24 hrs relative to control,6.0,0.9728462
679,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,607635,Inactive,inhibition of hdac6 in human hela cells assessed as increase in alpha tubulin acetylation at 0 6 um after 16 hrs by immunofluorescence microscopy,6.0,0.9728462
677,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,488276,Active,inhibition of hdac6,6.0,0.9728462
676,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,324957,Inactive,inhibition of hdac6 in hek293 cells at 10 um,6.0,0.9728462
811,CHEMBL1865,Histone deacetylase 6,CHEMBL3628323,1254048,Active,inhibition of hdac6  unknown origin incubated for 1 hr by fluor de lys substrate based fluorescence method,1.0,0.7724866
1471,CHEMBL1865,Histone deacetylase 6,CHEMBL3735770,1263145,Active,inhibition of human recombinant hdac6 using boc lys ac  amc as substrate after 30 mins by fluorescence assay,2.0,0.63173026
683,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1449332,Inactive,inhibition of hdac6 in human cal27 cells assessed as accumulation of acetylated alpha tubulin at 1 um after 24 hrs by immunoblot analysis,6.0,0.9728462
1002,CHEMBL1865,Histone deacetylase 6,CHEMBL3287016,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,1.0,0.77867806
1559,CHEMBL1865,Histone deacetylase 6,CHEMBL4105617,1452911,Active,inhibition of hdac6  unknown origin by fluorescence assay,1.0,0.618964
1975,CHEMBL1865,Histone deacetylase 6,CHEMBL3287019,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,1.0,0.77867806
365,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469177,Active,inhibition of hdac6 in human mv4 11 cells assessed as increase in acetylated tubulin level at 0 25 to 2 um after 24 hrs by western blot analysis,2.0,0.91201633
364,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469138,Active,downregulation of hdac6 protein expression in human mv4 11 cells at > 0 5 um after 24 hrs by western blot analysis,2.0,0.91201633
1807,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420643,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 48 hrs by western blot,2.0,0.85264623
1860,CHEMBL1865,Histone deacetylase 6,CHEMBL1093042,473174,Active,ex vivo inhibition of human hdac6 in human caco 2 cells by fluorometric cellular activity assay,2.0,0.8156098
1806,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420642,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 24 hrs by western blot,2.0,0.85264623
1805,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420641,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 48 hrs by western blot,2.0,0.85264623
1804,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420640,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 24 hrs by western blot,2.0,0.85264623
130,CHEMBL1865,Histone deacetylase 6,CHEMBL2170019,700671,Inactive,inhibition of hdac6 in human jurkat cells assessed as increase of acetylated alpha tubulin level at 2 to 20 um after 24 hrs by western blot analysis,2.0,0.926698
366,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469191,Inactive,downregulation of hdac6 protein expression in human pc3 cells at 1 to 2 um after 24 hrs by western blot method,2.0,0.91201633
402,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420642,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 24 hrs by western blot,2.5,0.61328125
403,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420643,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 48 hrs by western blot,2.5,0.61328125
401,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420641,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 48 hrs by western blot,2.5,0.61328125
1974,CHEMBL1865,Histone deacetylase 6,CHEMBL3287019,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity ,1.0,0.77867806
1622,CHEMBL1865,Histone deacetylase 6,CHEMBL1093713,473174,Active,ex vivo inhibition of human hdac6 in human caco 2 cells by fluorometric cellular activity assay,2.0,0.8156098
394,CHEMBL1865,Histone deacetylase 6,CHEMBL1934896,1439777,Active,inhibition of human hdac6 using boc lys ac  amc as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin based fluorescence assay,1.0,0.7724866
398,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420634,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 4 hrs by western blot,2.5,0.61328125
393,CHEMBL1865,Histone deacetylase 6,CHEMBL1934896,637889,Active,inhibition of recombinant human hdac6 using boc l lys acetyl  mca as substrate by fluorogenic enzymatic assay,1.0,0.7724866
1973,CHEMBL1865,Histone deacetylase 6,CHEMBL3287019,1156059,Inactive,inhibition of recombinant human hdac6 using boc lys epsilon acetyl  amc as substrate at 20 ug/ml after 3 hrs by fluorescence assay,1.0,0.77867806
399,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420635,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 4 hrs by western blot,2.5,0.61328125
400,CHEMBL1865,Histone deacetylase 6,CHEMBL538710,420640,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 24 hrs by western blot,2.5,0.61328125
1747,CHEMBL1865,Histone deacetylase 6,CHEMBL498908,1263053,Active,inhibition of recombinant hdac6  unknown origin expressed in escherichia coli bl21 de3 after 60 mins using trichostatin a by label free mass spectrometry based samdi assay,1.5,0.618964
367,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469192,Inactive,inhibition of hdac6 in human pc3 cells assessed as increase in acetylated tubulin level at 1 to 2 um after 24 hrs by western blot method,2.0,0.91201633
1000,CHEMBL3192,Histone deacetylase 8,CHEMBL3415624,1200973,Active,inhibition of hdac8  unknown origin using rhk ac k ac amc as substrate,1.0,0.32413793
1514,CHEMBL3192,Histone deacetylase 8,CHEMBL3352823,1170743,Inactive,inhibition of human recombinant hdac8 using [ac leu gly lys ac  amc substrate incubated for 15 to 30 mins,1.0,0.74353325
1508,CHEMBL3192,Histone deacetylase 8,CHEMBL343448,1254049,Active,inhibition of hdac8  unknown origin incubated for 1 hr by fluor de lys substrate based fluorescence method,3.5,0.6613555
1507,CHEMBL3192,Histone deacetylase 8,CHEMBL343448,765390,Active,inhibition of recombinant human hdac8 enzyme using ac leuglylys  tfa  amc as substrate after 15 to 30 mins,3.5,0.6613555
1506,CHEMBL3192,Histone deacetylase 8,CHEMBL343448,496808,Active,activity of human hdac8,3.5,0.6613555
1464,CHEMBL3192,Histone deacetylase 8,CHEMBL236902,301137,Active,inhibition of recombinant hdac8,3.5,0.6205339
850,CHEMBL1957,Insulin-like growth factor I receptor,CHEMBL180022,1481349,Active,inhibition of tel fused igf1r  unknown origin expressed in mouse baf3 cells assessed as growth inhibition after 72 hrs by celltiter glo assay,4.0,0.6341009
1435,CHEMBL4040,MAP kinase ERK2,CHEMBL14762,325563,Active,inhibition of erk2,2.0,0.22369832
1434,CHEMBL4040,MAP kinase ERK2,CHEMBL14762,126919,Active,inhibition of mitogen activated protein kinase 1  mapk erk2 ,2.0,0.22369832
2113,CHEMBL4040,MAP kinase ERK2,CHEMBL3798762,1296841,Active,inhibition of erk2 activated full length wild type mnk1a  unknown origin using biotin sgsgkrreilsrrpsyr nh2 as substrate after 2 hrs by htrf assay,19.0,0.25564295
62,CHEMBL4204,MAP kinase signal-integrating kinase 2,CHEMBL101253,256576,Inactive,average binding constant for mknk2 nanot active at 10 um,112.0,0.4096947
578,CHEMBL4204,MAP kinase signal-integrating kinase 2,CHEMBL302449,435477,Active,percentage mnk2 activity remaining in the presence of 0 1um inhibitor,24.5,0.86055094
992,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1822792,1345548,Active,human fms related tyrosine kinase 1  type iv rtks: vegf  vascular endothelial growth factor receptor family ,14.0,0.68827486
991,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1822792,1345520,Active,human fms related tyrosine kinase 4  type iv rtks: vegf  vascular endothelial growth factor receptor family ,14.0,0.68827486
1415,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1907944,73628,Active,inhibition of fms like tyrosine kinase receptor  flt 1 kinase activity at a concentration of 2 um of atp,12.0,0.38580438
762,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1084546,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,10.5,0.95985836
129,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345548,Active,human fms related tyrosine kinase 1  type iv rtks: vegf  vascular endothelial growth factor receptor family ,50.0,0.71000546
128,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345520,Active,human fms related tyrosine kinase 4  type iv rtks: vegf  vascular endothelial growth factor receptor family ,50.0,0.71000546
1685,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1784637,601681,Active,inhibition of human fms using poly[glu:tyr] by hotspot assay,7.0,0.75279987
990,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1822792,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,14.0,0.68827486
722,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2403108,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,14.0,0.8411713
127,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,50.0,0.71000546
1639,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1738758,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,34.5,0.25857493
413,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2436978,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,15.0,0.84514815
218,CHEMBL280,Matrix metalloproteinase 13,CHEMBL1801052,604454,Active,inhibition of human mmp13 assessed as cleavage of fluorogenic peptide mcapro leu gly leu dpa ala arg nh2 by fluorometric assay,1.5,0.8467083
1647,CHEMBL280,Matrix metalloproteinase 13,CHEMBL1683453,580296,Active,inhibition of recombinant human mmp13 assessed as substrate cleavage by measuring increase in fluorescence after 16 hrs,1.0,0.71540576
1386,CHEMBL280,Matrix metalloproteinase 13,CHEMBL1078396,464405,Active,inhibition of mmp13,2.0,0.71540576
1997,CHEMBL280,Matrix metalloproteinase 13,CHEMBL497908,397870,Active,inhibition of mmp13 by flipr assay,1.0,0.52421117
231,CHEMBL280,Matrix metalloproteinase 13,CHEMBL460899,346594,Active,inhibition of human recombinant mmp13,1.0,0.4064064
1728,CHEMBL280,Matrix metalloproteinase 13,CHEMBL2048505,670315,Active,inhibition of human recombinant mmp13 catalytic domain incubated for 20 mins by fluorimetric assay,18.0,0.74175644
1136,CHEMBL283,Matrix metalloproteinase 3,CHEMBL452083,362876,Active,inhibition of human recombinant mmp3,1.0,0.818561
1937,CHEMBL283,Matrix metalloproteinase 3,CHEMBL574370,440423,Active,inhibition of trypsin activated human pro mmp3 after 4 hrs by fluorimetry,1.5,0.7670725
464,CHEMBL283,Matrix metalloproteinase 3,CHEMBL1078396,464402,Active,inhibition of mmp3,9.5,0.63624597
748,CHEMBL283,Matrix metalloproteinase 3,CHEMBL584122,440423,Active,inhibition of trypsin activated human pro mmp3 after 4 hrs by fluorimetry,1.0,0.7670725
3,CHEMBL321,Matrix metalloproteinase 9,CHEMBL43147,310906,Active,inhibition of mmp9,1.0,0.8887142
446,CHEMBL321,Matrix metalloproteinase 9,CHEMBL579068,440421,Active,inhibition of para aminophenylmercuric acetate activated human recombinant pro mmp9 catalytic domain after 4 hrs by fluorimetry,1.5,0.85770524
1706,CHEMBL321,Matrix metalloproteinase 9,CHEMBL250266,349379,Active,inhibition of mmp9,2.0,0.5798008
1209,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3648902,1344400,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 ,3.0,0.7508291
1210,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3648902,1344402,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 ,3.0,0.7508291
1560,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3648905,1344399,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 ,3.0,0.7508291
1208,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3648902,1344399,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 ,3.0,0.7508291
1561,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3648905,1344400,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 ,3.0,0.7508291
1109,CHEMBL321,Matrix metalloproteinase 9,CHEMBL1779630,598240,Active,inhibition of mmp9,40.5,0.7410513
427,CHEMBL321,Matrix metalloproteinase 9,CHEMBL2151350,693529,Active,inhibition of recombinant mmp9 catalytic site using mca pro leu gly leu dpa ala arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay,1.5,0.5815816
1705,CHEMBL321,Matrix metalloproteinase 9,CHEMBL250266,311968,Active,inhibition of mmp9,2.0,0.5798008
2142,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3959985,1344400,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 ,3.0,0.7508291
2141,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3959985,1344399,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 ,3.0,0.7508291
313,CHEMBL321,Matrix metalloproteinase 9,CHEMBL104022,259187,Active,binding affinity to mmp9,1.0,0.8887142
1523,CHEMBL321,Matrix metalloproteinase 9,CHEMBL523956,349379,Active,inhibition of mmp9,2.5,0.4734411
765,CHEMBL332,Matrix metalloproteinase-1,CHEMBL591774,457416,Active,inhibition of mmp1,14.5,0.85085255
347,CHEMBL332,Matrix metalloproteinase-1,CHEMBL445971,349395,Inactive,inhibition of mmp1 up to 25 um,1.0,0.8215275
384,CHEMBL332,Matrix metalloproteinase-1,CHEMBL573935,440425,Active,inhibition of para aminophenylmercuric acetate activated human pro mmp1 after 4 hrs by fluorimetry,1.5,0.8399219
1858,CHEMBL332,Matrix metalloproteinase-1,CHEMBL503651,409923,Inactive,inhibition of human recombinant pro mmp1 by spectrofluorimeter,1.0,0.8215275
227,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259199,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 ,1.0,0.6657034
520,CHEMBL332,Matrix metalloproteinase-1,CHEMBL573934,440425,Active,inhibition of para aminophenylmercuric acetate activated human pro mmp1 after 4 hrs by fluorimetry,1.0,0.92326444
56,CHEMBL332,Matrix metalloproteinase-1,CHEMBL550548,419746,Active,inhibition of mmp1 mediated collagen degradation by sds page,1.5,0.92326444
228,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259200,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 ,1.0,0.6657034
1361,CHEMBL332,Matrix metalloproteinase-1,CHEMBL574370,440425,Active,inhibition of para aminophenylmercuric acetate activated human pro mmp1 after 4 hrs by fluorimetry,1.5,0.8399219
229,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259201,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 ,1.0,0.6657034
230,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259202,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 ,1.0,0.6657034
582,CHEMBL332,Matrix metalloproteinase-1,CHEMBL1795861,603756,Active,inhibition of human mmp1 by fluorometric assay,1.0,0.8783385
788,CHEMBL332,Matrix metalloproteinase-1,CHEMBL251917,349373,Active,inhibition of mmp1,1.0,0.8215275
787,CHEMBL332,Matrix metalloproteinase-1,CHEMBL251917,311967,Active,inhibition of mmp1,1.0,0.8215275
100,CHEMBL332,Matrix metalloproteinase-1,CHEMBL561036,419737,Active,inhibition of mmp1,1.0,0.92326444
18,CHEMBL332,Matrix metalloproteinase-1,CHEMBL127867,108894,Active,inhibitory activity against matrix metalloprotease 1  mmp1 ,1.0,0.887432
55,CHEMBL332,Matrix metalloproteinase-1,CHEMBL550548,419737,Active,inhibition of mmp1,1.5,0.92326444
233,CHEMBL332,Matrix metalloproteinase-1,CHEMBL1795351,603756,Active,inhibition of human mmp1 by fluorometric assay,2.0,0.8783385
1484,CHEMBL332,Matrix metalloproteinase-1,CHEMBL563026,419737,Active,inhibition of mmp1,1.0,0.92326444
1445,CHEMBL333,Matrix metalloproteinase-2,CHEMBL2048505,670311,Active,inhibition of human recombinant mmp2 catalytic domain incubated for 20 mins by fluorimetric assay,2.0,0.9020809
45,CHEMBL333,Matrix metalloproteinase-2,CHEMBL1801052,604449,Active,inhibition of human mmp2 assessed as cleavage of fluorogenic peptide mcapro leu gly leu dpa ala arg nh2 by fluorometric assay,1.5,0.9667722
1446,CHEMBL333,Matrix metalloproteinase-2,CHEMBL2048505,670322,Active,inhibition of mmp2 protein expression in human mda mb 231 cells at 50 um incubated for 24 hrs by western blot,2.0,0.9020809
1912,CHEMBL333,Matrix metalloproteinase-2,CHEMBL348088,107154,Active,inhibitory activity against human gelatinase a  matrix metalloprotease 2 mmp2 ,1.0,0.65850276
2168,CHEMBL333,Matrix metalloproteinase-2,CHEMBL2385443,750825,Active,inhibition of human full length mmp2 using mca pro leu gly leu dpa dnp  ala arg nh2 as substrate measured up to 120 mins by fluorescence assay,1.0,0.65850276
253,CHEMBL333,Matrix metalloproteinase-2,CHEMBL98917,310905,Active,inhibition of mmp2,1.0,0.90269965
732,CHEMBL333,Matrix metalloproteinase-2,CHEMBL1801046,604449,Active,inhibition of human mmp2 assessed as cleavage of fluorogenic peptide mcapro leu gly leu dpa ala arg nh2 by fluorometric assay,1.0,0.98032564
2111,CHEMBL333,Matrix metalloproteinase-2,CHEMBL250266,311966,Active,inhibition of mmp2,2.0,0.7227998
4,CHEMBL333,Matrix metalloproteinase-2,CHEMBL348335,107154,Active,inhibitory activity against human gelatinase a  matrix metalloprotease 2 mmp2 ,3.0,0.65850276
2112,CHEMBL333,Matrix metalloproteinase-2,CHEMBL250266,349374,Active,inhibition of mmp2,2.0,0.7227998
1677,CHEMBL333,Matrix metalloproteinase-2,CHEMBL1801398,604449,Active,inhibition of human mmp2 assessed as cleavage of fluorogenic peptide mcapro leu gly leu dpa ala arg nh2 by fluorometric assay,2.5,0.7977977
1372,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,146.0,0.6373471
1373,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,146.0,0.6373471
2104,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,5.5,0.6373471
1374,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,146.0,0.6373471
1458,CHEMBL233,Mu opioid receptor,CHEMBL1358924,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,44.0,0.6373471
241,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
1456,CHEMBL233,Mu opioid receptor,CHEMBL1358924,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,44.0,0.6373471
1571,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,53.0,0.6375462
2105,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,5.5,0.6373471
1549,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,119.5,0.6373471
248,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588435,Inactive,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprm1 homodimerization,1.5,0.68010896
247,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588411,Active,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprd1 homodimerization,1.5,0.68010896
1459,CHEMBL233,Mu opioid receptor,CHEMBL1358924,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,44.0,0.6373471
1457,CHEMBL233,Mu opioid receptor,CHEMBL1358924,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,44.0,0.6373471
1460,CHEMBL233,Mu opioid receptor,CHEMBL1358924,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,44.0,0.6373471
1461,CHEMBL233,Mu opioid receptor,CHEMBL1358924,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,44.0,0.6373471
2102,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,5.5,0.6373471
1548,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,119.5,0.6373471
1371,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,146.0,0.6373471
1572,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,53.0,0.6375462
1370,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,146.0,0.6373471
1369,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,146.0,0.6373471
1547,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,119.5,0.6373471
1131,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,165.0,0.6373471
1130,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,165.0,0.6373471
2103,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,5.5,0.6373471
1129,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,165.0,0.6373471
1128,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,165.0,0.6373471
1573,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,53.0,0.6375462
1102,CHEMBL233,Mu opioid receptor,CHEMBL229018,290599,Active,displacement of [3h]diprenorphine from human mop receptor expressed in cho cell membranes,1.5,0.8823289
1127,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,165.0,0.6373471
246,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588408,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput dose response assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,1.5,0.68010896
1551,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,119.5,0.6373471
2107,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,5.5,0.6373471
1700,CHEMBL233,Mu opioid receptor,CHEMBL1477197,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,100.5,0.6373471
1699,CHEMBL233,Mu opioid receptor,CHEMBL1477197,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,100.5,0.6373471
1568,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,53.0,0.6375462
1126,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,165.0,0.6373471
1698,CHEMBL233,Mu opioid receptor,CHEMBL1477197,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,100.5,0.6373471
1569,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,53.0,0.6375462
1697,CHEMBL233,Mu opioid receptor,CHEMBL1477197,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,100.5,0.6373471
1555,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504914,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,119.5,0.6373471
2106,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,5.5,0.6373471
1550,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,119.5,0.6373471
1554,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504900,Inactive,luminescence based cell based high throughput confirmation assay for inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,119.5,0.6373471
1553,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504900,Inactive,luminescence based cell based high throughput confirmation assay for inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,119.5,0.6373471
1696,CHEMBL233,Mu opioid receptor,CHEMBL1477197,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,100.5,0.6373471
236,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
245,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
244,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
243,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504905,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,1.5,0.68010896
235,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
1552,CHEMBL233,Mu opioid receptor,CHEMBL1387605,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,119.5,0.6373471
240,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,1.5,0.68010896
242,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
239,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a ,1.5,0.68010896
238,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
237,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,1.5,0.68010896
1570,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,53.0,0.6375462
1695,CHEMBL233,Mu opioid receptor,CHEMBL1477197,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors,100.5,0.6373471
1866,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,602250,Inactive,full deck counterscreen for antagonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental chok1 cell line,1.0,0.8141402
1865,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,602248,Inactive,full deck counterscreen for agonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line,1.0,0.8141402
1864,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,602247,Inactive,full deck counterscreen for positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line,1.0,0.8141402
1293,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL67932,602250,Inactive,full deck counterscreen for antagonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental chok1 cell line,45.5,0.057921678
1292,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL67932,602248,Inactive,full deck counterscreen for agonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line,45.5,0.057921678
1861,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,588814,Inactive,fluorescence based cell based primary high throughput screening assay to identify agonists of the human cholinergic receptor muscarinic 1  chrm1 ,1.0,0.8141402
1291,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL67932,602247,Inactive,full deck counterscreen for positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line,45.5,0.057921678
1863,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,588852,Active,fluorescence based cell based primary high throughput screening assay to identify antagonists of the human m1 muscarinic receptor  chrm1 ,1.0,0.8141402
1289,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL67932,588819,Inactive,fluorescence based cell based primary high throughput screening assay to identify positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 ,45.5,0.057921678
1290,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL67932,588852,Inactive,fluorescence based cell based primary high throughput screening assay to identify antagonists of the human m1 muscarinic receptor  chrm1 ,45.5,0.057921678
1288,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL67932,588814,Inactive,fluorescence based cell based primary high throughput screening assay to identify agonists of the human cholinergic receptor muscarinic 1  chrm1 ,45.5,0.057921678
2023,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1626,1409612,Active,activity of compound against muscarinic acetylcholine receptor m1  chrm1 by displacement of 3h qnb,32.5,0.6781606
1862,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,588819,Inactive,fluorescence based cell based primary high throughput screening assay to identify positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 ,1.0,0.8141402
418,CHEMBL211,Muscarinic acetylcholine receptor M2,CHEMBL1626,1409619,Active,activity of compound against muscarinic acetylcholine receptor m2  chrm2 by displacement of 3h qnb,32.5,0.679289
1641,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL91829,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um,44.5,0.6557711
2090,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL941,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um,37.0,0.6403992
13,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL24828,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um,70.0,0.8696093
1489,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL31965,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um,28.0,0.801847
870,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL607707,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um,32.0,0.741368
1854,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL428690,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um,114.0,0.82481205
571,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL553,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um,84.0,0.8035285
9,CHEMBL222,Norepinephrine transporter,CHEMBL4074774,1472455,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting method,2.0,0.7721621
1750,CHEMBL222,Norepinephrine transporter,CHEMBL3331485,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay,2.0,0.90220135
1165,CHEMBL222,Norepinephrine transporter,CHEMBL199103,1472455,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting method,1.0,0.7721621
353,CHEMBL222,Norepinephrine transporter,CHEMBL476108,342786,Active,binding affinity to rat net,5.5,0.93062717
1661,CHEMBL222,Norepinephrine transporter,CHEMBL3331469,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay,1.0,0.9027098
675,CHEMBL222,Norepinephrine transporter,CHEMBL243204,296172,Active,displacement of [125i]rti55 from human net expressed in cos1 cell membrane,1.5,0.7721621
250,CHEMBL222,Norepinephrine transporter,CHEMBL115710,145866,Active,displacement of [3h]nisoxetine from norepinephrine transporter  net of rat brain,3.5,0.7721621
737,CHEMBL222,Norepinephrine transporter,CHEMBL1516187,1075730,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting analysis,14.0,0.9027098
1877,CHEMBL222,Norepinephrine transporter,CHEMBL398009,296175,Active,inhibition of [3h]da uptake in human net expressed in cos1 cell membrane,1.0,0.7721621
2033,CHEMBL222,Norepinephrine transporter,CHEMBL80515,239454,Active,displacement of [3h]nisoxetine from norepinephrine transporter  net of rat cerebral cortex,1.5,0.7721621
2034,CHEMBL222,Norepinephrine transporter,CHEMBL80515,239454,Active,displacement of [3h]nisoxetine from norepinephrine transporter  net of rat cerebral cortex,1.5,0.7721621
1946,CHEMBL222,Norepinephrine transporter,CHEMBL1914693,628084,Active,displacement of [125i] inxt from net transfected in pig llc pk1 cells by radioligand competition binding assay,1.5,0.7721621
222,CHEMBL222,Norepinephrine transporter,CHEMBL3331501,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay,9.0,0.90220135
412,CHEMBL222,Norepinephrine transporter,CHEMBL3331504,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay,2.0,0.9027098
1976,CHEMBL222,Norepinephrine transporter,CHEMBL4062435,1472455,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting method,2.5,0.77913
769,CHEMBL222,Norepinephrine transporter,CHEMBL401069,309731,Active,displacement of [125i]rti55 from human net transfected in cos1 cells,1.0,0.7721621
1,CHEMBL222,Norepinephrine transporter,CHEMBL3126751,1075730,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting analysis,11.5,0.90220135
8,CHEMBL222,Norepinephrine transporter,CHEMBL4074774,1472455,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting method,2.0,0.7721621
338,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,434989,Inactive,fluorescence based cell based primary high throughput screening assay to identify antagonists of the orexin 1 receptor  ox1r hcrtr1 ,1.0,0.7984399
339,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,463079,Inactive,fluorescence based counterscreen for orexin 1 receptor  ox1r antagonists: cell based assay to identify antagonists of the parental cho cell line,1.0,0.7984399
283,CHEMBL5113,Orexin receptor 1,CHEMBL3672939,1258840,Active,flipr ca2+ flux assay: the utility of the compounds in accordance with the present invention as orexin receptor ox1r and/or ox2r antagonists may be readily determined without undue experimentation by methodology well known in the art including the flipr ca2+ flux assay  okumura et al biochem biophys res comm 280:976 981 2001 in a typical experiment the ox1 and ox2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the following experimental method for intracellular calcium measurements chinese hamster ovary  cho cells expressing the rat orexin 1 receptor or the human orexin 2 receptor are grown in iscove's modified dmem containing 2 mm l glutamine 0 5 g/ml g418 1% hypoxanthine thymidine supplement 100 u/ml penicillin 100 ug/ml streptomycin and 10% heat inactivated fetal calf serum  fcs the cells are seeded at 20 000 cells/well into becton dickinson black 384 well clear bottom sterile plates coated with poly d l,1.0,0.7984399
340,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,485270,Inactive,fret based cell based primary high throughput screening assay to identify antagonists of the orexin 1 receptor  ox1r hcrtr1 ,1.0,0.7984399
1146,CHEMBL4792,Orexin receptor 2,CHEMBL1422276,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,21.0,0.84988374
1169,CHEMBL4792,Orexin receptor 2,CHEMBL1575559,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,181.0,0.84988374
1384,CHEMBL4792,Orexin receptor 2,CHEMBL1556270,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,101.0,0.8501919
389,CHEMBL4792,Orexin receptor 2,CHEMBL1327720,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,73.0,0.84988374
1147,CHEMBL4792,Orexin receptor 2,CHEMBL1422276,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,21.0,0.84988374
388,CHEMBL4792,Orexin receptor 2,CHEMBL1327720,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,73.0,0.84988374
124,CHEMBL4792,Orexin receptor 2,CHEMBL1502109,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,24.0,0.84988374
123,CHEMBL4792,Orexin receptor 2,CHEMBL1502109,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,24.0,0.84988374
210,CHEMBL4792,Orexin receptor 2,CHEMBL1463349,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,52.0,0.84988374
1124,CHEMBL4792,Orexin receptor 2,CHEMBL1714761,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,37.0,0.84988374
258,CHEMBL4792,Orexin receptor 2,CHEMBL1418004,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,213.0,0.84988374
80,CHEMBL4792,Orexin receptor 2,CHEMBL1576843,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,48.0,0.84988374
81,CHEMBL4792,Orexin receptor 2,CHEMBL1576843,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,48.0,0.84988374
1004,CHEMBL4792,Orexin receptor 2,CHEMBL1372776,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,194.0,0.84988374
1005,CHEMBL4792,Orexin receptor 2,CHEMBL1372776,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,194.0,0.84988374
1010,CHEMBL4792,Orexin receptor 2,CHEMBL1536921,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,173.0,0.84988374
1011,CHEMBL4792,Orexin receptor 2,CHEMBL1536921,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,173.0,0.84988374
259,CHEMBL4792,Orexin receptor 2,CHEMBL1418004,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,213.0,0.84988374
1215,CHEMBL4792,Orexin receptor 2,CHEMBL1548353,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,134.0,0.84988374
1080,CHEMBL4792,Orexin receptor 2,CHEMBL1432793,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,139.0,0.84988374
1079,CHEMBL4792,Orexin receptor 2,CHEMBL1432793,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,139.0,0.84988374
1228,CHEMBL4792,Orexin receptor 2,CHEMBL1507474,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,110.0,0.84988374
1229,CHEMBL4792,Orexin receptor 2,CHEMBL1507474,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,110.0,0.84988374
201,CHEMBL4792,Orexin receptor 2,CHEMBL1559065,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,42.0,0.84988374
202,CHEMBL4792,Orexin receptor 2,CHEMBL1559065,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,42.0,0.84988374
209,CHEMBL4792,Orexin receptor 2,CHEMBL1463349,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,52.0,0.84988374
1216,CHEMBL4792,Orexin receptor 2,CHEMBL1548353,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,134.0,0.84988374
379,CHEMBL4792,Orexin receptor 2,CHEMBL1301892,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,67.0,0.84988374
284,CHEMBL4792,Orexin receptor 2,CHEMBL1501678,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,131.0,0.84988374
976,CHEMBL4792,Orexin receptor 2,CHEMBL1438621,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,118.0,0.84988374
1123,CHEMBL4792,Orexin receptor 2,CHEMBL1714761,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,37.0,0.84988374
912,CHEMBL4792,Orexin receptor 2,CHEMBL1584180,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,73.0,0.84988374
913,CHEMBL4792,Orexin receptor 2,CHEMBL1584180,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,73.0,0.84988374
1317,CHEMBL4792,Orexin receptor 2,CHEMBL1521046,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,168.0,0.84988374
1316,CHEMBL4792,Orexin receptor 2,CHEMBL1521046,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,168.0,0.84988374
1173,CHEMBL4792,Orexin receptor 2,CHEMBL1405608,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,1.0,0.84988374
1118,CHEMBL4792,Orexin receptor 2,CHEMBL1351929,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,63.0,0.84988374
977,CHEMBL4792,Orexin receptor 2,CHEMBL1438621,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,118.0,0.84988374
1117,CHEMBL4792,Orexin receptor 2,CHEMBL1351929,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,63.0,0.84988374
1284,CHEMBL4792,Orexin receptor 2,CHEMBL1304258,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,13.0,0.84988374
297,CHEMBL4792,Orexin receptor 2,CHEMBL1379934,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,66.0,0.84988374
296,CHEMBL4792,Orexin receptor 2,CHEMBL1379934,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,66.0,0.84988374
1283,CHEMBL4792,Orexin receptor 2,CHEMBL1304258,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,13.0,0.84988374
294,CHEMBL4792,Orexin receptor 2,CHEMBL1518032,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,155.0,0.84988374
293,CHEMBL4792,Orexin receptor 2,CHEMBL1518032,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,155.0,0.84988374
285,CHEMBL4792,Orexin receptor 2,CHEMBL1501678,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,131.0,0.84988374
1174,CHEMBL4792,Orexin receptor 2,CHEMBL1405608,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,1.0,0.84988374
1170,CHEMBL4792,Orexin receptor 2,CHEMBL1575559,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,181.0,0.84988374
380,CHEMBL4792,Orexin receptor 2,CHEMBL1301892,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,67.0,0.84988374
844,CHEMBL4792,Orexin receptor 2,CHEMBL1588256,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,72.0,0.84988374
1813,CHEMBL4792,Orexin receptor 2,CHEMBL1967103,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,78.0,0.84988374
1528,CHEMBL4792,Orexin receptor 2,CHEMBL1526293,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,42.0,0.84988374
1812,CHEMBL4792,Orexin receptor 2,CHEMBL1967103,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,78.0,0.84988374
1811,CHEMBL4792,Orexin receptor 2,CHEMBL1720383,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,97.0,0.84988374
1810,CHEMBL4792,Orexin receptor 2,CHEMBL1720383,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,97.0,0.84988374
1808,CHEMBL4792,Orexin receptor 2,CHEMBL1721724,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,14.0,0.84988374
1437,CHEMBL4792,Orexin receptor 2,CHEMBL1468272,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,70.0,0.850627
1527,CHEMBL4792,Orexin receptor 2,CHEMBL1496820,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,114.0,0.84988374
1526,CHEMBL4792,Orexin receptor 2,CHEMBL1496820,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,114.0,0.84988374
764,CHEMBL4792,Orexin receptor 2,CHEMBL1386871,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,30.0,0.84988374
1438,CHEMBL4792,Orexin receptor 2,CHEMBL1468272,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,70.0,0.850627
1480,CHEMBL4792,Orexin receptor 2,CHEMBL1481716,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,49.0,0.84988374
1481,CHEMBL4792,Orexin receptor 2,CHEMBL1481716,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,49.0,0.84988374
554,CHEMBL4792,Orexin receptor 2,CHEMBL1418095,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,77.0,0.84988374
553,CHEMBL4792,Orexin receptor 2,CHEMBL1418095,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,77.0,0.84988374
1743,CHEMBL4792,Orexin receptor 2,CHEMBL1493516,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,109.0,0.84988374
1496,CHEMBL4792,Orexin receptor 2,CHEMBL1419029,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,72.0,0.84988374
1742,CHEMBL4792,Orexin receptor 2,CHEMBL1493516,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,109.0,0.84988374
1444,CHEMBL4792,Orexin receptor 2,CHEMBL1478565,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,161.5,0.84988374
1497,CHEMBL4792,Orexin receptor 2,CHEMBL1419029,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,72.0,0.84988374
1704,CHEMBL4792,Orexin receptor 2,CHEMBL1511752,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,147.0,0.84988374
1703,CHEMBL4792,Orexin receptor 2,CHEMBL1511752,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,147.0,0.84988374
1443,CHEMBL4792,Orexin receptor 2,CHEMBL1478565,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,161.5,0.84988374
763,CHEMBL4792,Orexin receptor 2,CHEMBL1386871,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,30.0,0.84988374
1385,CHEMBL4792,Orexin receptor 2,CHEMBL1556270,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,101.0,0.8501919
1809,CHEMBL4792,Orexin receptor 2,CHEMBL1721724,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,14.0,0.84988374
1529,CHEMBL4792,Orexin receptor 2,CHEMBL1526293,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,42.0,0.84988374
584,CHEMBL4792,Orexin receptor 2,CHEMBL1583293,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,165.0,0.84988374
583,CHEMBL4792,Orexin receptor 2,CHEMBL1583293,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,165.0,0.84988374
1604,CHEMBL4792,Orexin receptor 2,CHEMBL1721971,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,1.0,0.84988374
1814,CHEMBL4792,Orexin receptor 2,CHEMBL1479657,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,36.0,0.84988374
756,CHEMBL4792,Orexin receptor 2,CHEMBL1583817,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,109.0,0.84988374
576,CHEMBL4792,Orexin receptor 2,CHEMBL1364699,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,75.0,0.84988374
1563,CHEMBL4792,Orexin receptor 2,CHEMBL1605702,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,75.0,0.84988374
757,CHEMBL4792,Orexin receptor 2,CHEMBL1583817,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,109.0,0.84988374
1562,CHEMBL4792,Orexin receptor 2,CHEMBL1605702,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,75.0,0.84988374
575,CHEMBL4792,Orexin receptor 2,CHEMBL1364699,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,75.0,0.84988374
843,CHEMBL4792,Orexin receptor 2,CHEMBL1588256,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,72.0,0.84988374
1819,CHEMBL4792,Orexin receptor 2,CHEMBL1493746,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,28.0,0.84988374
1818,CHEMBL4792,Orexin receptor 2,CHEMBL1493746,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,28.0,0.84988374
1817,CHEMBL4792,Orexin receptor 2,CHEMBL1532403,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,171.0,0.84988374
1816,CHEMBL4792,Orexin receptor 2,CHEMBL1532403,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,171.0,0.84988374
1815,CHEMBL4792,Orexin receptor 2,CHEMBL1479657,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,36.0,0.84988374
1603,CHEMBL4792,Orexin receptor 2,CHEMBL1721971,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider,1.0,0.84988374
1731,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3799504,1296807,Active,inhibition of pi3kalpha mutant in human bt474 cells assessed as inhibition of akt phosphorylation at thr 308 residue after 2 hrs by elisa,2.0,0.6831081
1065,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL164,641152,Active,growth inhibition of human hct116 cells overexpressing pi3kalpha after 48 hrs by mtt assay,86.5,0.6491955
984,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3585605,1231395,Active,inhibition of cell proliferation of human nzov9 cells containing wild type p53 protein and p110alpha y1021c mutant incubated for 5 days by [3h]thymidine incorporation assay,1.0,0.85852766
754,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1242025,507072,Active,inhibition of recombinant pi3kalpha by radioactive phosphotransfer assay in presence of 10 um atp,3.0,0.92699057
1046,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2057363,673070,Active,inhibition of pi3kalpha in human hl60 cell lysate by kinobead assay,1.0,0.94942224
1066,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL164,641153,Active,growth inhibition of human hct116 cells overexpressing pi3kalpha h1047r mutant after 48 hrs by mtt assay,86.5,0.6491955
931,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2064481,674825,Active,inhibition of pi3kalpha by high throughput chemoproteomics binding assay,1.0,0.64249
1899,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911123,626778,Active,inhibition of mouse recombinant pi3k p110alpha expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging,1.0,0.6831081
1281,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2375967,744343,Active,inhibition of mouse pi3kalpha,1.0,0.5570859
1282,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2375967,744343,Active,inhibition of mouse pi3kalpha,1.0,0.5570859
1904,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911008,626774,Active,antiproliferative activity against human nzov9 cells expressing p110alpha kinase y1021c mutant assessed as incorporation of [3h]thymidine after 5 days,2.0,0.6831081
1905,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911008,626775,Active,antiproliferative activity against human nzb5 cells expressing wild type p110alpha assessed as incorporation of [3h]thymidine after 5 days,2.0,0.6831081
1906,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911008,626778,Active,inhibition of mouse recombinant pi3k p110alpha expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging,2.0,0.6831081
1803,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589376,1233503,Active,cytotoxic activity against human skov3 cells expressing pik3ca mutant incubated for 72 hrs by srb assay,2.0,0.85852766
1802,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589376,1233502,Active,cytotoxic activity against human hela cells over expressing pi3k p110alpha incubated for 72 hrs by srb assay,2.0,0.85852766
1801,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589376,1233493,Active,inhibition of gst tagged bovine p110alpha expressed in sf9/baculovirus system using [gamma 33p]atp by scintillation proximity assay,2.0,0.85852766
268,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4071083,1482747,Active,antiproliferative activity against human skov3 cells harboring pik3ca mutant after 72 hrs by cck 8 assay,1.0,0.9513068
999,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2376095,744343,Active,inhibition of mouse pi3kalpha,1.0,0.5570859
1067,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL164,641156,Active,inhibition of pi3kalpha in human hct116 cells using [32p]atp at 25 um after 10 mins,86.5,0.6491955
739,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1241680,507072,Active,inhibition of recombinant pi3kalpha by radioactive phosphotransfer assay in presence of 10 um atp,1.5,0.86173874
1240,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3585594,1231395,Active,inhibition of cell proliferation of human nzov9 cells containing wild type p53 protein and p110alpha y1021c mutant incubated for 5 days by [3h]thymidine incorporation assay,1.0,0.85852766
1068,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL164,641158,Active,inhibition of pi3kalpha h1047r mutant in human hct116 cells using [32p]atp at 25 um after 10 mins,86.5,0.6491955
1073,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2059908,673070,Active,inhibition of pi3kalpha in human hl60 cell lysate by kinobead assay,1.0,0.94942224
1070,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL164,641162,Active,inhibition of pi3kalpha h1047r mutant in human hct116 cells assessed as inhibition of akt ser473 phosphorylation at 25 um by immunoblot analysis,86.5,0.6491955
1382,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4078233,1447232,Active,inhibition of pi3kalpha mutant in human bt474 cells assessed as decrease in akt phosphorylation at thr308 after 2 hrs,2.0,0.6831081
1125,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2064337,676027,Active,inhibition of n terminus poly his tagged human pi3kalpha expressed in baculovirus infected insect sf9 cells coexpressing p85alpha using pi 4 5 p2 as substrate preincubated with compound for 15 mins measured after 10 mins by htrf assay,1.0,0.85852766
1546,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1645100,549727,Active,inhibition of human p110alpha pi3k fragment by alphascreen assay,6.0,0.85852766
817,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2064489,674825,Active,inhibition of pi3kalpha by high throughput chemoproteomics binding assay,1.0,0.84039426
1112,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3121315,1070710,Active,inhibition of pi3kalpha  1 to 1068 /6xhis tagged p85  1 to 724  unknown origin using dic8 pip2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,1.5,0.64249
1069,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL164,641161,Active,inhibition of pi3kalpha in human hct116 cells assessed as inhibition of akt ser473 phosphorylation at 25 um by immunoblot analysis,86.5,0.6491955
2064,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3799515,1296807,Active,inhibition of pi3kalpha mutant in human bt474 cells assessed as inhibition of akt phosphorylation at thr 308 residue after 2 hrs by elisa,2.0,0.6831081
97,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589377,1233503,Active,cytotoxic activity against human skov3 cells expressing pik3ca mutant incubated for 72 hrs by srb assay,5.0,0.85852766
1440,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911121,626774,Active,antiproliferative activity against human nzov9 cells expressing p110alpha kinase y1021c mutant assessed as incorporation of [3h]thymidine after 5 days,2.5,0.6831081
1897,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911123,626774,Active,antiproliferative activity against human nzov9 cells expressing p110alpha kinase y1021c mutant assessed as incorporation of [3h]thymidine after 5 days,1.0,0.6831081
1694,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1240545,507072,Active,inhibition of recombinant pi3kalpha by radioactive phosphotransfer assay in presence of 10 um atp,3.0,0.82028747
528,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1242030,507072,Active,inhibition of recombinant pi3kalpha by radioactive phosphotransfer assay in presence of 10 um atp,1.5,0.93186766
751,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL566046,446234,Active,inhibition of mouse recombinant pi3kalpha expressed in baculovirus infected sf21 cells,7.0,0.85852766
791,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4060108,1482747,Active,antiproliferative activity against human skov3 cells harboring pik3ca mutant after 72 hrs by cck 8 assay,1.0,0.9513068
983,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3585605,1231394,Active,inhibition of cell proliferation of human nzb5 cells containing wild type p110alpha gene incubated for 5 days by [3h]thymidine incorporation assay,1.0,0.85852766
1898,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911123,626775,Active,antiproliferative activity against human nzb5 cells expressing wild type p110alpha assessed as incorporation of [3h]thymidine after 5 days,1.0,0.6831081
1074,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2059908,674825,Active,inhibition of pi3kalpha by high throughput chemoproteomics binding assay,1.0,0.94942224
95,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589377,1233493,Active,inhibition of gst tagged bovine p110alpha expressed in sf9/baculovirus system using [gamma 33p]atp by scintillation proximity assay,5.0,0.85852766
1441,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911121,626775,Active,antiproliferative activity against human nzb5 cells expressing wild type p110alpha assessed as incorporation of [3h]thymidine after 5 days,2.5,0.6831081
96,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3589377,1233502,Active,cytotoxic activity against human hela cells over expressing pi3k p110alpha incubated for 72 hrs by srb assay,5.0,0.85852766
1442,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911121,626778,Active,inhibition of mouse recombinant pi3k p110alpha expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging,2.5,0.6831081
1596,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3600770,1238225,Active,inhibition of pi3kbeta  unknown origin pre incubated for 20 mins before phosphatidylinositol 4 5 bisphosphate substrate addition by kinase glo plus luminescence assay,1.0,0.7892932
1846,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1242758,507073,Active,inhibition of recombinant pi3kbeta by radioactive phosphotransfer assay in presence of 10 um atp,1.0,0.8268903
1286,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1241675,507073,Active,inhibition of recombinant pi3kbeta by radioactive phosphotransfer assay in presence of 10 um atp,2.5,0.8135377
958,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1241587,507073,Active,inhibition of recombinant pi3kbeta by radioactive phosphotransfer assay in presence of 10 um atp,1.0,0.8245416
1483,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3121311,1070709,Active,inhibition of pi3kbeta  1 to 1070 /6xhis tagged p85  1 to 724  unknown origin using dic8 pip2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,4.5,0.46830383
1297,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1242034,507073,Active,inhibition of recombinant pi3kbeta by radioactive phosphotransfer assay in presence of 10 um atp,2.5,0.8130326
2053,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3643932,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,3.0,0.24246284
1716,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL1911121,626776,Active,inhibition of bovine recombinant pi3k p110delta expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging,2.5,0.69054055
1211,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3805337,1299722,Active,inhibition human full length pi3kdelta catalytic subunit/p85alpha assessed as formation of pip3 after 30 mins by europium labeled grp based tr fret assay,2.0,0.76557297
378,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646594,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,2.0,0.29646164
2121,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL1911120,626776,Active,inhibition of bovine recombinant pi3k p110delta expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging,2.5,0.69054055
377,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646594,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,2.0,0.29646164
1929,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL1911008,626776,Active,inhibition of bovine recombinant pi3k p110delta expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging,2.0,0.69054055
2135,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3698629,1258232,Active,adp glo kinase assay: some compounds of formula  i described herein were assayed in vitro for their ability to inhibit the lipid kinase activity of pi3ks by using a non radioactive method in details his and gst tagged recombinant proteins  purchased from jenabioscience germany pi3kalpha  pr 335 pi3kbeta  pr 344 pi3kgamma  pr 343 pi3kdelta  pr 345 for each isoform pi3kalpha  beta  gamma and delta were incubated with 10 um of atp with lipid micells containg the appropriate substrate phosphatidylinositol and the phosphatidilserine and different concentrations of the formula  i compounds after 30 minutes of incubation at room temperature the amount of adp produced from atp following the activation of kinase was measured with a luminescent kinase assay adp glo kinase assay  purchased from promega usa  v9101 the luminescent signal positively correlates with the formed adp and therefore with the kinase activity ,2.5,0.24246284
723,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3121310,1070708,Active,inhibition of pi3kdelta  1 to 1044 /6xhis tagged p85  1 to 724  unknown origin using dic8 pip2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,4.5,0.55168474
1212,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3805337,1299722,Active,inhibition human full length pi3kdelta catalytic subunit/p85alpha assessed as formation of pip3 after 30 mins by europium labeled grp based tr fret assay,2.0,0.76557297
58,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2326965,729013,Active,inhibition of pi3k p110delta  unknown origin ,5.0,0.89490277
1149,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2381269,746368,Active,inhibition of gst fused human recombinant pi3kdelta expressed in baculovirus infected sf9 cells after 1 hr by scintillation proximity assay in presence of [gamma 33p] atp,1.0,0.89490277
800,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2165036,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,1.0,0.89490277
695,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL379156,1120063,Active,inhibition of pi3kdelta  unknown origin by lipid kinase assay,14.5,0.66038454
799,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2165036,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,1.0,0.89490277
1023,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3357868,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,2.5,0.3268193
1024,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3357868,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,2.5,0.3268193
694,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL379156,266957,Active,inhibition of human pi3kdelta,14.5,0.66038454
2054,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3643932,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein ,3.0,0.24246284
2134,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3698629,1258232,Active,adp glo kinase assay: some compounds of formula  i described herein were assayed in vitro for their ability to inhibit the lipid kinase activity of pi3ks by using a non radioactive method in details his and gst tagged recombinant proteins  purchased from jenabioscience germany pi3kalpha  pr 335 pi3kbeta  pr 344 pi3kgamma  pr 343 pi3kdelta  pr 345 for each isoform pi3kalpha  beta  gamma and delta were incubated with 10 um of atp with lipid micells containg the appropriate substrate phosphatidylinositol and the phosphatidilserine and different concentrations of the formula  i compounds after 30 minutes of incubation at room temperature the amount of adp produced from atp following the activation of kinase was measured with a luminescent kinase assay adp glo kinase assay  purchased from promega usa  v9101 the luminescent signal positively correlates with the formed adp and therefore with the kinase activity ,2.5,0.24246284
1045,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3905764,1343864,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.0,0.6605698
1042,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3955003,1325760,Active,binding affinity to human pi3kgamma  144 to 1102 residues expressed in mammalian expression system by kinomescan assay,1.5,0.819508
115,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3589376,1233495,Active,inhibition of his tagged p110gamma  unknown origin expressed in sf9/baculovirus system using [gamma 33p]atp by scintillation proximity assay,1.0,0.7628683
1248,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3956037,1325760,Active,binding affinity to human pi3kgamma  144 to 1102 residues expressed in mammalian expression system by kinomescan assay,1.5,0.819508
1702,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL466956,342873,Active,inhibition of pi3kgamma,1.0,0.819508
1177,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3112861,1068548,Active,inhibition of c terminal ploy his tagged human pi3kgamma expressed in baculovirus infected sf9 cells using pi 4 5 p2 as substrate after 15 mins by htrf assay,1.0,0.8213312
1478,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3893512,1343863,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.5,0.5540541
1479,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3893512,1343864,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.5,0.5540541
1044,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3905764,1343863,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.0,0.6605698
1522,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3926413,1343864,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.0,0.5540541
1521,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3926413,1343863,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.0,0.5540541
257,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3112866,1068548,Active,inhibition of c terminal ploy his tagged human pi3kgamma expressed in baculovirus infected sf9 cells using pi 4 5 p2 as substrate after 15 mins by htrf assay,1.0,0.8213312
1043,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3905764,1343862,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.0,0.6605698
2128,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL1241858,507075,Active,inhibition of recombinant pi3kgamma by radioactive phosphotransfer assay in presence of 10 um atp,2.0,0.5978924
1280,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL512293,342873,Active,inhibition of pi3kgamma,1.0,0.819508
1301,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3951402,1343862,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.5,0.6605698
1302,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3951402,1343863,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.5,0.6605698
1303,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3951402,1343864,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.5,0.6605698
1304,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3951402,1343865,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window ,1.5,0.6605698
1618,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3787648,1291859,Active,agonist activity at human ppar delta by cell based cotransfection assay,8.0,0.6532258
1504,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL215126,270634,Inactive,transactivation of murine pparalpha in cv1 cells by luciferase reporter gene assay,1.0,0.82064897
1678,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL447538,276054,Active,displacement of fluormone from ppar gamma,55.0,0.48280177
34,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL394849,291758,Active,displacement of [3h]rosiglitazone from ppar gamma,6.5,0.48280177
1693,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760423,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay,1.0,0.82064897
1487,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL425116,279989,Active,agonist activity at human ppar delta by fret assay,1.0,0.6532258
1488,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL425116,279990,Active,agonist activity at ppar gamma in mouse 3t3l1 cells assessed as increase in insulin receptor by irba,1.0,0.6532258
1239,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,156625,Active,binding affinity for human ppar delta receptor,1.0,0.82064897
1737,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760270,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay,1.0,0.82064897
1503,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL215126,270633,Inactive,displacement of [3h]2  4 {2 [3  2 4 difluoro phenyl  1 heptyl ureido] ethyl} phenoxy  2 methyl butyric acid from murine pparalpha by spa,1.0,0.82064897
1238,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,156617,Active,maximum transcriptional activation of human ppar delta receptor,1.0,0.82064897
1237,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,156148,Inactive,maximum transcriptional activation of human ppar alpha receptor iainactive,1.0,0.82064897
1236,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,155978,Active,maximum transcriptional activation of human ppar gamma receptor,1.0,0.82064897
1502,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL215126,270625,Inactive,displacement of [3h]2  4 {2 [3  2 4 difluoro phenyl  1 heptyl ureido] ethyl} phenoxy  2 methyl butyric acid from human pparalpha by spa,1.0,0.82064897
1231,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL221580,276054,Active,displacement of fluormone from ppar gamma,29.0,0.48280177
701,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL115463,156362,Active,in vitro transcription activation on human peroxisome proliferator activated receptor gamma  ppar gamma ,1.0,0.82064897
700,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL115463,156234,Active,in vitro transcription activation on human peroxisome proliferator activated receptor delta  ppar delta ,1.0,0.82064897
699,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL115463,156219,Inactive,in vitro transcription activation on human peroxisome proliferator activated receptor alpha  ppar alpha inactive,1.0,0.82064897
217,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156945,Active,maximum transcriptional activation of human ppar gamma receptor,1.0,0.82064897
216,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156625,Active,binding affinity for human ppar delta receptor,1.0,0.82064897
215,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156617,Active,maximum transcriptional activation of human ppar delta receptor,1.0,0.82064897
214,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156148,Inactive,maximum transcriptional activation of human ppar alpha receptor iainactive,1.0,0.82064897
1057,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699405,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control ,1.0,0.48280177
1058,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699405,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control ,1.0,0.48280177
1509,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760419,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay,1.0,0.82064897
1669,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3393178,1190558,Active,transactivation of gal4 tagged pparalpha ligand binding domain  unknown origin expressed in cos7 cells measured after overnight incubation by luciferase reporter gene assay,1.0,0.82064897
771,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL222560,280960,Active,activity at human placenta ppar delta expressed in hek293 cells by ppar gal4 transactivation assay,1.5,0.6532258
1631,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL54097,157293,Active,in vitro agonist activity tested for transactivation in human ppar gamma gal4 chimeric cos 1 cells,1.0,0.82064897
1632,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL54097,157294,Active,in vitro binding affinity against human ppar gamma  peroxisome proliferator activated gamma receptor ,1.0,0.82064897
1591,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL221292,276172,Active,activity at human ppar delta by cell based transactivation assay,1.0,0.6532258
1577,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3786533,1291855,Active,agonist activity at human ppar delta by cell based reporter assay,2.0,0.6532258
1576,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3786533,1291848,Active,agonist activity at ppar delta  unknown origin transfected in hek293 cells after 24 hrs by dual luciferase reporter gene assay,2.0,0.6532258
1410,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3753473,1272055,Active,binding affinity to gst tagged human ppar gamma receptor by fret assay,8.5,0.48280177
1859,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760413,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay,1.0,0.82064897
1629,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760410,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay,1.0,0.82064897
988,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1778830,597760,Active,agonist activity at human pparalpha lbd expressed in cv1 cells co transfected with gal4 after 40 hrs by luciferase based transactivation assay,1.5,0.6532258
1630,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL54097,157292,Active,in vitro binding affinity against human ppar delta  peroxisome proliferator activated delta receptor ,1.0,0.82064897
1617,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3787648,1291848,Active,agonist activity at ppar delta  unknown origin transfected in hek293 cells after 24 hrs by dual luciferase reporter gene assay,8.0,0.6532258
898,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760399,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay,1.0,0.82064897
1467,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL524829,348373,Active,displacement of radiolabeled ligand from human pparalpha by competition binding assay,1.0,0.82064897
1468,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL524829,665203,Active,agonist activity at pparalpha,1.0,0.82064897
894,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760425,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay,1.0,0.82064897
1378,CHEMBL3979,Peroxisome proliferator-activated receptor delta,CHEMBL3780991,1288257,Inactive,transactivation of ppardelta  unknown origin expressed in hek293a cells after 16 to 18 hrs by luciferase reporter assay,70.0,0.39073807
1774,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259401,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1145,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL1956360,648526,Active,agonist activity at gal4 tagged human ppargamma ligand binding domain expressed in hepg2 cells assessed as transactivation after 20 hrs by beta galactosidase reporter gene assay,1.0,0.7448143
1144,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL280065,1224823,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc ,2.0,0.7448999
1336,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen,4.0,0.878581
1383,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL393593,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba,1.0,0.878581
1334,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1337,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen,4.0,0.878581
1143,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL280065,1224822,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc  cell viability counter screen,2.0,0.7448999
1333,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1338,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen,4.0,0.878581
1339,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1340,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1346,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259401,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1341,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1347,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1345,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259401,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1348,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1349,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
536,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL430182,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba,1.0,0.878581
1332,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1687,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL3920153,1343332,Active,reporter gene assay: transactivation assay expression vectors were prepared by inserting the ligand binding domain cdna  complementary dna of human pparalpha  amino acid 168 468 and human ppargamma  amino acid 205 505 3 x2032 to and in frame with the yeast gal4 transcription factor dna binding domain and the nuclear localization signal from the t antigen of polyoma virus into the mammalian expression vector psgs  stratagene the resulting expression vectors psggal pparalpha and psggal ppargamma were used in co transfection experiments together with a modified pgl3 promoter plasmid  promega containing five copies of the uas gal4 recognition site 2 5  x3bc g psggal pparalpha or psggal ppargamma were mixed with 25  x3bc g pgl3p 1 xd7 uas and 22 5  x3bc g pbluescript  stratagene in 0 95 ml ice cold pbs containing between 9 12 million u 2 os  human osteosarcoma cells the cell/dna mixture was incubated on ice for 5 minutes and then divided between two 0 4 cm cuvettes and ele,1.0,0.7448143
1543,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL3779912,1288254,Active,antagonist activity at ppargamma  unknown origin expressed in hek293a cells after 16 to 18 hrs by luciferase reporter assay,50.0,0.7448143
1544,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL525552,348374,Active,displacement of radiolabeled ligand from human ppargamma by competition binding assay,1.0,0.878581
1545,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL525552,665205,Active,agonist activity at ppargamma,1.0,0.878581
1344,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1343,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1342,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1634,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL273035,320687,Active,agonist activity at human ppargamma expressed in cv1 cells by transactivation assay,1.0,0.7448143
1405,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL233177,299304,Active,displacement of [3h]5  4  3  5 methyl 2 phenyloxazol 4 yl propanoyl benzyl thiazolidine 2 4 dione from human ppargamma after 2 hrs by spa assay,1.0,0.878581
350,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL360992,246429,Inactive,agonist activity against human ppargamma in cos 1 cell gal4 assay na not active  less than 20% activation at 10 um ,1.0,0.878581
5,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL393805,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba,1.0,0.878581
1142,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL280065,1224821,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc ,2.0,0.7448999
691,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL221755,277150,Active,agonist potency at ppargamma in cv1 cells by cell based transient transfection assay,1.0,0.878581
1773,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1330,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen,4.0,0.878581
1754,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1755,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1012,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL241063,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba,1.0,0.878581
1756,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1757,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1331,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen,4.0,0.878581
1758,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743191,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1759,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743191,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1760,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen,4.0,0.878581
1761,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen,4.0,0.878581
1762,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1763,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1778,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL1956149,649220,Inactive,agonist activity at n terminal his tagged human ppargamma expressed in escherichia coli bl21 assessed as transactivation activity,1.0,0.878581
1764,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1765,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1114583,Active,displacement of [3h]brl49653 from homo sapiens  human ppargamma receptor by scintillation proximity assay,4.0,0.878581
1766,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen,4.0,0.878581
1777,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1767,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen,4.0,0.878581
1768,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen,4.0,0.878581
1769,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1770,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1771,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1776,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1772,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library,4.0,0.878581
1775,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary,4.0,0.878581
1753,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1752,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1335,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1114583,Active,displacement of [3h]brl49653 from homo sapiens  human ppargamma receptor by scintillation proximity assay,4.0,0.878581
1322,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1329,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen,4.0,0.878581
702,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL1086861,469032,Inactive,agonist activity at ppargamma receptor expressed in hek293 cells co transfected with gal4 at 1 um by transactivation assay,1.0,0.878581
327,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL239563,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba,1.0,0.878581
1328,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743191,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1327,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1326,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1325,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary,4.0,0.878581
1324,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
1323,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway,4.0,0.878581
965,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL381207,255118,Active,cellular inhibition of vegf induced human pdgfr phosphorylation in 3t3 murine fibroblasts,26.5,0.6176318
2163,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL428690,256661,Inactive,average binding constant for pdgfrb nanot active at 10 um,120.5,0.74707866
966,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL381207,255118,Active,cellular inhibition of vegf induced human pdgfr phosphorylation in 3t3 murine fibroblasts,26.5,0.6176318
775,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL4072731,1444973,Active,inhibition of human his tagged pdgfrbeta  558 to 1106 residues expressed in baculovirus by elisa,1.0,0.5323019
406,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL2010872,653741,Active,inhibition of pdgfr at 1 um,3.0,0.6489577
2010,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL1614710,1345555,Active,human kit proto oncogene receptor tyrosine kinase  type iii rtks: pdgfr csfr kit flt3 receptor family ,29.0,0.33910486
2156,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL209704,268027,Active,inhibition of pdgfrbeta,5.0,0.31686983
2028,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL378024,268027,Active,inhibition of pdgfrbeta,6.0,0.31686983
1985,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL429743,326901,Active,inhibition of pdgfrbeta,9.0,0.5600002
1465,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL2436978,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,64.0,0.64344734
2019,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL477197,341702,Active,inhibition of pdgfr by elisa,166.5,0.52251595
232,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL1725279,256661,Inactive,average binding constant for pdgfrb nanot active at 10 um,42.0,0.8289658
2009,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL1614710,1345508,Active,human colony stimulating factor 1 receptor  type iii rtks: pdgfr csfr kit flt3 receptor family ,29.0,0.33910486
1964,CHEMBL1824,Receptor protein-tyrosine kinase erbB-2,CHEMBL608533,1234682,Active,inhibition of wild type gst tagged flt3 kinase domain  y567 to s993  unknown origin expressed in baculovirus infected insect sf9 cells using her2 peptide as substrate after 4 hrs by kinase glo assay,15.0,0.70874625
881,CHEMBL1824,Receptor protein-tyrosine kinase erbB-2,CHEMBL605957,458722,Active,inhibition of erbb2 after 80 mins by radiometric protein kinase assay,44.0,0.42380455
1619,CHEMBL1824,Receptor protein-tyrosine kinase erbB-2,CHEMBL1725279,256662,Inactive,average binding constant for erbb2 nanot active at 10 um,13.5,0.5410643
407,CHEMBL1824,Receptor protein-tyrosine kinase erbB-2,CHEMBL91829,256662,Inactive,average binding constant for erbb2 nanot active at 10 um,21.0,0.4602279
1893,CHEMBL2973,Rho-associated protein kinase 2,CHEMBL2023841,659384,Active,binding affinity to his6 tagged recombinant human rock2 by fluorescence anisotropy assay,1.0,0.7099175
59,CHEMBL2973,Rho-associated protein kinase 2,CHEMBL502835,397087,Inactive,inhibition of human rock2 at 10 umol/l,50.0,0.93536526
842,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL1289926,1117328,Inactive,human p70s6k1 kinase inhibition screen,22.5,0.8694234
1646,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL1421,1117328,Inactive,human p70s6k1 kinase inhibition screen,54.5,0.8467426
1795,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL477772,1117328,Inactive,human p70s6k1 kinase inhibition screen,7.0,0.8606247
1101,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL3884319,1336094,Active,inhibition of human recombinant gst tagged rps6kb1 cytoplasmic domain  1 to 421 residues expressed in baculovirus expression system,27.5,0.7353923
1873,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL31965,1117328,Inactive,human p70s6k1 kinase inhibition screen,28.0,0.80561495
465,CHEMBL4282,Serine/threonine-protein kinase AKT,CHEMBL596991,457294,Active,inhibition of pkb in human pc3m cells assessed as gsk3 beta phosphorylation by elisa,1.0,0.8389554
417,CHEMBL4282,Serine/threonine-protein kinase AKT,CHEMBL535,479511,Inactive,inhibition of akt1,91.0,0.9605935
1273,CHEMBL4722,Serine/threonine-protein kinase Aurora-A,CHEMBL373882,277423,Active,inhibition of aura,25.0,0.53764886
1399,CHEMBL4630,Serine/threonine-protein kinase Chk1,CHEMBL302449,435712,Active,percentage chk1 activity remaining in the presence of 0 1um inhibitor,4.0,0.7461764
1466,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL14762,256650,Inactive,average binding constant for pim1 nanot active at 10 um,69.0,0.34069517
2025,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1682351,577972,Active,inhibition of pim1 after 1 hr using biotinylated al1peptide as substrate,7.0,0.34285277
75,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387465,749898,Active,inhibition of pim1  unknown origin using fam pimtide as substrate after 90 mins by spectrophotometry in presence of atp,2.0,0.9974651
42,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387471,749894,Active,cytotoxicity against mouse ba/f3 cells overexpressing pim1 after 18 hrs by celltitre glo assay,1.0,0.9974651
90,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL496587,410272,Active,inhibition of human recombinant pim1 by atp depletion assay,1.0,0.9601372
74,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387465,749894,Active,cytotoxicity against mouse ba/f3 cells overexpressing pim1 after 18 hrs by celltitre glo assay,2.0,0.9974651
43,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387471,749898,Active,inhibition of pim1  unknown origin using fam pimtide as substrate after 90 mins by spectrophotometry in presence of atp,1.0,0.9974651
118,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL496996,410272,Active,inhibition of human recombinant pim1 by atp depletion assay,1.0,0.9601372
564,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL4088576,1481671,Inactive,inhibition of human pim1 using kkrnrtltk as substrate in presence of [gamma 33p] atp,95.0,0.9364081
70,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL494355,418377,Active,inhibition of pim1 in presence of 1 um atp,1.0,0.9601372
1633,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL460472,662116,Active,inhibition of pim1,59.0,0.54484177
332,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL3794146,1293772,Active,inhibition of pim1  unknown origin using bad peptide preincubated for 15 mins followed by atp addition measured after 60 to 100 mins by kinase glo reagent based luminescence assay,1.0,0.9601372
835,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL24828,256650,Inactive,average binding constant for pim1 nanot active at 10 um,5.5,0.80653393
68,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL535,256650,Inactive,average binding constant for pim1 nanot active at 10 um,13.0,0.9998279
25,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1910907,626549,Active,inhibition of pim1 using bad peptide as substrate preincubated for 15 mins measured after 60 to 100 mins by luminescence assay,1.0,0.9974651
579,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL10,256650,Inactive,average binding constant for pim1 nanot active at 10 um,46.0,0.4040438
61,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL3792742,1293772,Active,inhibition of pim1  unknown origin using bad peptide preincubated for 15 mins followed by atp addition measured after 60 to 100 mins by kinase glo reagent based luminescence assay,2.0,0.9601372
60,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1910912,626549,Active,inhibition of pim1 using bad peptide as substrate preincubated for 15 mins measured after 60 to 100 mins by luminescence assay,1.0,0.9974651
2036,CHEMBL4523,Serine/threonine-protein kinase PIM2,CHEMBL24828,256570,Inactive,average binding constant for pim2 nanot active at 10 um,115.0,0.36693668
1679,CHEMBL4523,Serine/threonine-protein kinase PIM2,CHEMBL4088576,1481672,Inactive,inhibition of human pim2 using rsrhssypagt as substrate in presence of [gamma 33p] atp,35.0,0.8197065
26,CHEMBL4523,Serine/threonine-protein kinase PIM2,CHEMBL939,256570,Inactive,average binding constant for pim2 nanot active at 10 um,102.0,0.9341084
1536,CHEMBL4523,Serine/threonine-protein kinase PIM2,CHEMBL21156,505,Active,compound screen assay human pim2,9.0,0.6883645
1625,CHEMBL5407,Serine/threonine-protein kinase PIM3,CHEMBL296586,435814,Active,percentage pim3 activity remaining in the presence of 1um inhibitor,53.0,0.68207955
2003,CHEMBL5407,Serine/threonine-protein kinase PIM3,CHEMBL302449,435922,Active,percentage pim3 activity remaining in the presence of 0 1um inhibitor,24.5,0.747364
1085,CHEMBL5407,Serine/threonine-protein kinase PIM3,CHEMBL3794146,1293774,Active,inhibition of pim3  unknown origin using bad peptide preincubated for 15 mins followed by atp addition measured after 60 to 100 mins by kinase glo reagent based luminescence assay,2.0,0.5027861
2157,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3956709,1343927,Active,b raf  v600e kinase assay: in a dilution series 10 ul/well of test substance solution are placed in a multiwell plate the dilution series is selected so that generally a range of concentrations of 2 um to 0 119 nm or 0 017 nm is covered if necessary the initial concentration of 2 um is changed to 50 um 10 um or 0 4 um or 0 2857 um and further dilution is carried out accordingly the final concentration of dmso is 5% 10 ul/well of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase  e g from upstate in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 1 h at rt under with shaking the kinase reaction is started by the addition of 20 ul/well atp solution [final concentration: 250 um atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  ,23.0,0.22854884
1874,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1242285,507076,Active,inhibition of recombinant mtor by radioactive phosphotransfer assay in presence of 10 um atp,1.0,0.73570704
2022,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1242034,507076,Active,inhibition of recombinant mtor by radioactive phosphotransfer assay in presence of 10 um atp,2.5,0.68183255
970,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1421,507076,Active,inhibition of recombinant mtor by radioactive phosphotransfer assay in presence of 10 um atp,91.5,0.19498624
1311,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1242199,507076,Active,inhibition of recombinant mtor by radioactive phosphotransfer assay in presence of 10 um atp,1.0,0.73570704
838,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL296419,567,Inactive,primary hts assay for 5 hydroxytryptamine  serotonin receptor subtype 1a  5ht1a agonists,7.0,0.850663
1535,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL611,567,Inactive,primary hts assay for 5 hydroxytryptamine  serotonin receptor subtype 1a  5ht1a agonists,37.0,0.52704597
1519,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL515783,416168,Active,inhibition of rat hippocampus 5ht1a receptor by competitive binding assay,1.0,0.43187067
1510,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL219916,567,Inactive,primary hts assay for 5 hydroxytryptamine  serotonin receptor subtype 1a  5ht1a agonists,2.0,0.76321304
956,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL490,438555,Active,binding affinity to 5ht1a receptor,1.0,0.23650238
955,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL490,438555,Active,binding affinity to 5ht1a receptor,1.0,0.23650238
1203,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL567,567,Inactive,primary hts assay for 5 hydroxytryptamine  serotonin receptor subtype 1a  5ht1a agonists,23.5,0.53961426
1821,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL728,567,Inactive,primary hts assay for 5 hydroxytryptamine  serotonin receptor subtype 1a  5ht1a agonists,5.5,0.84824586
1943,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL437490,457688,Active,displacement of [3h] 8 oh dpat from 5ht1a receptor in wistar rat hippocampus homogenate,2.0,0.32690206
939,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL518752,416168,Active,inhibition of rat hippocampus 5ht1a receptor by competitive binding assay,1.0,0.43187067
305,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL490632,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser,7.5,0.9677863
1206,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL526,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,110.0,0.87033975
1084,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL496,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,17.5,0.90660655
1078,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL56,720643,Inactive,late stage for the probe development effort to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a : luminescence based cell based high throughput dose response assay for agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,5.0,0.92086196
1077,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL56,720642,Inactive,late stage counterscreen for the probe development effort to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a : luminescence based cell based high throughput dose response assay to identify agonists of the mu 1 opioid receptor  oprm1 ,5.0,0.92086196
1038,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL395059,292752,Inactive,agonist activity at 5ht2a receptor expressed in hek293 cells assessed as intracellular calcium mobilisation up to 10 um,1.0,0.86518335
1037,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL395059,292746,Active,displacement of [3h]ketanserin from 5ht2a receptor expressed in hek293 cells,1.0,0.86518335
841,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL211719,269244,Active,binding affinity to human 5ht2a receptor,1.0,0.86518335
1013,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL490634,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser,14.0,0.7837784
2035,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL58,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,170.0,0.7337418
354,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL440687,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,1.5,0.31781423
1269,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL223584,280444,Active,activity at human 5ht2a expressed in hek293e cells assessed as elevation of intracellular calcium by 384 flipr assay relative to serotonin,1.0,0.86518335
982,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL517712,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,7.0,0.7314866
893,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL18772,441265,Active,displacement of [3h]ketanserin from 5ht2a receptor in rat cortex,7.0,0.86062044
376,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL964,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,48.5,0.73583543
195,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL492917,418828,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux by flipr assay,1.0,0.86518335
382,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL234006,292752,Inactive,agonist activity at 5ht2a receptor expressed in hek293 cells assessed as intracellular calcium mobilisation up to 10 um,1.0,0.86518335
207,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL489408,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser,13.5,0.92943066
1686,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL472678,418828,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux by flipr assay,1.0,0.86518335
349,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL476839,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser,8.5,0.96405476
428,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL1323615,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,12.5,0.9200838
577,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL509418,418828,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux by flipr assay,2.5,0.86518335
569,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL1670,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,6.0,0.756775
1423,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL212686,269244,Active,binding affinity to human 5ht2a receptor,1.5,0.67362493
892,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL18772,375323,Active,displacement of [3h]ketanserin from 5ht2a receptor in rat cortex,7.0,0.86062044
902,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL388882,292775,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells by measuring intracellular calcium mobilization upto 10 um,1.0,0.86518335
901,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL388882,292770,Active,displacement of [3h]ketanserin from human 5ht2a receptor expressed in hek293 cells,1.0,0.86518335
381,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL234006,292746,Active,displacement of [3h]ketanserin from 5ht2a receptor expressed in hek293 cells,1.0,0.86518335
2101,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL211980,269244,Active,binding affinity to human 5ht2a receptor,1.5,0.67362493
545,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL588119,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,63.0,0.8625496
1119,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL3770174,1280456,Inactive,agonist activity at recombinant human 5ht2a receptor expressed in flp in 293 cells assessed as calcium flux by flipr assay,1.0,0.86518335
83,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL402143,320831,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells,3.5,0.96941483
2133,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL238730,305569,Active,displacement of [3h]ketanserin from human cloned 5ht2a receptor expressed in hek293 cells,3.0,0.6528891
57,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL515472,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser,1.5,0.97759753
1584,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL547,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a ,103.5,0.5921355
84,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL402143,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser,3.5,0.96941483
1120,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL3770174,1280456,Inactive,agonist activity at recombinant human 5ht2a receptor expressed in flp in 293 cells assessed as calcium flux by flipr assay,1.0,0.86518335
1482,CHEMBL1833,Serotonin 2b (5-HT2b) receptor,CHEMBL475384,418829,Inactive,agonist activity at human 5ht2b receptor expressed in hek293 cells assessed as calcium flux by flipr assay,1.5,0.35255137
570,CHEMBL1833,Serotonin 2b (5-HT2b) receptor,CHEMBL509446,410403,Active,binding affinity to 5ht2b receptor at 500 nm to 2 um,3.5,0.058212068
1730,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL391984,308686,Active,displacement of [3h]mesulergine human cloned serotonin 5ht2c receptor,1.5,0.5155973
429,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL2037519,664319,Inactive,binding affinity to human 5ht2c receptor by radioligand displacement assay,9.0,0.66427267
1672,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL2037523,664319,Inactive,binding affinity to human 5ht2c receptor by radioligand displacement assay,1.5,0.3671783
880,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL2037527,664319,Inactive,binding affinity to human 5ht2c receptor by radioligand displacement assay,1.5,0.3671783
853,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL1946255,664319,Inactive,binding affinity to human 5ht2c receptor by radioligand displacement assay,2.0,0.75093645
565,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL183460,305571,Active,displacement of [3h]mesulergine from human cloned 5ht2c receptor expressed in hek293 cells,4.0,0.93745095
1285,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL221692,298485,Inactive,displacement of [3h]mesulergine from 5ht2c receptor expressed in cho cells,27.5,0.914798
534,CHEMBL228,Serotonin transporter,CHEMBL3407785,1443748,Inactive,enhancing of [125i]rti 55 binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis,6.0,0.96643484
2143,CHEMBL228,Serotonin transporter,CHEMBL4062435,1472454,Active,displacement of [3h]citalopram from sprague dawley rat brain sert after 60 mins by liquid scintillation counting method,6.5,0.8018852
573,CHEMBL228,Serotonin transporter,CHEMBL4074774,1472454,Active,displacement of [3h]citalopram from sprague dawley rat brain sert after 60 mins by liquid scintillation counting method,1.0,0.7886081
46,CHEMBL228,Serotonin transporter,CHEMBL559490,431883,Active,inhibition of [3h]hydroxytryptamine creatinine sulfate uptake at human sert expressed in human jar cells,1.0,0.84005564
2158,CHEMBL228,Serotonin transporter,CHEMBL199103,1472454,Active,displacement of [3h]citalopram from sprague dawley rat brain sert after 60 mins by liquid scintillation counting method,6.5,0.7886081
441,CHEMBL228,Serotonin transporter,CHEMBL358967,471665,Active,inhibition of [3h]5 ht uptake at sert in rat brain synaptosome,1.0,0.9661891
203,CHEMBL228,Serotonin transporter,CHEMBL2064645,1443748,Inactive,enhancing of [125i]rti 55 binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis,7.0,0.96643484
1402,CHEMBL228,Serotonin transporter,CHEMBL3916231,1324591,Active,displacement of [3h]citalopram from sert in sprague dawley rat brain stem membranes incubated for 60 mins by radioligand binding assay,1.0,0.8056065
318,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259103,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m ,1.0,0.9661891
319,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m ,1.0,0.9661891
320,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m ,1.0,0.9661891
321,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m ,1.0,0.9661891
204,CHEMBL228,Serotonin transporter,CHEMBL2064645,1443749,Inactive,enhancing of [3h]mazindol binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis,7.0,0.96643484
574,CHEMBL228,Serotonin transporter,CHEMBL4074774,1472454,Active,displacement of [3h]citalopram from sprague dawley rat brain sert after 60 mins by liquid scintillation counting method,1.0,0.7886081
78,CHEMBL228,Serotonin transporter,CHEMBL566886,459713,Active,inhibition of [3h]serotonin uptake at human sert expressed in hek293 cells,1.0,0.96694547
383,CHEMBL228,Serotonin transporter,CHEMBL3084884,273269,Active,displacement of [3h]citalopram from sert in sprague dawley rat brain,4.0,0.79384923
1729,CHEMBL228,Serotonin transporter,CHEMBL1914695,628083,Active,displacement of [125i] idam from sert transfected in pig llc pk1 cells by radioligand competition binding assay,1.5,0.7886081
1871,CHEMBL228,Serotonin transporter,CHEMBL814,1346943,Active,human sert  monoamine transporter subfamily ,6.0,0.8071927
535,CHEMBL228,Serotonin transporter,CHEMBL3407785,1443749,Inactive,enhancing of [3h]mazindol binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis,6.0,0.96643484
721,CHEMBL228,Serotonin transporter,CHEMBL243204,296171,Active,displacement of [125i]rti55 from human sert expressed in cos1 cell membrane,1.5,0.7886081
1872,CHEMBL228,Serotonin transporter,CHEMBL814,1346955,Active,rat sert  monoamine transporter subfamily ,6.0,0.8071927
1103,CHEMBL228,Serotonin transporter,CHEMBL3085025,257285,Active,displacement of [3h]citalopram from sert,1.0,0.8455421
1970,CHEMBL228,Serotonin transporter,CHEMBL1632209,541184,Active,inhibition of [3h]5 ht uptake at sert in rat cortical synaptosomes,9.0,0.3008773
567,CHEMBL228,Serotonin transporter,CHEMBL668,1346943,Active,human sert  monoamine transporter subfamily ,27.0,0.84233844
1726,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
1724,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
1727,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
927,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
928,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
929,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
926,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
930,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,1054299,Active,agonist activity at s1p1 receptor  unknown origin ,1.0,0.79027355
1725,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3,1.0,0.79027355
2057,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL3699118,1258344,Active,in vitro assay: receptor binding assay: membranes were prepared from cho cells expressing s1p1 or s1p3 for use in ligand and 35s gtpgammas binding studies cells were suspended in 50 mm tris ph 7 4 2 mm edta 250 mm sucrose  buffer a and 1x complete protease inhibitor cocktail  roche and disrupted at 4 c by nitrogen decompression using a cell disruption bomb  parr instrument following centrifugation at 1000 rpm for 10 min at 4 c the supernatant was suspended in buffer a and centrifuged again at 19000 rpm for 60 min at 4 c the pellet was then suspended in 10 mm hepes ph 7 4 1 mm edta 250 mm sucrose  buffer b and 1x complete edta free protease inhibitor cocktail and homogenized using a potter membranes were flash frozen in liquid nitrogen and stored at  80 c [33p]sphingosine 1 phosphate  3000 ci/mmol american radiolabeled chemicals inc was added to test compounds in dmso membranes and wga spa beads  ge healthcare were added to give a final volume of 100 ul in 96 we,1.0,0.32704404
2056,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL3699118,1258344,Active,in vitro assay: receptor binding assay: membranes were prepared from cho cells expressing s1p1 or s1p3 for use in ligand and 35s gtpgammas binding studies cells were suspended in 50 mm tris ph 7 4 2 mm edta 250 mm sucrose  buffer a and 1x complete protease inhibitor cocktail  roche and disrupted at 4 c by nitrogen decompression using a cell disruption bomb  parr instrument following centrifugation at 1000 rpm for 10 min at 4 c the supernatant was suspended in buffer a and centrifuged again at 19000 rpm for 60 min at 4 c the pellet was then suspended in 10 mm hepes ph 7 4 1 mm edta 250 mm sucrose  buffer b and 1x complete edta free protease inhibitor cocktail and homogenized using a potter membranes were flash frozen in liquid nitrogen and stored at  80 c [33p]sphingosine 1 phosphate  3000 ci/mmol american radiolabeled chemicals inc was added to test compounds in dmso membranes and wga spa beads  ge healthcare were added to give a final volume of 100 ul in 96 we,1.0,0.32704404
351,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL518292,485,Inactive,primary hts assay for s1p3 antagonists,64.0,0.32704404
2161,CHEMBL1936,Stem cell growth factor receptor,CHEMBL65,704295,Active,cytotoxicity against human du145 cells after 2 days by cell counting kit 8 analysis,223.0,0.023660174
2159,CHEMBL1936,Stem cell growth factor receptor,CHEMBL65,704293,Active,cytotoxicity against human t47d cells after 2 days by cell counting kit 8 analysis,223.0,0.023660174
1362,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1784637,1345563,Active,human platelet derived growth factor receptor alpha  type iii rtks: pdgfr csfr kit flt3 receptor family ,1.0,0.77871126
2070,CHEMBL1936,Stem cell growth factor receptor,CHEMBL10,256660,Inactive,average binding constant for kit nanot active at 10 um,91.0,0.48695388
2026,CHEMBL1936,Stem cell growth factor receptor,CHEMBL274654,1345590,Active,human platelet derived growth factor receptor beta  type iii rtks: pdgfr csfr kit flt3 receptor family ,26.5,0.5239575
1006,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1081312,1345563,Active,human platelet derived growth factor receptor alpha  type iii rtks: pdgfr csfr kit flt3 receptor family ,14.0,0.82556903
2165,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1822792,1345590,Active,human platelet derived growth factor receptor beta  type iii rtks: pdgfr csfr kit flt3 receptor family ,34.0,0.64862484
845,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1084546,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,10.5,0.91042125
2160,CHEMBL1936,Stem cell growth factor receptor,CHEMBL65,704294,Active,cytotoxicity against human hct15 cells after 2 days by cell counting kit 8 analysis,223.0,0.023660174
1298,CHEMBL1936,Stem cell growth factor receptor,CHEMBL49120,1345590,Active,human platelet derived growth factor receptor beta  type iii rtks: pdgfr csfr kit flt3 receptor family ,1.0,0.8670476
1914,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1940274,1386988,Active,inhibition of kit exon 11 deletion  557 to 558 residues and v654a mutant  unknown origin transfected in mouse ba/f3 cells assessed as inhibition of cell growth incubated for 72 hrs by mts assay,1.0,0.54358166
1916,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1940274,1386990,Active,inhibition of kit exon 11 deletion  557 to 558 residues and d816h mutant and t670i mutant  unknown origin transfected in mouse ba/f3 cells assessed as inhibition of cell growth incubated for 72 hrs by mts assay,1.0,0.54358166
2164,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1822792,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,34.0,0.64862484
1505,CHEMBL1936,Stem cell growth factor receptor,CHEMBL2436978,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family ,3.0,0.7451507
1913,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1940274,639903,Inactive,inhibition of c kit,1.0,0.54358166
2162,CHEMBL1936,Stem cell growth factor receptor,CHEMBL65,704296,Active,cytotoxicity against human hek293 cells after 2 days by cell counting kit 8 analysis,223.0,0.023660174
1915,CHEMBL1936,Stem cell growth factor receptor,CHEMBL1940274,1386989,Active,inhibition of kit exon 11 deletion  557 to 558 residues and d816h mutant  unknown origin transfected in mouse ba/f3 cells assessed as inhibition of cell growth incubated for 72 hrs by mts assay,1.0,0.54358166
1495,CHEMBL204,Thrombin,CHEMBL604954,459567,Active,anticoagulant potency in human plasma assessed as concentration required to double the prothrombin time,10.5,0.26735628
470,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,255763,Active,inhibitory activity against abl kinase,1.0,0.9118318
469,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,254706,Active,inhibitory concentration against v abl tyrosine kinase,1.0,0.9118318
495,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1301434,Active,inhibition of human abl using eaiyaapfakkk as substrate after 40 mins by scintillation counting analysis in presence of [gamma 33p atp],1.0,0.9118318
455,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,588664,Inactive,trfret based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the ras and rab interactor 1 protein  rin1 and the c abl oncogene 1 non receptor tyrosine kinase  abl ,43.0,0.9028985
466,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,32559,Active,inhibition of abl kinase,1.0,0.9118318
602,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491334,Active,inhibition of human abl y253h mutant after 2 hrs by tr fret assay,1.0,0.70338285
601,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491334,Active,inhibition of human abl y253h mutant after 2 hrs by tr fret assay,1.0,0.70338285
467,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,32559,Active,inhibition of abl kinase,1.0,0.9118318
454,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,588664,Inactive,trfret based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the ras and rab interactor 1 protein  rin1 and the c abl oncogene 1 non receptor tyrosine kinase  abl ,43.0,0.9028985
468,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,240522,Active,inhibition of v abl tyrosine kinase,1.0,0.9118318
753,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1081198,470464,Active,inhibition of abl1 after 1 hr,3.0,0.49163067
497,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386050,Active,inhibition of wild type bcr abl1  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
452,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,256670,Inactive,average binding constant for abl1 t315i nanot active at 10 um,43.0,0.9028985
594,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491316,Active,antitumor activity against mouse ba/f3 cells expressing abl t315i mutant xenografted in nude mouse assessed as increase in overall survival at 30 mg/kg po qd for 19 days,1.0,0.70338285
614,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491343,Active,antiproliferative activity against mouse ba/f3 cells expressing abl f255v mutant after 3 days by mts assay,1.0,0.70338285
595,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491331,Active,inhibition of human abl t315a mutant after 2 hrs by tr fret assay,1.0,0.70338285
596,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491331,Active,inhibition of human abl t315a mutant after 2 hrs by tr fret assay,1.0,0.70338285
615,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491344,Active,antiproliferative activity against mouse ba/f3 cells expressing abl f359v mutant after 3 days by mts assay,1.0,0.70338285
597,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491332,Active,inhibition of human abl f317l mutant after 2 hrs by tr fret assay,1.0,0.70338285
598,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491332,Active,inhibition of human abl f317l mutant after 2 hrs by tr fret assay,1.0,0.70338285
599,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491333,Active,inhibition of human abl f317v mutant after 2 hrs by tr fret assay,1.0,0.70338285
505,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386086,Active,inhibition of bcr abl1 y253h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
504,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386085,Active,inhibition of bcr abl1 q252h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
453,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,256671,Inactive,average binding constant for abl1 y253f nanot active at 10 um,43.0,0.9028985
616,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,601428,Active,inhibition of wild type human abl using [eaiyaapfakkk] peptide substrate after 1 hr by tr fret assay,1.0,0.70338285
503,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386085,Active,inhibition of bcr abl1 q252h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
603,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491335,Active,inhibition of human abl f255k mutant after 2 hrs by tr fret assay,1.0,0.70338285
502,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386084,Active,inhibition of bcr abl1 g250h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
600,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491333,Active,inhibition of human abl f317v mutant after 2 hrs by tr fret assay,1.0,0.70338285
496,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1345606,Active,human abl proto oncogene 1 non receptor tyrosine kinase  abl family ,1.0,0.9118318
447,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,256665,Inactive,average binding constant for abl1 nanot active at 10 um,43.0,0.9028985
448,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,256666,Inactive,average binding constant for abl1 q252h nanot active at 10 um,43.0,0.9028985
449,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,256667,Inactive,average binding constant for abl1 e255k nanot active at 10 um,43.0,0.9028985
450,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,256668,Inactive,average binding constant for abl1 h396p nanot active at 10 um,43.0,0.9028985
451,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1725279,256669,Inactive,average binding constant for abl1 m351t nanot active at 10 um,43.0,0.9028985
498,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386050,Active,inhibition of wild type bcr abl1  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
501,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386084,Active,inhibition of bcr abl1 g250h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
623,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724975,Active,inhibition of human recombinant abl1 m351t mutant expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
499,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386051,Active,inhibition of bcr abl1 t315i mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
618,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,601429,Active,inhibition of human abl t315i mutant using [eaiyaapfakkk] peptide substrate after 2 hrs by tr fret assay,1.0,0.70338285
641,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1301834,Active,inhibition of human wild type bcr abl expressed in mouse baf3 cells assessed as inhibition of cell proliferation after 72 hrs by mtt assay,1.0,0.70338285
642,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1301835,Active,inhibition of human bcr abl t315i mutant expressed in mouse baf3 cells assessed as inhibition of cell proliferation after 72 hrs by mtt assay,1.0,0.70338285
643,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1301835,Active,inhibition of human bcr abl t315i mutant expressed in mouse baf3 cells assessed as inhibition of cell proliferation after 72 hrs by mtt assay,1.0,0.70338285
644,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1343790,Active,abl1  t315i kinase activity assay: serially diluting the compound of the present invention from 1 um initial concentration in three fold fashion and formulating 10 concentrations  50 8 pm 152 0 pm 457 0 pm 1 37 nm 4 12 nm 12 3 nm 37 0 nm 111 0 nm 333 0 nm and 1 0 um 5 0 um abltide was added into each well and then human t315i mutant enzyme was added [gamma 33p] atp was added at room temperature with final concentration of 1 0 um and the reaction was performed for 120 minutes 20 ul aliquots were transferred onto the ion exchange chromatography paper p81 the paper was thoroughly washed with a 0 75% phosphoric acid solution three times and then washed with acetone once finally gamma 33p radioactivity was measured ,1.0,0.70338285
645,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1345606,Active,human abl proto oncogene 1 non receptor tyrosine kinase  abl family ,1.0,0.70338285
646,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386050,Active,inhibition of wild type bcr abl1  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
647,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386050,Active,inhibition of wild type bcr abl1  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
640,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1301834,Active,inhibition of human wild type bcr abl expressed in mouse baf3 cells assessed as inhibition of cell proliferation after 72 hrs by mtt assay,1.0,0.70338285
648,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386051,Active,inhibition of bcr abl1 t315i mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
617,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,601429,Active,inhibition of human abl t315i mutant using [eaiyaapfakkk] peptide substrate after 2 hrs by tr fret assay,1.0,0.70338285
487,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624987,Active,binding constant for abl1 q252h  phosphorylated kinase domain,1.0,0.9118318
484,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624984,Active,binding constant for abl1 h396p  phosphorylated kinase domain,1.0,0.9118318
483,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624983,Active,binding constant for abl1 h396p  non phosphorylated kinase domain,1.0,0.9118318
482,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624982,Active,binding constant for abl1 f317l  phosphorylated kinase domain,1.0,0.9118318
481,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624981,Active,binding constant for abl1 f317l  non phosphorylated kinase domain,1.0,0.9118318
480,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624980,Active,binding constant for abl1 f317i  phosphorylated kinase domain,1.0,0.9118318
479,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624979,Active,binding constant for abl1 f317i  non phosphorylated kinase domain,1.0,0.9118318
649,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386051,Active,inhibition of bcr abl1 t315i mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
650,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386084,Active,inhibition of bcr abl1 g250h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
639,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1283290,Active,cytotoxicity against mouse ba/f3 cells expressing bcr abl t315i mutant after 72 hrs by mtt assay,1.0,0.70338285
637,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1240469,Active,inhibition of bcr abl t315i mutant  unknown origin using tyr2 peptide substrate after 2 hrs by fret based z' lyte assay,1.0,0.70338285
624,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724976,Active,inhibition of human recombinant abl1 h396p mutant expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
621,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,601432,Active,antiproliferative activity against bcr abl negative parental mouse ba/f3 cells,1.0,0.70338285
625,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724977,Active,inhibition of human recombinant abl1 g250e mutant expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
626,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724978,Active,inhibition of human recombinant abl1 q252h mutant expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
620,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,601431,Active,antiproliferative activity against mouse ba/f3 cells expressing abl t315i mutant,1.0,0.70338285
627,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724979,Active,inhibition of human recombinant abl1 e255k mutant expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
628,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724980,Active,inhibition of human recombinant abl1 t315i mutant expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
486,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624986,Active,binding constant for abl1 q252h  non phosphorylated kinase domain,1.0,0.9118318
638,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1240469,Active,inhibition of bcr abl t315i mutant  unknown origin using tyr2 peptide substrate after 2 hrs by fret based z' lyte assay,1.0,0.70338285
619,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,601430,Active,antiproliferative activity against mouse ba/f3 cells expressing wild type bcr abl,1.0,0.70338285
629,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724981,Active,inhibition of human recombinant wild type abl1 expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
630,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,739102,Active,cytotoxicity against mouse ba/f3 cells transfected with wild type bcr abl after 48 hrs by xtt assay,1.0,0.70338285
631,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,759166,Active,inhibition of abl t315i mutant  unknown origin  mediated phosphorylation of biotinylated poly glu tyr preincubated for 30 to 60 mins prior to substrate addition by tr fret assay,1.0,0.70338285
632,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,759168,Active,inhibition of human wild type abl  ser229 to gln513  mediated phosphorylation of biotinylated poly glu tyr expressed in escherichia coli bl21 de3 preincubated for 30 to 60 mins prior to substrate addition by tr fret assay,1.0,0.70338285
633,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1240405,Active,antiproliferative activity against human k562 cells expressing wild type bcr abl after 72 hrs by cck 8 assay,1.0,0.70338285
634,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1240407,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl t315i mutant after 72 hrs by cck 8 assay,1.0,0.70338285
635,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1240468,Active,inhibition of wild type bcr abl  unknown origin using tyr2 peptide substrate after 2 hrs by fret based z' lyte assay,1.0,0.70338285
636,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1240468,Active,inhibition of wild type bcr abl  unknown origin using tyr2 peptide substrate after 2 hrs by fret based z' lyte assay,1.0,0.70338285
485,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624985,Active,binding constant for abl1 m351t  phosphorylated kinase domain,1.0,0.9118318
500,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386051,Active,inhibition of bcr abl1 t315i mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
488,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624988,Active,binding constant for abl1 t315i  non phosphorylated kinase domain,1.0,0.9118318
477,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,507680,Active,inhibition of abl t315i mutant,1.0,0.9118318
492,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624992,Active,binding constant for abl1 phosphorylated kinase domain,1.0,0.9118318
664,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386091,Active,inhibition of bcr abl1 e459k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
665,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386091,Active,inhibition of bcr abl1 e459k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
493,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1283290,Active,cytotoxicity against mouse ba/f3 cells expressing bcr abl t315i mutant after 72 hrs by mtt assay,1.0,0.9118318
666,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1431278,Active,inhibition of recombinant human abl using peptide substrate eaiyaapfakkk in presence of [33 p]atp by kinase hotspot assay,1.0,0.70338285
667,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1435454,Active,inhibition of recombinant abl  unknown origin using poly  glu tyr 4:1 as substrate after 60 mins by elisa,1.0,0.70338285
668,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1454437,Active,displacement of cat 1 from catalytic site of n terminal his6 tagged abl  83 to 534 residues  unknown origin expressed in escherichia coli co expressing protein tyrosine phosphatase 1b at 25 um by 19f nmr spectroscopy based dual site competition assay,1.0,0.70338285
494,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1299348,Active,inhibition of abl  unknown origin ,1.0,0.9118318
663,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386090,Active,inhibition of bcr abl1 f359v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
669,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1454442,Active,displacement of cat 1 from catalytic site of n terminal his6 tagged abl t315i mutant  unknown origin at 25 um by 19f nmr spectroscopy based dual site competition assay,1.0,0.70338285
610,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491339,Active,antiproliferative activity against mouse ba/f3 cells expressing abl f317l mutant after 3 days by mts assay,1.0,0.70338285
609,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491338,Active,antiproliferative activity against mouse ba/f3 cells expressing abl t315a mutant after 3 days by mts assay,1.0,0.70338285
622,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,724974,Active,inhibition of human recombinant abl1 y253f mutant expressed in insect cells after 30 mins by fret assay,1.0,0.70338285
608,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491337,Active,inhibition of human abl f359v mutant after 2 hrs by tr fret assay,1.0,0.70338285
607,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491337,Active,inhibition of human abl f359v mutant after 2 hrs by tr fret assay,1.0,0.70338285
606,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491336,Active,inhibition of human abl f255v mutant after 2 hrs by tr fret assay,1.0,0.70338285
605,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491336,Active,inhibition of human abl f255v mutant after 2 hrs by tr fret assay,1.0,0.70338285
604,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491335,Active,inhibition of human abl f255k mutant after 2 hrs by tr fret assay,1.0,0.70338285
611,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491340,Active,antiproliferative activity against mouse ba/f3 cells expressing abl f317v mutant after 3 days by mts assay,1.0,0.70338285
478,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624978,Active,binding constant for abl1 e255k  phosphorylated kinase domain,1.0,0.9118318
661,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386089,Active,inhibition of bcr abl1 e355g mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
659,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386088,Active,inhibition of bcr abl1 e255v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
476,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,507429,Active,inhibition of abl1,1.0,0.9118318
475,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,463625,Active,inhibition of wild type abl,1.0,0.9118318
474,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,271012,Active,inhibition of bcr abl fusion protein,1.0,0.9118318
651,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386084,Active,inhibition of bcr abl1 g250h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
652,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386085,Active,inhibition of bcr abl1 q252h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
653,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386085,Active,inhibition of bcr abl1 q252h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
654,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386086,Active,inhibition of bcr abl1 y253h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
473,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,271012,Active,inhibition of bcr abl fusion protein,1.0,0.9118318
660,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386089,Active,inhibition of bcr abl1 e355g mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
472,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,255819,Active,inhibitory concentration against abl transformed rat fibroblast cells,1.0,0.9118318
655,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386086,Active,inhibition of bcr abl1 y253h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
656,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386087,Active,inhibition of bcr abl1 e255k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
657,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386087,Active,inhibition of bcr abl1 e255k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
658,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386088,Active,inhibition of bcr abl1 e255v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
490,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624990,Active,binding constant for abl1 y253f  phosphorylated kinase domain,1.0,0.9118318
491,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624991,Active,binding constant for abl1 non phosphorylated kinase domain,1.0,0.9118318
471,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,255763,Active,inhibitory activity against abl kinase,1.0,0.9118318
612,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491341,Active,antiproliferative activity against mouse ba/f3 cells expressing abl y253h mutant after 3 days by mts assay,1.0,0.70338285
489,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624989,Active,binding constant for abl1 t315i  phosphorylated kinase domain,1.0,0.9118318
662,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,1386090,Active,inhibition of bcr abl1 f359v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.70338285
588,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491287,Active,inhibition of human abl t315i mutant after 2 hrs by tr fret assay,1.0,0.70338285
1977,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL124660,256665,Inactive,average binding constant for abl1 nanot active at 10 um,15.0,0.7974882
166,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624983,Active,binding constant for abl1 h396p  non phosphorylated kinase domain,2.0,0.9839207
165,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624982,Active,binding constant for abl1 f317l  phosphorylated kinase domain,2.0,0.9839207
164,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624981,Active,binding constant for abl1 f317l  non phosphorylated kinase domain,2.0,0.9839207
163,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624980,Active,binding constant for abl1 f317i  phosphorylated kinase domain,2.0,0.9839207
162,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624979,Active,binding constant for abl1 f317i  non phosphorylated kinase domain,2.0,0.9839207
161,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624978,Active,binding constant for abl1 e255k  phosphorylated kinase domain,2.0,0.9839207
160,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435897,Active,binding constant for abl1 t315i kinase domain,2.0,0.9839207
159,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435776,Active,binding constant for abl1 y253f kinase domain,2.0,0.9839207
510,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386088,Active,inhibition of bcr abl1 e255v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
167,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624984,Active,binding constant for abl1 h396p  phosphorylated kinase domain,2.0,0.9839207
158,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435775,Active,binding constant for abl1 kinase domain,2.0,0.9839207
156,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435515,Active,binding constant for abl1 q252h kinase domain,2.0,0.9839207
509,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386088,Active,inhibition of bcr abl1 e255v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
155,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435514,Active,binding constant for abl1 m351t kinase domain,2.0,0.9839207
153,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,350250,Active,inhibition of abl1,2.0,0.9839207
152,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256671,Active,average binding constant for abl1 y253f nanot active at 10 um,2.0,0.9839207
151,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256670,Active,average binding constant for abl1 t315i nanot active at 10 um,2.0,0.9839207
150,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256669,Active,average binding constant for abl1 m351t nanot active at 10 um,2.0,0.9839207
149,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256668,Active,average binding constant for abl1 h396p nanot active at 10 um,2.0,0.9839207
508,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386087,Active,inhibition of bcr abl1 e255k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
157,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435644,Active,binding constant for abl1 e255k kinase domain,2.0,0.9839207
168,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624985,Active,binding constant for abl1 m351t  phosphorylated kinase domain,2.0,0.9839207
511,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386089,Active,inhibition of bcr abl1 e355g mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
512,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386089,Active,inhibition of bcr abl1 e355g mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
183,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1394735,Active,inhibition of recombinant human abl expressed in insect cells using ulight tk peptide as substrate after 60 mins by lance method,2.0,0.9839207
182,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1350953,Active,inhibition of abl1  unknown origin ,2.0,0.9839207
181,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1308928,Active,inhibition of abl  unknown origin incubated for 1 hr by spectrophotometric analysis,2.0,0.9839207
180,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1300795,Active,inhibition of abl  unknown origin by mobility shift assay,2.0,0.9839207
1983,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL124660,256671,Inactive,average binding constant for abl1 y253f nanot active at 10 um,15.0,0.7974882
1982,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL124660,256670,Inactive,average binding constant for abl1 t315i nanot active at 10 um,15.0,0.7974882
1981,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL124660,256669,Inactive,average binding constant for abl1 m351t nanot active at 10 um,15.0,0.7974882
1980,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL124660,256668,Inactive,average binding constant for abl1 h396p nanot active at 10 um,15.0,0.7974882
179,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1236888,Active,inhibition of bcr abl1  unknown origin assessed as atp remaining by kinase glo luminescent kinase assay,2.0,0.9839207
178,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1236888,Active,inhibition of bcr abl1  unknown origin assessed as atp remaining by kinase glo luminescent kinase assay,2.0,0.9839207
177,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1069558,Active,inhibition of abl  unknown origin after 30 mins,2.0,0.9839207
176,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,629262,Active,inhibition of abl1,2.0,0.9839207
1979,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL124660,256667,Inactive,average binding constant for abl1 e255k nanot active at 10 um,15.0,0.7974882
1978,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL124660,256666,Inactive,average binding constant for abl1 q252h nanot active at 10 um,15.0,0.7974882
175,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624992,Active,binding constant for abl1 phosphorylated kinase domain,2.0,0.9839207
174,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624991,Active,binding constant for abl1 non phosphorylated kinase domain,2.0,0.9839207
173,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624990,Active,binding constant for abl1 y253f  phosphorylated kinase domain,2.0,0.9839207
172,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624989,Active,binding constant for abl1 t315i  phosphorylated kinase domain,2.0,0.9839207
171,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624988,Active,binding constant for abl1 t315i  non phosphorylated kinase domain,2.0,0.9839207
170,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624987,Active,binding constant for abl1 q252h  phosphorylated kinase domain,2.0,0.9839207
169,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624986,Active,binding constant for abl1 q252h  non phosphorylated kinase domain,2.0,0.9839207
507,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386087,Active,inhibition of bcr abl1 e255k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
148,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256667,Active,average binding constant for abl1 e255k nanot active at 10 um,2.0,0.9839207
154,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435146,Active,binding constant for abl1 h396p kinase domain,2.0,0.9839207
146,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256665,Active,average binding constant for abl1 nanot active at 10 um,2.0,0.9839207
593,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491315,Active,antitumor activity against mouse ba/f3 cells expressing abl t315i mutant xenografted in nude mouse assessed as increase in overall survival at 10 mg/kg po qd for 19 days,1.0,0.70338285
592,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491293,Active,inhibition of abl t315i mutant autophosphorylation,1.0,0.70338285
591,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491292,Active,inhibition of abl autophosphorylation,1.0,0.70338285
1626,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL169920,228813,Active,concentration required for inhibition of v abl receptor by tyrosine kinase enzyme assay,13.5,0.37438616
1627,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL169920,228813,Active,concentration required for inhibition of v abl receptor by tyrosine kinase enzyme assay,13.5,0.37438616
590,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491289,Active,antiproliferative activity against mouse ba/f3 cells expressing abl t315i mutant after 3 days by mts assay,1.0,0.70338285
589,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491288,Active,antiproliferative activity against mouse ba/f3 cells expressing wild type abl after 3 days by mts assay,1.0,0.70338285
613,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491342,Active,antiproliferative activity against mouse ba/f3 cells expressing abl f255k mutant after 3 days by mts assay,1.0,0.70338285
587,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491287,Active,inhibition of human abl t315i mutant after 2 hrs by tr fret assay,1.0,0.70338285
586,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL1171837,491286,Active,inhibition of wild type human abl after 1 hr by tr fret assay,1.0,0.70338285
147,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256666,Active,average binding constant for abl1 q252h nanot active at 10 um,2.0,0.9839207
101,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL50,31746,Active,cytotoxic effect on v abl transformed murine ann 1 cells,64.0,0.6247915
516,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386091,Active,inhibition of bcr abl1 e459k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
515,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386091,Active,inhibition of bcr abl1 e459k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
506,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386086,Active,inhibition of bcr abl1 y253h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
184,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1481070,Active,inhibition of human abl1 using eaiyaapfakkk as substrate in presence of [gamma 32p]atp,2.0,0.9839207
514,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386090,Active,inhibition of bcr abl1 f359v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
143,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,228824,Active,inhibition of abl tyrosine kinase,2.0,0.9839207
144,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,228824,Active,inhibition of abl tyrosine kinase,2.0,0.9839207
145,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,240823,Active,inhibition of c abl tyrosine kinase activity,2.0,0.9839207
513,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386090,Active,inhibition of bcr abl1 f359v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay,1.0,0.9118318
940,CHEMBL2959,Tyrosine-protein kinase ITK/TSK,CHEMBL1421,329183,Inactive,binding affinity to itk from human k562 cells extract by lc msms,54.5,0.6733506
941,CHEMBL2959,Tyrosine-protein kinase ITK/TSK,CHEMBL1421,329187,Inactive,inhibition of recombinant itk,54.5,0.6733506
847,CHEMBL2959,Tyrosine-protein kinase ITK/TSK,CHEMBL50,1345086,Inactive,primary high throughput screening by co culture imaging for identification hits as a selective cytotoxic compound to cancer cells in an emt like state,34.5,0.34888503
942,CHEMBL2959,Tyrosine-protein kinase ITK/TSK,CHEMBL1421,329195,Active,inhibition of itk f435t mutant,54.5,0.6733506
1166,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL941,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um,44.0,0.8317526
27,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL428690,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um,48.0,0.9709202
566,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3884319,1336071,Active,inhibition of human recombinant gst tagged jak1 cytoplasmic domain  866 to 1154 residues expressed in baculovirus expression system,58.0,0.8450426
1396,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675694,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.5,0.7917431
1822,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL607707,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um,88.0,0.84392065
442,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3622829,1251066,Active,inhibition of jak1  unknown origin using 87 um of atp and tyr6 peptide by z' lyte kinase assay,1.0,0.9577667
1295,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.0,0.7917431
1395,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675694,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.5,0.7917431
1400,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675691,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,5.0,0.7917431
372,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3622828,1251066,Active,inhibition of jak1  unknown origin using 87 um of atp and tyr6 peptide by z' lyte kinase assay,2.0,0.9201065
1294,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.0,0.7917431
1401,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675691,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,5.0,0.7917431
356,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL553,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um,62.0,0.97018784
132,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675685,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,5.0,0.9201065
731,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL189963,1125297,Active,inhibition of gst fused human flt3 cytoplasmic domain  amino acids 564 to 993 using ulight jak1 as substrate after 1 hr by tr fret assay,19.5,0.5482805
131,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675685,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,5.0,0.9201065
814,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675697,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,7.5,0.7917431
1475,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675692,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,38.0,0.7917431
1476,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675692,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,38.0,0.7917431
813,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675697,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,7.5,0.7917431
715,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL1725279,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um,143.0,0.92673755
993,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL10,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um,10.0,0.8209374
73,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL31965,1117354,Active,human jak2 kinase inhibition screen,28.0,0.9408174
1232,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675700,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
1233,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675700,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
47,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL460472,662115,Active,inhibition of jak2,5.0,0.89707255
113,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1081484,465242,Active,antiproliferative activity against human set2 cells harboring jak2 v617f mutant after 72 hrs by calorimetry,1.5,0.98545474
112,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1081484,465238,Active,inhibition of gst tagged jak2 assessed as inhibition of biotinylated jak3tide peptide phosphorylation after 60 mins by caliper mobility shift assay,1.5,0.98545474
1141,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601708,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay,3.0,0.70071083
1230,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3702969,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
35,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1725279,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,64.0,0.99679947
552,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4115248,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.0,0.8596959
91,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3746463,1267685,Inactive,inhibition of jak2 in human hel 92 1 7 cells assessed as reduction in stat5 phosphorylation after 2 hrs by western blot analysis,1.0,0.9621804
88,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3814195,1306231,Active,inhibition of jak2  unknown origin using tyrosine 6 peptide as substrate by z' lyte assay,2.0,0.8596959
1245,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3645545,1257634,Active,in vitro kinase enzyme assay: in vitro kinase enzyme assay using jak3 jak2 jak1 and tyk2 ,57.0,0.70071083
1089,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.0,0.8963303
1246,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3645545,1257635,Active,in vitro kinase enzyme assay: in vitro kinase enzyme assay using jak3 jak2 jak1 and tyk2 ,57.0,0.70071083
1088,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.0,0.8963303
1247,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL2322139,727997,Active,inhibition of jak2  unknown origin after 2 5 hrs by time resolved fluorescence resonance energy transfer assay in presence of 100 um atp,1.0,0.87496024
1027,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3927316,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,2.0,0.8596959
2127,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601237,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay,2.0,0.70071083
76,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1336,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,4.0,0.9450266
72,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL31965,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,28.0,0.9408174
840,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675688,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
1453,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL24828,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,26.0,0.86357623
1834,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067888,Active,inhibition of jak2 v617f mutant in human set2 cells assessed as inhibition of stat5 phosphorylation after 24 hrs by western blotting analysis,1.5,0.83418125
802,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675692,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
801,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675692,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
1833,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067886,Active,inhibition of jak2 v617f mutant in human uke1 cells assessed as inhibition of stat5 phosphorylation after 24 hrs by western blotting analysis,1.5,0.83418125
798,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675697,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
797,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675697,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
1835,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067889,Active,inhibition of jak2 v617f mutant in human set2 cells assessed as inhibition of stat5 phosphorylation after 1 hr by western blotting analysis,1.5,0.83418125
792,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3622836,1251067,Active,inhibition of jak2  unknown origin using 35 um of atp and tyr6 peptide by z' lyte kinase assay,2.0,0.8963303
1831,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067883,Active,in vivo inhibition of jak2 in mouse transfected with mouse ba/f3 cells expressing tel jak2 assessed as inhibition of stat5 phosphorylation at 10 mg/kg po after 6 hrs by western blotting analysis,1.5,0.83418125
310,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3779913,1287924,Active,inhibition of jak2  unknown origin ,2.0,0.8596959
270,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675694,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
269,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675694,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
266,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596566,Active,inhibition of human jak2,1.0,0.8016677
265,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596564,Active,inhibition of tel fused jak2 induced proliferation of mouse ba/f3 cells,1.0,0.8016677
1832,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067885,Active,inhibition of jak2 v617f mutant in human uke1 cells assessed as inhibition of stat5 phosphorylation after 1 hr by western blotting analysis,1.5,0.83418125
818,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3907227,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.8596959
1836,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067890,Active,cytotoxicity against human uke1 cells expressing jak2 v617f mutant after 72 hrs by mts assay,1.5,0.83418125
1837,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067891,Active,cytotoxicity against human set2 cells expressing jak2 v617f mutant after 72 hrs by mts assay,1.5,0.83418125
839,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675688,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
1403,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4109366,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.0,0.8596959
1404,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4109366,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.0,0.8596959
363,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3651005,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,1.0,0.70071083
1377,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675693,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,6.0,0.8963303
1376,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675693,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,6.0,0.8963303
416,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL2325897,726697,Active,inhibition of jak2  unknown origin  mediated phosphorylation of biotin kaietdkeyytvkd incubated for 10 mins prior to substrate addition measured after 30 mins by scintillation counting analysis in presence of [gamma 33p]atp,1.5,0.8596959
585,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL941,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,11.0,0.95847034
886,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL10,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,8.0,0.94158304
311,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3779913,1287932,Active,inhibition of jak2 in human cd34+ cells assessed as inhibition of epo mediated cell proliferation,2.0,0.8596959
1847,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL103667,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,22.5,0.8268286
1841,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067943,Active,inhibition of jak2  unknown origin ,1.5,0.83418125
1840,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067941,Active,cytotoxicity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by mts assay,1.5,0.83418125
1839,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067930,Active,inhibition of human jak2,1.5,0.83418125
1838,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3116050,1067894,Active,inhibition of jak2 in mouse ba/f3 cells expressing tel jak2 assessed as inhibition of stat5 phosphorylation by western blotting analysis,1.5,0.83418125
264,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596562,Active,inhibition of jak2 after 60 min,1.0,0.8016677
568,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3114785,1070027,Active,inhibition of jak2  unknown origin ,1.5,0.9580085
1595,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3699482,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
925,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3651050,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,1.0,0.70071083
687,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647910,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
689,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3943946,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.8596959
1305,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.8596959
1306,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.8596959
1307,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.8596959
1308,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1468044,Active,inhibition of recombinant human jak2 using fitc kggeeeeyfelvkk as substrate in presence of 1 mm atp by mobility shift assay,1.0,0.8596959
1309,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1468047,Active,inhibition of jak2 in cd34+ human whole blood assessed as reduction in eop induced stat5 phosphorylation preincubated for 45 mins followed by eop addition measured after 15 mins by flow cytometric analysis,1.0,0.8596959
967,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3746743,1267667,Active,inhibition of n terminal gst fused recombinant jak2  831 to 1132 residues  unknown origin expressed in insect cells using 5fam geeplywsfpakkk nh2 as substrate by microfluidic capillary electrophoresis method,1.0,0.8596959
924,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3218297,1119787,Active,inhibition of jak2  unknown origin ,93.5,0.24332224
260,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596355,Active,inhibition of stat5 phosphorylation in ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 10 mg/kg po upto 2 hrs,1.0,0.8016677
1796,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4113802,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.0,0.8596959
686,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647910,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
728,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL56543,360729,Active,inhibition of human jak2 v617f mutant expressed in cos7 cells,7.0,0.8619848
729,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL56543,550411,Inactive,inhibition of il 6 induced jak2 phosphorylation in human ht 29 cells at 10 to 20 um by western blotting,7.0,0.8619848
261,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596357,Active,inhibition of stat5 phosphorylation in ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 5 mg/kg po upto 2 hrs,1.0,0.8016677
1797,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647897,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
932,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675699,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.0,0.8963303
933,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675699,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,3.0,0.8963303
1321,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3699496,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
768,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL91829,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um,44.5,0.9018439
730,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL56543,550412,Active,inhibition of il 6 induced jak2 phosphorylation in human ht 29 cells at 50 to 100 um by western blotting,7.0,0.8619848
766,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675691,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
767,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675691,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 ,1.0,0.8963303
262,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596359,Active,inhibition of stat5 phosphorylation in ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 2 5 mg/kg po upto 2 hrs,1.0,0.8016677
1800,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4113009,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.0,0.8596959
1799,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647897,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
1798,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647897,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
263,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL1774056,596364,Active,free drug level in plasma of ncr mouse tansplanted with tel jak2 expressing mouse ba/f3 cells at 10 mg/kg po after 6 hrs,1.0,0.8016677
685,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647910,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.0,0.8596959
1713,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
533,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3896766,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
532,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3896766,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1712,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1711,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
518,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3937827,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
519,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3937827,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1714,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1715,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
517,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3937827,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1710,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
531,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3896766,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1709,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343589,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1152,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3983502,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
1780,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917860,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
213,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3956651,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1972,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647770,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1971,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647770,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
251,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917134,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
252,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917134,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
1954,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702904,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1953,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702904,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
212,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3956651,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1952,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3950892,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
271,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4115248,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,2.5,0.3360896
1939,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703038,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1938,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703038,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
287,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3926748,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
288,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3926748,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
289,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3926748,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
333,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1951,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3950892,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
191,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
190,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
189,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
28,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3779913,1287925,Active,inhibition of jak3  unknown origin ,2.0,0.3360896
2151,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699544,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
2150,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699544,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
2149,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699544,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
2148,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699544,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
92,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
93,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
94,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
2109,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647735,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
2108,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647735,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
2100,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703098,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
2099,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703098,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
138,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
139,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
140,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
2030,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112766,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
2029,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112766,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
334,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1779,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917860,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
335,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
344,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
435,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3897648,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
436,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3897648,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
437,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3897648,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1793,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940644,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1792,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940644,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1791,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940644,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1790,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
420,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647813,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1789,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
1787,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
1786,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
1785,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
1784,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655082,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1783,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655082,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1782,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655082,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1781,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917860,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1788,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
419,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647813,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
397,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4108322,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
396,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4108322,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
345,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
346,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1887,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647840,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1886,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647840,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1883,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4113261,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
1882,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4113261,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
1881,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1880,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1879,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1878,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
357,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3924451,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
358,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3924451,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
373,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
374,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
375,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
390,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
391,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
343,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
392,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
561,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940421,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
896,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658865,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
837,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647758,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
836,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647758,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1272,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3950399,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1271,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3950399,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1270,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3950399,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1268,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917864,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
828,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1267,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917864,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
1007,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913397,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1008,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913397,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1009,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913397,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1635,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3955124,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,2.0,0.5738988
1636,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3955124,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,2.0,0.5738988
1525,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3925466,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1642,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3921889,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1643,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3921889,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1644,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3921889,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
854,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647742,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1645,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3921889,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1312,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4101725,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,2.5,0.3360896
1314,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4101725,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,2.5,0.3360896
863,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3907076,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
860,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3907076,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
859,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3907076,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
858,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3907076,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1379,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699489,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
895,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658865,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
1380,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699489,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
855,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647742,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
897,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658865,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.0,0.87607884
914,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343589,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
915,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
916,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
917,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
918,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
919,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
920,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1315,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4101725,1468058,Active,inhibition of recombinant human jak3 using fitc kggeeeeyfelvkk as substrate in presence of 4 um atp by mobility shift assay,2.5,0.3360896
1313,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4101725,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,2.5,0.3360896
1524,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3925466,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
827,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1071,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647906,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
1091,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655090,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1092,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655090,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
819,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343589,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1486,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3622828,1251068,Active,inhibition of jak3  unknown origin using 16 um of atp and tyr6 peptide by z' lyte kinase assay,1.0,0.8133465
780,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946758,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
749,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3622836,1251068,Active,inhibition of jak3  unknown origin using 16 um of atp and tyr6 peptide by z' lyte kinase assay,2.0,0.70917434
1107,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3984681,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1108,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3984681,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1113,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647928,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1176,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699517,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1175,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699517,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1114,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647928,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
779,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946758,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1137,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3973072,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1138,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3973072,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
778,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946758,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1139,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3973072,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1090,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655090,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1204,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647833,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1205,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647833,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.5738988
1083,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655086,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1072,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647906,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.5738988
826,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
696,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658869,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
697,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658869,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
698,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658869,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
825,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
824,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
823,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
861,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3907076,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
822,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
562,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940421,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1153,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3983502,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.5738988
560,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940421,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
820,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
1081,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655086,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1082,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655086,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 ,1.5,0.87607884
1214,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3918506,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
1213,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3918506,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati,1.5,0.5738988
821,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
862,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3907076,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts ,1.0,0.87607884
776,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL50,213412,Active,ability to inhibit protein tyrosine kinase activity of p56lck  isolated from bovine thymus in vitro ,16.0,0.70023495
864,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,223955,Active,inhibition of human p56 lck tyrosine kinase  lck64 509 ,2.0,0.9461948
865,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,223955,Active,inhibition of human p56 lck tyrosine kinase  lck64 509 ,2.0,0.9461948
866,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,223984,Active,inhibition of human p56 lck tyrosine kinase,2.0,0.9461948
867,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,748778,Active,inhibition of lck  64 to 509 amino acids  unknown origin by htrf assay,2.0,0.9461948
1167,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL2151321,692428,Active,inhibition of lck,5.5,0.7450632
777,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL50,378681,Active,inhibition of lck,16.0,0.70023495
2032,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL375840,277449,Active,inhibition of lck,1.5,0.2546495
1017,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL428690,224128,Active,inhibition of p56 lck tyrosine kinase,13.5,0.90487266
1018,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL428690,256657,Inactive,average binding constant for lck nanot active at 10 um,13.5,0.90487266
1218,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,631,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 1  src 1 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
117,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL103667,636416,Active,inhibition of c src,1.0,0.9079436
1447,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL941,256676,Inactive,average binding constant for src nanot active at 10 um,2.0,0.810576
116,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL103667,256676,Inactive,average binding constant for src nanot active at 10 um,1.0,0.9079436
1448,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL941,317425,Active,inhibition of recombinant human c src,2.0,0.810576
1450,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL941,595768,Active,inhibition of human recombinant c src by filter binding assay,2.0,0.810576
1219,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,631,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 1  src 1 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
1451,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL941,1286551,Active,inhibition of tel src  unknown origin expressed in mouse ba/f3 cells assessed as growth inhibition after 72 hrs by celltiter glo or cck 8 assay,2.0,0.810576
1197,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL276711,588354,Inactive,luminescence based cell based primary high throughput screening assay to identify inhibitors of the steroid receptor coactivator 1  src1 ncoa1 ,8.0,0.6587895
1196,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL276711,224432,Active,evaluated for inhibitory activity towards p60 c src tyrosine kinase,8.0,0.6587895
2153,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL191023,242306,Active,inhibition of glutamate/tyrosine  4:1 copolymer phosphorylation by avian c src tyrosine kinase,3.0,0.1951788
1449,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL941,370598,Active,inhibition of human recombinant c src by filter binding assay,2.0,0.810576
1220,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,731,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 3  src 3 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
1224,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,1049,Inactive,measurement of tr fret detection format artefact in the screen for agonists of steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
1222,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,1032,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
1223,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,1032,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
1892,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL91829,256676,Inactive,average binding constant for src nanot active at 10 um,35.0,0.7524114
1225,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,1049,Inactive,measurement of tr fret detection format artefact in the screen for agonists of steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
1226,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,588354,Inactive,luminescence based cell based primary high throughput screening assay to identify inhibitors of the steroid receptor coactivator 1  src1 ncoa1 ,95.5,0.65939397
1076,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL247667,1345717,Active,human lck proto oncogene src family tyrosine kinase  src family ,3.0,0.2667824
1039,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL67211,227681,Active,inhibition of src in presence of 1 mm atp,1.0,0.41911256
387,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1725279,588354,Inactive,luminescence based cell based primary high throughput screening assay to identify inhibitors of the steroid receptor coactivator 1  src1 ncoa1 ,8.0,0.91672534
386,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1725279,256676,Inactive,average binding constant for src nanot active at 10 um,8.0,0.91672534
2017,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL578061,588354,Inactive,luminescence based cell based primary high throughput screening assay to identify inhibitors of the steroid receptor coactivator 1  src1 ncoa1 ,12.0,0.49724668
1984,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL495727,412619,Active,inhibition of src t341m mutant,5.5,0.76275474
290,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL3952373,1322599,Active,inhibition of human src by time resolved fluorescence or time resolved fluorescence assay,2.5,0.13708685
547,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1997617,205329,Active,inhibition of src protein tyrosine kinase,2.0,0.9041303
1221,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1421720,731,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 3  src 3 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma ,95.5,0.65939397
1296,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL598797,461284,Active,inhibition of src,10.5,0.65963227
546,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1997617,205329,Active,inhibition of src protein tyrosine kinase,2.0,0.9041303
1670,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL428690,256676,Inactive,average binding constant for src nanot active at 10 um,16.0,0.8443916
549,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1997617,1407822,Active,inhibition of fyn  unknown origin using src family kinase bisamide rhodamine 110 peptide substrate after 1 hr by fluorescence assay,2.0,0.9041303
548,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL1997617,205333,Active,inhibition of src protein tyrosine kinase,2.0,0.9041303
1537,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL192856,242306,Active,inhibition of glutamate/tyrosine  4:1 copolymer phosphorylation by avian c src tyrosine kinase,3.0,0.1951788
443,CHEMBL2599,Tyrosine-protein kinase SYK,CHEMBL535,256647,Inactive,average binding constant for syk nanot active at 10 um,6.0,0.86155194
444,CHEMBL2599,Tyrosine-protein kinase SYK,CHEMBL535,479746,Inactive,inhibition of syk,6.0,0.86155194
281,CHEMBL2599,Tyrosine-protein kinase SYK,CHEMBL428690,256647,Inactive,average binding constant for syk nanot active at 10 um,1.5,0.67025286
1436,CHEMBL2599,Tyrosine-protein kinase SYK,CHEMBL31965,256647,Inactive,average binding constant for syk nanot active at 10 um,28.0,0.65605867
1184,CHEMBL2599,Tyrosine-protein kinase SYK,CHEMBL24828,256647,Inactive,average binding constant for syk nanot active at 10 um,18.5,0.7208547
1171,CHEMBL2599,Tyrosine-protein kinase SYK,CHEMBL119385,256647,Inactive,average binding constant for syk nanot active at 10 um,43.0,0.28255367
878,CHEMBL4128,Tyrosine-protein kinase TIE-2,CHEMBL939,256617,Inactive,average binding constant for tek nanot active at 10 um,16.0,0.3891445
2130,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.37402713
1719,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647730,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
2132,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.37402713
1996,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3651059,1258734,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,117.0,0.4219981
906,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652347,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 ,1.0,0.5550511
1995,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3651059,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,117.0,0.4219981
2129,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.37402713
1517,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3650982,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,109.0,0.4219981
1935,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3650984,1258734,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,89.0,0.4219981
1518,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3650982,1258734,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,109.0,0.4219981
1718,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647730,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
2131,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,1.5,0.37402713
1934,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3650984,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,89.0,0.4219981
849,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702976,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
922,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3917864,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.37402713
1671,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702969,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.5,0.23019472
911,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3651026,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w,97.0,0.28918818
1966,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699500,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
1455,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647906,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
848,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702976,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
1967,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699500,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
908,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652347,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 ,1.0,0.5550511
921,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3917864,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde,1.5,0.37402713
907,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652347,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 ,1.0,0.5550511
1454,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647906,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction ,2.0,0.37402713
2007,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909551,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2011,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3960877,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1993,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3972979,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1994,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3972979,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
2124,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3961923,1340084,Active,inhibition of recombinant human n terminal his6 tagged vegfr2  790 end residues expressed in baculovirus infected insect sf21 cells using btn flt3 as substrate after 1 hr by time resolved fluorescence assay,2.0,0.55833596
2008,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909551,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
2006,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909551,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2005,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909551,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1998,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3905866,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1999,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3905866,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2000,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3905866,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2001,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3905866,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2002,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3905866,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
978,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690413,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,19.0,0.29427695
2004,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909551,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1992,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3972979,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1187,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3903811,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1991,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3972979,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2137,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979028,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
975,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1684800,578728,Active,inhibition of flt3,17.5,0.6849142
937,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3918495,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
938,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3918495,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1689,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942506,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1960,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690579,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,4.5,0.29427695
1961,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690579,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,4.5,0.29427695
1962,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690579,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,4.5,0.29427695
1963,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690579,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,4.5,0.29427695
1607,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975903,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,3.0,0.438154
1612,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1690,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942506,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1613,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1741,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3948234,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
947,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3957473,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
948,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3957473,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
949,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3957473,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
950,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3957473,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2012,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3960877,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
960,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3966941,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
961,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3966941,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
962,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3966941,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
963,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3966941,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1739,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3948234,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1185,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3903811,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1186,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3903811,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
964,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3966941,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1990,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3972979,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1740,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3948234,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
981,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690413,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,19.0,0.29427695
2014,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3960877,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1649,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909752,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1650,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909752,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2065,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,16.0,0.29427695
2066,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,16.0,0.29427695
2067,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,16.0,0.29427695
2068,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,16.0,0.29427695
1651,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909752,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1652,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909752,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1653,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3909752,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1656,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3928239,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1657,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3928239,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1658,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3928239,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1659,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3928239,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1660,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3928239,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1032,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3935264,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
527,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3892005,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
524,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3892005,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2098,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1271480,527867,Active,inhibition of flt3 by hot spot filtration binding assay,1.0,0.5213088
1086,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3915533,1340083,Active,inhibition of recombinant human n terminal his6 tagged fgfr3 expressed in insect sf21 cells using btn flt3 as substrate after 3 hrs by time resolved fluorescence assay,3.0,0.4320537
1087,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3915533,1340084,Active,inhibition of recombinant human n terminal his6 tagged vegfr2  790 end residues expressed in baculovirus infected insect sf21 cells using btn flt3 as substrate after 1 hr by time resolved fluorescence assay,3.0,0.4320537
525,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3892005,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
137,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
136,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
135,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
134,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2091,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3907488,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2092,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3907488,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2093,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3907488,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2094,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3907488,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2095,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3907488,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
523,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3892005,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1031,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3935264,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1030,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3935264,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1029,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3935264,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2015,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3960877,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1738,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3948234,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
979,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690413,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,19.0,0.29427695
980,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690413,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,19.0,0.29427695
2123,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3961923,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,2.0,0.55833596
2122,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3961923,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,2.0,0.55833596
1188,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3903811,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1189,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3903811,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
994,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL274654,1345590,Active,human platelet derived growth factor receptor beta  type iii rtks: pdgfr csfr kit flt3 receptor family ,11.0,0.67915714
1190,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1614,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1736,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943080,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1735,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943080,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1734,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943080,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1733,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943080,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1732,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943080,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1615,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1028,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3935264,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1673,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3963296,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.5,0.61314756
1250,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,2.0,0.61314756
1251,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,2.0,0.61314756
1252,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,2.0,0.61314756
1253,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,2.0,0.61314756
2013,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3960877,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1674,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3963296,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.5,0.61314756
1691,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942506,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1194,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1193,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1192,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1191,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1616,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1692,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942506,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
936,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3918495,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
526,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3892005,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
934,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3918495,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
432,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3919173,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
431,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3919173,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
430,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3919173,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1425,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3890607,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1424,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3890607,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1492,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904294,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1493,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904294,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1494,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904294,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1683,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943860,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1530,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969815,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
830,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1414,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690525,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,21.0,0.29427695
1531,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969815,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1682,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943860,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1532,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969815,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1412,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690525,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,21.0,0.29427695
1411,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690525,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,21.0,0.29427695
831,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
832,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
833,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
834,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1533,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969815,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1534,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969815,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1394,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3931154,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1393,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3931154,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
935,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3918495,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1391,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3931154,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1390,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3931154,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1413,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690525,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,21.0,0.29427695
1681,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943860,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1426,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3890607,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1427,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3890607,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
22,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3288854,1155232,Active,binding affinity to flt3  unknown origin ,1.5,0.91437674
460,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3921476,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
459,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3921476,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
458,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3921476,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
457,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3921476,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
456,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3921476,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
23,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3288854,1440304,Active,antiproliferative activity against human mv4 11 cells harboring flt3 itd mutant after 72 hrs by mts assay,1.5,0.91437674
720,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975714,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
781,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969475,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
782,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969475,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
783,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969475,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
784,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969475,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
719,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975714,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
718,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975714,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
717,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975714,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1160,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927219,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
716,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975714,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
785,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969475,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
786,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1081312,1345563,Active,human platelet derived growth factor receptor alpha  type iii rtks: pdgfr csfr kit flt3 receptor family ,14.0,0.93682593
434,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3919173,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
433,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3919173,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1161,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927219,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1162,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927219,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1163,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927219,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1164,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927219,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1680,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943860,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1490,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904294,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1491,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904294,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1428,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3890607,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1538,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912569,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1684,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3943860,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1392,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3931154,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1540,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912569,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1178,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690474,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,2.0,0.29427695
1688,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942506,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1587,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975954,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1586,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975954,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
891,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3937972,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1921,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979885,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1588,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975954,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1920,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979885,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1918,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979885,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1917,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979885,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
890,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3937972,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
889,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3937972,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
888,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3937972,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
887,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3937972,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1919,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979885,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1539,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912569,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1589,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975954,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1180,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690474,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,2.0,0.29427695
2136,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979028,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
133,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3986661,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1606,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975903,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,3.0,0.438154
2138,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979028,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2139,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979028,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1605,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975903,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,3.0,0.438154
1179,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690474,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w,2.0,0.29427695
1590,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3975954,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
276,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
277,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
278,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
279,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
280,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3950910,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1181,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690474,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate ,2.0,0.29427695
2140,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979028,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1911,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3889890,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1675,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3963296,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.5,0.61314756
1367,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3982668,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1888,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345555,Active,human kit proto oncogene receptor tyrosine kinase  type iii rtks: pdgfr csfr kit flt3 receptor family ,7.5,0.78282714
1891,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345590,Active,human platelet derived growth factor receptor beta  type iii rtks: pdgfr csfr kit flt3 receptor family ,7.5,0.78282714
1579,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3908149,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1580,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3908149,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1581,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3908149,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1910,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3889890,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1565,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL101253,1345590,Active,human platelet derived growth factor receptor beta  type iii rtks: pdgfr csfr kit flt3 receptor family ,42.0,0.7897336
1582,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3908149,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1564,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL101253,256620,Inactive,average binding constant for flt3 nanot active at 10 um,42.0,0.7897336
1583,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3908149,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1890,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345563,Active,human platelet derived growth factor receptor alpha  type iii rtks: pdgfr csfr kit flt3 receptor family ,7.5,0.78282714
1366,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3982668,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1889,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345555,Active,human kit proto oncogene receptor tyrosine kinase  type iii rtks: pdgfr csfr kit flt3 receptor family ,7.5,0.78282714
1364,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3982668,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1363,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3982668,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1676,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3963296,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.5,0.61314756
1907,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3889890,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1908,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3889890,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1542,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912569,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.65462506
1909,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3889890,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1541,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912569,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
1365,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3982668,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay,1.0,0.65462506
2016,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL2385195,750074,Active,inhibition of flt 3  unknown origin using poly  glu tyr 4:1 as substrate after 30 mins by htrf assay,20.5,0.44960853
2152,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL125898,161423,Active,inhibition of chimeric pdgf receptor with flt 3 cytoplasmic domain phosphorylation in cho cells,4.5,0.5586042
2120,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL1172957,491928,Active,inhibition vegfr1,78.0,0.33797026
1097,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL126699,161423,Active,inhibition of chimeric pdgf receptor with flt 3 cytoplasmic domain phosphorylation in cho cells,5.0,0.44260165
1266,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL605003,743402,Inactive,identification of small molecule correctors of the cystic fibrosis transmembrane conductance regulator  cftr delta508 mutation function in fischer rat thyroid  frt cells measured in cell based system using plate reader   7017 02_other_dose_cherrypick_activity,43.0,0.3753738
2170,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL1668418,568310,Active,inhibition of human recombinant flt 3 kinase expressed in insect cells after 90 mins,3.0,0.5094602
1151,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL1173482,491758,Active,inhibition of human kdr phosphorylation in huvec cells after 24 hrs by western blotting,1.0,0.8468608
121,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3941174,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay,1.0,0.98806894
1150,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL1173482,491750,Active,inhibition of kdr,1.0,0.8468608
98,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL204985,263662,Active,inhibitory activity against vegfr2,27.5,0.9354977
99,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL380372,268025,Active,inhibition of vegfr2,2.0,0.9354977
110,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL378299,268025,Active,inhibition of vegfr2,1.0,0.9485113
33,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247228,306347,Active,inhibition of human vegfr2 by htrf method,1.0,0.9739595
2147,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL1946170,1386991,Active,inhibition of kdr  unknown origin transfected in mouse ba/f3 cells assessed as inhibition of cell growth incubated for 72 hrs by mts assay,15.5,0.49992335
126,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL119385,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um,7.0,0.8772546
122,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3941174,1340079,Active,inhibition of vegfr2  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay,1.0,0.98806894
87,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205406,263662,Active,inhibitory activity against vegfr2,2.0,0.9354977
1172,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL211662,268025,Active,inhibition of vegfr2,1.0,0.9485113
1469,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653137,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,36.0,0.7176871
557,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL378024,268025,Active,inhibition of vegfr2,1.0,0.9485113
141,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL204727,263662,Active,inhibitory activity against vegfr2,14.0,0.9354977
255,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL396107,306347,Active,inhibition of human vegfr2 by htrf method,12.5,0.9535383
1745,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653141,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,12.0,0.7176871
1746,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653141,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,12.0,0.7176871
1748,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653105,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,2.0,0.7176871
1749,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653105,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,2.0,0.7176871
272,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247252,306347,Active,inhibition of human vegfr2 by htrf method,6.0,0.9535383
1933,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653098,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,6.0,0.7176871
1932,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653098,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,6.0,0.7176871
899,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3945072,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay,1.0,0.87018967
295,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247790,306347,Active,inhibition of human vegfr2 by htrf method,11.5,0.9535383
298,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL377230,268025,Active,inhibition of vegfr2,1.0,0.9354977
316,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL295528,89312,Active,inhibition of human vegf receptor 2  kdr kinase ,1.0,0.8558844
317,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL391184,306347,Active,inhibition of human vegfr2 by htrf method,8.0,0.9535383
221,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,1444933,Active,inhibition of vegfr2  unknown origin using fam labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of atp by mobility shift assay,6.0,0.974791
1896,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653101,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,10.0,0.7176871
348,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205405,263662,Active,inhibitory activity against vegfr2,1.5,0.9354977
857,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3917220,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay,1.0,0.87018967
710,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL383990,268025,Active,inhibition of vegfr2,15.5,0.9354977
1843,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL217092,415074,Active,inhibition of vegfr2,1.0,0.8296427
1842,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL217092,272212,Active,inhibition of kdr,1.0,0.8296427
714,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL1084453,483435,Active,inhibition of kdr,2.5,0.8126055
816,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL1172957,491926,Active,inhibition kdr,44.0,0.66447514
1439,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3940489,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay,1.0,0.87018967
790,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL10,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um,15.0,0.861206
789,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL208600,268025,Active,inhibition of vegfr2,2.5,0.9354977
438,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL377346,268025,Active,inhibition of vegfr2,1.0,0.9485113
1485,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL290106,1117353,Active,human kdr kinase inhibition screen,33.0,0.58608055
752,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL206410,263662,Active,inhibitory activity against vegfr2,2.0,0.9354977
1470,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653137,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,36.0,0.7176871
1895,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653101,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,10.0,0.7176871
1310,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL1940272,1386991,Active,inhibition of kdr  unknown origin transfected in mouse ba/f3 cells assessed as inhibition of cell growth incubated for 72 hrs by mts assay,1.5,0.718646
223,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL383299,263662,Active,inhibitory activity against vegfr2,2.0,0.9354977
219,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um,6.0,0.974791
558,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653095,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,4.5,0.7176871
559,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653095,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,4.5,0.7176871
1234,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653115,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,41.5,0.7176871
1235,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653115,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,41.5,0.7176871
2058,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL602471,460492,Active,inhibition of recombinant kdr by tr fret assay,12.5,0.7720191
1034,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3943570,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay,2.0,0.8510242
1026,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653113,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,26.5,0.7176871
1025,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653113,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,26.5,0.7176871
1648,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL395665,298789,Active,inhibition of kdr,14.0,0.8133809
572,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3544983,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay,1.5,0.8510242
1016,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL380702,263662,Active,inhibitory activity against vegfr2,1.5,0.9354977
1014,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3928883,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay,1.0,0.87018967
220,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,414724,Active,inhibition of vegfr2 by liquid scintillation counting,6.0,0.974791
581,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL375819,277448,Active,inhibition of kdr,1.0,0.8133809
1262,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653111,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,2.0,0.7176871
208,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205893,263662,Active,inhibitory activity against vegfr2,1.5,0.9354977
1263,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653111,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,2.0,0.7176871
211,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3986135,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay,1.0,0.87018967
755,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL209265,268025,Active,inhibition of vegfr2,1.5,0.9354977
1287,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL521652,414724,Active,inhibition of vegfr2 by liquid scintillation counting,1.0,0.63804203
197,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL428690,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um,13.5,0.986209
193,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205108,263662,Active,inhibitory activity against vegfr2,1.5,0.9354977
192,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL91829,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um,1.5,0.9876309
2021,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653133,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,13.0,0.7176871
2020,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653133,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 ,13.0,0.7176871
187,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL31965,1117353,Active,human kdr kinase inhibition screen,2.5,0.998845
186,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL31965,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um,2.5,0.998845
185,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL209704,268025,Active,inhibition of vegfr2,1.0,0.9485113
2037,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL521201,406973,Active,inhibition of human recombinant vegfr2,2.0,0.6476948
987,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL209783,268025,Active,inhibition of vegfr2,2.5,0.9354977
1100,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL553,256622,Inactive,average binding constant for jnk1 nanot active at 10 um,49.0,0.82968175
1585,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL24828,256622,Inactive,average binding constant for jnk1 nanot active at 10 um,36.0,0.747647
1855,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL31965,256622,Inactive,average binding constant for jnk1 nanot active at 10 um,28.0,0.82414967
2154,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL91829,256622,Inactive,average binding constant for jnk1 nanot active at 10 um,21.0,0.58616143
461,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL535,256622,Inactive,average binding constant for jnk1 nanot active at 10 um,34.0,0.9419158
1578,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL939,256622,Inactive,average binding constant for jnk1 nanot active at 10 um,34.0,0.6956812
1249,CHEMBL2637,c-Jun N-terminal kinase 3,CHEMBL607707,256636,Inactive,average binding constant for jnk3 nanot active at 10 um,3.0,0.25921687
